日本臨牀　70/増刊7　乳癌(第2版)

出版社： 日本臨牀社
発行日： 2012-09-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 乳癌（第2版）―基礎と臨床の最新研究動向
電子書籍版： 2012-09-20 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 日本臨牀　70/増刊7　乳癌（第2版）

    ―目次―

    特集　乳癌（第2版）―基礎と臨床の最新研究動向

    I． 乳癌の診断と治療の変遷と展望　　　　　　 　 　
    　１． 病理診断の変遷と展望　
    　２． 外科治療の変遷と展望　
    　３． 放射線治療の変遷と展望 　
    　４． 化学療法の変遷と展望　
    　５． 内分泌療法の変遷と展望　

    II． 乳癌の疫学 　 　
    　１． 日本における乳癌の疫学的動向　
    　２． 乳癌の疫学―国際比較―　
    　３． 乳癌の危険因子 　 　

    III． 乳癌の分子生物学と発癌機序 　 　
    　１． 分子生物学 　 　
    　２． 発癌機序 　 　

    IV． 乳癌の浸潤・転移 　 　
    　１． 乳癌の浸潤・転移の機序：概論　
    　２． 乳癌骨転移の臨床的特徴　
    　３． 乳癌肝転移の臨床的特徴　
    　４． 乳癌肺転移の臨床的特徴　
    　５． 乳癌脳転移の臨床的特徴　
    　６． 乳癌胃・子宮転移の臨床的特徴　
    　７． 乳癌髄膜播種の臨床的特徴

    V． 乳癌の予後因子 　 　
    　１． 乳癌治療における予後因子解析の意義：概　論 　
    　２． リンパ節検索個数の乳癌予後因子としての評価　
    　３． 乳癌におけるBmi-1発現　
    　４． pCR(病理学的完全奏効)の予後因子としての意義　
    　５． 乳癌における新たな予後因子としてのHOXB9遺伝子　
    　６． トリプルネガティブ乳癌におけるmicroRNA-210　
    　７． 原発性乳癌におけるBRCA1のヘテロ接合性喪失(LOH)　
    　８． 再発予後因子としてのKi-67 labeling index

    VI． 乳癌取扱い規約・乳癌診療ガイドライン 　 　
    　１． 取扱い規約・ガイドラインを作成する意義：概　論　
    　２． 乳癌取扱い規約(第16版)とUICC TNM分類(第7版)の比較　
    　３． 乳癌診療ガイドラインとNCCNガイドラインの比較

    VII． 乳癌治療戦略を目指した基礎研究 　 　
    　１． EMT・微小環境から考える新しいseed & soil理論　
    　２． TRAIL陽性NK細胞の抗腫瘍メカニズムと治療効果　
    　３． 乳癌におけるRORα発現およびGR発現による
    　　　　アロマターゼ遺伝子制御　
    　４． 遺伝子診断の基礎 　 　
    　５． 乳癌幹細胞を標的とした治療戦略

    VIII． 乳癌の検査・診断 　 　
    　１． 乳癌の検査・診断：概論(流れ) 　
    　２． 乳癌の検査・診断 　 　

    OX． 乳癌の治療戦略 　 　
    　１． 乳癌の治療戦略：概論(ガイドラインのアルゴリズム解説)
    　２． 外科治療 　 　
    　３． 放射線療法 　 　
    　４． 化学療法 　 　
    　５． 分子標的薬治療 　 　
    　６． 内分泌療法 　 　
    　７． 乳房再建 　 　
    　８． 治療に伴う有害反応対策 　 　
    　９． ハイリスク症例に対する乳癌治療 　 　
    　10． 遺伝子治療・免疫治療 　 　

    X． 乳癌治療におけるQOL評価 　 　
    　１． 乳癌治療におけるQOL評価の意義と方法(概論) 　
    　２． 乳房温存療法の晩期有害事象とQOL　
    　３． 若年性乳癌患者のQOL 　
    　４． 乳癌患者における経済的困窮とQOL　
    　５． 乳癌治療における地域連携 ―QOL向上のために―

    XI． 乳癌治療とインフォームドコンセント 　 　
    　１． 患者目線の乳癌医療：
    　　　　概論(インフォームドコンセントについて)
    　２． 乳癌手術におけるインフォームドコンセントの要点　
    　３． 乳癌化学療法におけるインフォームドコンセントの要点

    XII． 特　論 　 　
    　１． 多施設共同大規模データベースの意義 　 　
    　２． 乳がん検診の現況と問題点　
    　３． 地域連携パスの構築と課題 　
    　４． 再発乳癌を支えるチーム医療　
    　５． 乳癌診療の医療経済評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 乳癌の診断・治療の変遷と展望

P.12 掲載の参考文献
1) 藤森正雄,泉雄勝:乳癌の病理組織学.日本外科学大系29,胸部損傷,胸壁・乳房,p126-135,中山書店,1968.
 
2) 菅野晴夫,坂元吾偉:早期乳癌の病理.早期乳癌:臨床と病理,p222-223,中山書店,1976.
 
3) International Agency for Research on Cancer(IARC):WHO histological classification of tumours of the breast.World Health Organization Classification of Tumours,Pathology&Genetics,Tumours of the Breast and Female Genital Organs(ed by Tavassoli FA,et al),IARC Press,Lyon,2003.
 
4) 日本乳癌学会(編):臨床・病理乳癌取扱い規約,第16版,金原出版,2008.
 
5) Page DL,et al:Intraductal carcinoma of the breast:follow-up after biopsy only,Cancer 49:751-758,1982.
PubMed
6) Elston CW,Ellis IO:Pathological prognostic factors in breast cancer.I.The value of histological grade in breast cancer:experience from a large study with long-term follow-up.Histopathology 19:403-410,1991.
 
7) 黒住昌史:病理検索.乳房温存療法ガイドライン 医療者向け(標準的な乳房温存療法の実施要項の研究班編),p22-26,金原出版,2005.
 
8) Singletary SE,Connolly JL:Breast cancer staging:working with the sixth edition of the AICC Cancer Staging Manual.CA Cancer J Clin 56:37-47,2006.
 
9) Kurosumi M:Immunohistochemical assessment of hormone receptor status using a new scoring system(J-Score)in breast cancer.Breast Cancer 14:189-193,2007.
PubMed
10) Kurosumi M:Trends of HER2 testing and trastuzumab therapy.Breast Cancer 16:284-287,2009.
PubMed
11) 黒住昌史:免疫組織診断とsubtype分類.病理診断プラクティス,p38-43,中山書店,2011.
 
12) 黒住昌史:術前療法の組織学的効果判定.病理診断プラクティス,p83-86,中山書店,2011.
 
P.17 掲載の参考文献
1) Halsted WS:The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June,1889,to January,1894.Ann Surg 20:497-555,1894.
 
2) Patey DH,Dyson WH:The prognosis of carcinoma of the breast in relation to the type of operation performed.Br J Cancer 2:7-13,1948.
 
3) Auchincloss H:Significance for location and number of axillary metastases in carcinoma of the breast.Ann Surg 158:37-46,1963.
PubMed
4) McWhirter R:The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast.Br J Radiol 21:599-610,1948.
PubMed
5) Crile G Jr:Treatment of breast cancer by local excision.Am J Surg 109:400-403,1965.
PubMed
6) Fisher B,et al:Eight-year of a randomized clinical trial comparing total mastectomy and Iumpectomy with or without irradiation in the treatment of breast cancer.N Engl J Med 320:822-828,1989.
PubMed
7) Fisher B,et al:Twenty-five-year follow-up of a randomized trial comparing radical mastectomy,total mastectomy,and total mastectomy followed by irradiation.N Engl J Med 347:567-575,2002.
PubMed
8) Fisher B,et al:Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med 347:1233-1241,2002.
PubMed
9) Veronesi U,et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.N Engl J Med 347:1227-1232,2002.
PubMed
10) Cabanas RM:An approach for the treatment of penile carcinoma.Cancer 39:456-466,1977.
PubMed
11) Morton DL,et al:Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 127:392-399,1992.
PubMed
12) Krag DN,et al:Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer:results from the NSABP B-32 randomised phase III trial.Lancet Oncol 8:881-888,2007.
PubMed
13) Giuliano AE,et al:Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial.JAMA 305:569-575,2011.
PubMed
14) 喜島祐子ほか:乳房温存術における1期的再建.外科 68:930-937,2006.
 
P.21 掲載の参考文献
1) Stenbeck T:Ein Fall von Hautkrebs geheilt durch Behandlung mit Rontogenstrahlen.Mitt Grenzgeb Med Chir 6:347-349,1900.
 
2) Keynes G:The radium treatment of carcinoma of the breast.Br J Surg 19:415-480,1932.
 
3) Keynes G:Conservative treatment of cancer of the breast.Br Med J 2(4004):643-647,1937.
PubMed
4) Baclesse F:Roentgen therapy as the sole method of treatment of cancer of the breast.Am J Roentgenol Radium Ther Nucl Med 62:311-319,1949.
 
5) Mustakallio S:Conservative treatment of breast carcinoma-review of 25 years of follow-up.Clin Radiol 23:110-116,1972.
PubMed
6) Peters MV:Wedge resection with or without radiation in early breast cancer.Int J Radiat Oncol Biol Phys 2:1151-1156,1977.
 
7) Calle R,et al:Conservative treatment of operable breast carcinoma by irradiation with or without limited surgery-10-year results.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p2-9,JB Lippincott,Philadelphia,1983.
 
8) Pierquin B:Conservative treatment for carcinoma of the breast:Experience of Creteil-ten-year results.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p11-14,JB Lippincott,Philadelphia,1983.
 
9) Pierquin B,et al:Radical radiation therapy of breast cancer.Int J Radiat Oncol Biol Phys 6:17-24,1980.
PubMed
10) Amalric RE,et al:Conservative therapy of operable breast cancer-results at five,ten,and fifteen years in 2216 consecutive cases.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p15-21,JB Lippincott,Philadelphia,1983.
 
11) Clark RM:Alternatives to mastectomy-The Princes Margaret Hospital experience.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p35-46,JB Lippincott,Philadelphia,1983.
 
12) Harris JR, Hellman S:The results of primary radiation therapy for early breast cancer at the Joint Center for Radiation Therapy.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p47-52,JB Lippincott,Philadelphia,1983.
 
13) Montague ED:Conservative surgery and radiation therapy in the treatment of operable breast cancer.Cancer 53(3 Suppl):700-704,1984.
 
14) Hayward J:The Guy's Hospital trials on breast conservation.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),p 77-90,JB Lippincott,Philadelphia,1983.
 
15) Veronesi U,et al:Comparing radical mastectomy with quadrantectomy,axillary dissection,and radiotherapy in patients with small cancers of the breast.N Engl J Med 305:6-11,1981.
PubMed
16) Veronesi U,et al:Results of quadrantectomy,axillary dissection,and radiotherapy(QUART) in TIN0 patients.In:Conservative Management of Breast Cancer:New Surgical and Radiotherapeutic Techniques(ed by Harris JR,et al),P91-99,JB LipPincott,Philadelphia,1983.
 
17) Sarrazin D,et al:Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less.Cancer 53:1209-1213,1984.
 
18) Fisher B,et al:Five-year results of randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.N Engl J Med 312:665-673,1985.
 
19) The START Trialists'Group.The UK Standardisation of Breast Radiotherapy(START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer:a randomized trial.Lancet 371:1098-1107,2008.
 
20) Whelan T,et al:Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer.J Natl Cancer Inst 94:1143-1150,2002.
PubMed
21) Smith BD,et al:Fractionation for whole breast irradiation:An American Society for Radiation Oncology(ASTRO) Evidence-Based Guideline.Int J Radiat Oncol Biol Phys 81:59-68,2011.
PubMed
22) Smith BD,et al:Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology(ASTRO).Int J Radiat Oncol Biol Phys 74:987-1001,2009.
PubMed
P.28 掲載の参考文献
1) Jacobson JA,et al:Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.N Engl J Med 332:907-911,1995.
 
2) Serlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
 
3) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials.Lancet 365:1687-1717,2005.
 
4) Fossati R,et al:Cytotoxic and hormonal treatment for metastatic breast cancer:a systematic review of published randomized trials involving 31,510 women.J Clin Oncol 16:3439-3460,1998.
PubMed
5) 日本乳癌学会:乳癌診療ガイドライン1.治療編2011年版. 金原出版,2011.
 
6) Toi M,et al:Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.Jpn J Clin Oncol 35:310-315,2005.
PubMed
7) Albain KS,et al:Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.J Clin Oncol 26:3950-3957,2008.
PubMed
8) Watanabe T,et al:Oral uracil and tegafur compared with classic cyclophosphamide,methotrexate,fluorouracil as postoperative chemotherapy in patients with node-negative,high-risk breast cancer:National Surgical Adjuvant Study for Breast Cancer O1 Trial.J Clin Oncol 27:1368-1374,2009.
 
9) Fumoleau P,et al:Multicentre,phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer.Eur J Cancer 40:536-542,2004.
PubMed
10) Perez EA,et al:Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline,a taxane,or both.J Clin Oncol 22:2849-2855,2004.
 
11) Gradishar WJ,et al:Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.J Clin Oncol 23:7794-7803,2005.
PubMed
12) Cortes J,et al:Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer(EMBRACE):a phase 3 Open-label randomised study.Lancet 377:914-923,2011.
PubMed
13) Vogel CL,et al:Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol 20:719-726,2002.
PubMed
14) Geyer CE,et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med 355:2733-2743,2006.
PubMed
15) J O'Shanghnessy LS,et al:A randomized phase III study of iniparib(BSI-201) in combination with gemcitabine/carboplatin(G/C) in metastatic triple-negative breast cancer(TNBC).J Clin Oncol 29(Suppl),2011(2011 ASCO Annual Meeting Abstr 1007).
 
P.33 掲載の参考文献
1) Prat A,Perou CM:Mammary development meets cancer genomics.Nat Med 15:842-844,2009.
PubMed
2) Yamashita H,et al:Estrogen receptor-positive breast cancer in Japanese women:trends in incidence,characteristics,and prognosis.Ann Oncol 22:1318-1325,2011.
PubMed
3) Allred DC,et al:The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.Breast Cancer Res 6:240-245,2004.
PubMed
4) Hammond ME,et al:American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.J Clin Oncol 28:2784-2795,2010.
 
5) Harvey JM,et al:Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol 17:1474-1481,1999.
 
6) Yamashita H,et al:Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.Breast Cancer 13:74-83,2006.
PubMed
7) Endo Y,et al:High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.Int J Clin Oncol 16:512-518,2011.
PubMed
8) Adams BD,et al:The micro-ribonucleic acid(miRNA) miR-206 targets the human estrogen receptor-alpha(ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell Iines.Mol Endocrinoi 21:1132-1147,2007.
 
9) Kondo N,et al:miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.Cancer Res 68:5004-5008,2008.
PubMed
10) Ybshimoto N,et al:Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer.Breast Cancer Res Treat 130:331-339,2011.
 
11) Toyama T,et al:No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.JPn J Clin Oncol 39:651-656,2009.
PubMed
12) Osborne CK,et al:Fulvestrant:an oestrogen receptor antagonist with a novel mechanism of action.Br J Cancer 90(Suppl 1)lS2-S6,2004.
 
13) Ingle JN,et al:Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.J Clin Oncol 28:4674-4682,2010.
PubMed
14) Johnston SR:New strategies in estrogen receptor-positlve breast cancer.Clin Cancer Res 16:1979-1987,2010.
PubMed
15) Baselga J,et al:Everolimus in postmenopausal hormone-receptor-positive advanced breastcancer.N Engl J Med 366(6):520-529,2012.
 

II 乳癌の疫学

P.41 掲載の参考文献
1) http://ganjoho.jp/professional/statistics/index.html;Accessed January 24,2012.
 
P.49 掲載の参考文献
1) 「がんの統計」編集委員会:がんの統計'10,財団法人がん研究振興財団,2010.
 
2) Curado MP,et al:Cancer Incidence in Five Continents,Vol.IX,p534-537,IARC Scientific Publications,Lyon,2007.
 
3) 田島和雄:乳がんの早期発見による死亡率低減(二次予防).日乳癌検診会誌 19:23-29,2010.
 
4) IARC/WHO:GLOBOCAN 2008:Cancer Incidence and Prevalence Worldwide in 2008.
PubMed
5) Parkin DM,et al:Cancer Incidence in Five Continents,Vol.VII,p858-869,IARC Publications,Lyon,1997.
 
6) Hirose K,et al:Effect of body size on breast cancer risk among Japanese women.Int J Cancer 80:349-355,1999.
PubMed
7) World Cancer Research Fund and American Institute for Cancer Research:Food,Nutrition,and Prevention of Cancer,a Global Perspective,p252-287,The American Institute for Cancer Research,Washington DC,1997.
 
8) World Cancer Research Fund and American Institute for Cancer Research:Food,Nutrition,Physical Activity,and Prevention of Cancer,a Global Perspective,p289-299,The American Institute for Cancer Research,Washington DC,2007.
 
9) Hirose K,et al:Dietary factors protective against breast cancer in Japanese premenopausal and postmenopausal women.Int J Cancer 107:276 -282,2003.
 
10) Hirose K,et al:Soybean products and reduction of breast cancer risk:a case-control study in Japan.Br J Cancer 93:15-22,2005.
 
11) Kuriki K,et al:Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese.Int J Cancer 121:377-385,2007.
 
P.53 掲載の参考文献
1) World Cancer Research Fund and American Institute for Cancer Research.Food,Nutrition,Physical Activity and the Prevention of Cancer:a Global Perspective.American Institute for Cancer Research,Washington DC,2007.
 
2) Collishaw NE,et al:Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk.Toronto,Canada:Ontario Tobacco Research Unit,OTRU Special Report Series,2009.
 
3) Missmer SA,et al:Meat and dairy food consumption and breast cancer:a pooled analysis of cohort studies.Int J Epidemiol 31(1):78-85,2002.
PubMed
4) Yamamoto S,et al:Soy,isoflavones,and breast cancer risk in Japan.J Natl Cancer Inst 95:906-913,2003.
PubMed
5) Hunter DJ,et al:Non-dietary factors as risk factors for breast cancer,and as effect modifiers of the association of fat intake and risk of breast cancer.Cancer Causes Control 8(1):49-56,1997.
PubMed
6) Nagata C,et al:Effects of menstrual and reproductive factors on the risk of breast cancer:metaanalysis of the case-control studies in Japan.JPn J Cancer Res 86(10):910-915,1995.
PubMed
7) Kelsey JL,et al:Reproductive factors and breast cancer.Epidemiol Rev 15(1):36-47,1993.
PubMed
8) Kahlenborn C,et al:Oral contraceptive use as a risk factor for premenopausal breast cancer:a meta-analysis.Mayo Clin Proc 81(10):1290-1302,2006.
PubMed
9) Breast cancer and hormonal contraceptives:collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.Collaborative Group on Hormonal Factors in Breast Cancer.Lancet 347(9017):1713-1727,1996.
 
P.58 掲載の参考文献
1) Sattin RW,et al:Family history and the risk of breast cancer.J Am Med Assoc 253:1908-1913,1985.
 
2) 増岡秀次,森満:乳癌の症例対照研究(第一報).札幌医誌 59:549-560,1990.
 
3) Lynch HT,et al:Familial breast cancer,familial cancer syndromes,and predisposition to breast neoplasia.In:The Breast(ed by Bland KI,Copeland-III EM),p262-291,WB Saunders,Philadelphia,1991.
 
4) 野水整,土屋敦雄:家族性乳癌の臨床.家族性乳癌(阿部力哉監),p7-16,篠原出版,1996.
 
5) Miki Y,et al:A strong candidate for the breast and ovarian cancer susceptibility gene Brca1.Science 265:2088-2090,1994.
 
6) Wooster R,et al:Identification of the breast cancer susceptibility gene BRCA2.Nature 378:789-792,1995.
PubMed
7) 霞富士雄ほか:家族性乳癌の臨床-BRCA-1,BRCA-2遺伝子を含む-.遺伝子医学 3:431-438,1999.
 
8) Da Silva L,Lakhani SR:Pathology of hereditary breast cancer.Mod Pathol 23:S46-S51,2010.
PubMed
9) Tan DSP,et al:Hereditary breast cancer:from molecular pathology to tailored therapies.J Clin Pathol 61:1073-1082,2008.
PubMed
10) Sugano K et al:Cross-section analysis of germline BRCA1 and BRCA2 mutation in Japanese patients suspected to have hereditary breast/ovarian cancer.Cancer Sci 99:1967-1976,2008.
 
11) 野水整ほか:わが国における遺伝性乳癌の臨床病理学的検討.癌の臨床 44:433-440,1998.
Medical*Online
12) 三好康雄,野口眞三郎:日本人の家族性乳癌におけるBRCA1,BRCA2遺伝子変異と臨床病理学的特徴の検討.家族性腫瘍 6:12-16,2006.
Medical*Online
13) Chen S,Parmigiani G:Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol 25:1329-1333,2008.
 
14) Clark AS,Domchek SM:Clinical management of hereditary breast cancer syndromes.J Mammary Gland Boil Neoplasia 16:17-25,2011.
 

III 乳癌の分子生物学と発癌機序

P.64 掲載の参考文献
1) Prat A,et al:Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Breast Cancer Res 12:R68,2010.
PubMed
2) Manie E,et al:High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.Cancer Res 69:663-671,2009.
 
3) Jiang Z,et al:Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.J Clin Invest 120:3296-3309,2010.
PubMed
4) Muller PA,et al:Mutant p53 drives invasion by promoting integrin recycling.Cell 139:1327-1341,2009.
PubMed
5) Kroemer G,Pouyssegur J:Tumor cell metabolism:cancer's Achilles'heel.Cancer Cell 13:472-482,2008.
 
6) Locasale JW,et al:Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.Nat Genet 43:869-874,2011.
PubMed
7) Prensner JR Chinnaiyan AM:Metabolism unhinged:IDH mutations in cancer.Nat Med 17:291-293,2011.
PubMed
8) Zhao S,et al:Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.Science 324:261-265,2009.
PubMed
9) Li X,et al:Extensive in vivo metabolite-protein interactions revealed by large-scale systematic analyses.Cell 143:639-650,2010.
PubMed
10) Ronnov-Jessen L,Bissell MJ:Breast cancer by proxy:can the microenvironment be both the cause and consequence?Trends Mol Med 15:5-13,2008.
PubMed
11) Levental KR,et al:Matrix crosslinking forces tumor progression by enhancing integrin signaling.Cell 139:891-906,2009.
PubMed
12) Dupont S,et al:Role of YAP/TAZ in mechanotransduction.Nature 474:179-183,2011.
PubMed
13) Chan SW,et al:A role for TAZ in migration,invasion,and tumorigenesis of breast cancer cells.Cancer Res 68:2592-2598,2008.
PubMed
14) McKnight SL:On getting there from here.Science 330:1338-1339,2010.
PubMed
P.70 掲載の参考文献
1) Moasser MM:The oncogene HER2:its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene 26:6469-6487,2007.
PubMed
2) Nielsen TO,et al:Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res 10:5367-5374,2004.
PubMed
3) Zwijsen RM,et al:CDK-independent activation of estrogen receptor by cyclin D1.Cell 88:405-415,1997.
PubMed
4) Rodriguez-Pinilla SM,et al:MYC amplification in breast cancer:a chromogenic in situ hybridisation study.J Clin Pathol 60:1017-1023,2007.
PubMed
5) Ponzo MG,et al:Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.Proc Natl Acad Sci USA 106:12903-12908,2009.
PubMed
6) Wulf GM,et al:Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.EMBO J 20:3459-3472,2001.
PubMed
7) Stemke-Hale K,et al:An integrative genomic and proteomic analysis of PIK3CA,PTEN,and AKT mutations in breast cancer.Cancer Res 68:6084-6091,2008.
PubMed
8) Saal LH,et al:PIK3CA mutations correlate with hormone receptors,node metastasis,and ERBB2,and are mutually exclusive with PTEN loss in human breast carcinoma.Cancer Res 65:2554-2559,2005.
PubMed
9) Zhou BP,et al:Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.Nat Cell Biol 3:245-252,2001.
PubMed
10) Kinzler KW,Vogelstein B:Cancer-susceptibility genes.Gatekeepers and caretakers.Nature 386:761-763,1997.
PubMed
11) Ohta T,et al:The BRCA1 ubiquitin ligase and homologous recombination repair.FEBS Lett 585:2836-2844,2011.
PubMed
12) 太田智彦:がんのゲノム解析と診療への応用-乳癌.日本臨牀 68(増刊号8):438-443,2010.
 
13) Meindl A,et al:Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.Nat Genet 42:410-414,2010.
PubMed
14) Saal LH,et al:Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.Nat Genet 40:102-107,2008.
PubMed
15) Luo J,et al:Principles of cancer therapy:oncogene and non-oncogene addiction.Cell 136:823-837,2009.
PubMed
P.75 掲載の参考文献
1) Feigelson HS,et al:Cytochrome P450c17alpha gene(CYP17)polymorphism is associated with serum estrogen and progesterone concentrations.Cancer Res 58:585-587,1998.
PubMed
2) Ye Z,Parry JM:The CYP17 MspA1 polymorphism and breast cancer risk:a meta-analysis.Muta-genesis 17:119-126,2002.
 
3) Ma X,et al:Association between CYP19 polymorphisms and breast cancer risk:results from 10,592cases and 11,720 controls.Breast Cancer Res Treat 122:495-501,2010.
PubMed
4) Yao L,et al:Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk:a meta-analysis involving 25,087 subjects.Breast Cancer Res Treat 122:503-507,2010.
 
5) Miyoshi Y,et al:Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women.Breast J 8:209-215,2002.
PubMed
6) Paracchini V,et al:Meta-and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer:a HuGE-GSEC review.Am J Epidemiol 165:115-125,2007.
PubMed
7) Mitrunen K,et al:Polymorphic catechol-O-methyltransferase gene and breast cancer risk.Cancer Epidemiol Biomarkers Prev 10:635-640,2001.
PubMed
8) Mao C,et al:Lack of association between catechol-0-methyltransferase Val108/158Met polymor-phism and breast cancer risk:a meta-analysis of 25,627 cases and 34,222 controls.Breast Cancer Res Treat 121:719-725,2010.
 
9) Gonzalez-Zuloeta Ladd AM,et al:Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk.Breast Cancer Res Treat 107:415-419,2008.
PubMed
10) Gold B,et al:Estrogen receptor genotypes and haplotypes associated with breast cancer risk.Cancer Res 64:8891-8900,2004.
PubMed
11) Surekha D,et al:Oestrogen receptor beta(ERbeta) polymorphism and its influence on breast cancer risk.J Genet 88:261-266,2009.
 
12) Treeck O,et al:Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility.J Steroid Biochem Mol Biol 114:207-211,2009.
PubMed
13) Lu S,et al:HER2 Ile655Val polymorphism contributes to breast cancer risk:evidence from 27 case-control studies.Breast Cancer Res Treat 124:771-778,2010.
PubMed
14) Yu KD,et al:A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTMI1 in breast cancer.EASEB J 23:2274-2287,2009.
PubMed
15) Egan KM,et al:Genetic polymorphisms in GSTMI,GSTP1,and GSTT1 and the risk for breast cancer:results from the Shanghai Breast Cancer Study and meta-analysis.Cancer Epidemiol Biomarkers Prev 13:197-204,2004.
 
P.83 掲載の参考文献
1) Reya T,et al:Stem cells,cancer,and cancer stem cells.Nature 414:105-111,2001.
PubMed
2) Bonnet D,Dick JE:Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med 3:730-737,1997.
PubMed
3) Al-Hajj M,et al:Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA 100:3983-3988,2003.
PubMed
4) Clevers H:The cancer stem cell:premises,promises and challenges.Nat Med 17:313-319,2011.
PubMed
5) Sheridan C,et al:CD44+/CD24-breast cancer cells exhibit enhanced invasive properties:an early step necessary for metastasis.Breast Cancer Res 8:R59,2006.
PubMed
6) Hirschmann-Jax C,et al:A distinct"side population"of cells with high drug efflux capacity in human tumor cells.Proc Natl Acad Sci USA 101:14228-14233,2004.
PubMed
7) Ginestier C,et al:ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell Stem Cell 1:555-567,2007.
 
8) Ponti D,et al:Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.Cancer Res 65:5506-5511,2005.
PubMed
9) Fridriksdottir AJ,et al:Mammary gland stem cells:current status and future challenges.Int J Dev Biol 55:719-729,2011.
PubMed
10) Nakshatri H,et al:Breast cancer stem cells and intrinsic subtypes:controversies rage on.Curr Stem Cell Res Ther 4:50-60,2009.
PubMed
11) Korkaya H,et al:Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.PLoS Biol 7:e1000121,2009.
PubMed
12) Conley SJ,et al:Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.Proc Natl Acad Sci USA 109:2784-2789,2012.
PubMed
13) Harrison H,et al:Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.Cancer Res 70:709-718,2010.
PubMed
14) Yu F,et al:MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.J Biol Chem 287:465-473,2012.
 
15) Liu S,et al:Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.Cancer Res 66:6063-6071,2006.
PubMed
16) Barginear MF,et al:The hedgehog pathway as a therapeutic target for treatment of breast cancer.Breast Cancer Res Treat 116:239-246,2009.
PubMed
17) Mani SA,et al:The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell 133:704-715,2008.
PubMed
18) Guo W,et al:Slug and Sox9 cooperatively determine the mammary stem cell state.Cell 148:1015-1028,2012.
PubMed
19) Shimono Y,et al:Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.Cell 138:592-603,2009.
PubMed
20) Wellner U,et al:The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.Nat Cell Biol 11:1487-1495,2009.
PubMed
21) Korkaya H,et al:Breast cancer stem cells,cytokine networks,and the tumor microenvironment.J Clin Invest 121:3804-3809,2011.
PubMed
22) Hirohashi Y,et al:Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.Immunotherapy 2:201-211,2010.
PubMed
23) Hirohashi Y,et al:Cytotoxic T lymphocytes:Sniping cancer stem cells.Oncoimmunology 1:123-125,2012.
PubMed
P.87 掲載の参考文献
1) Iorio MV,et al:MicroRNA gene expression deregulation in human breast cancer.Cancer Res 65(16):7065-7070,2005.
PubMed
2) Fu SW,et al:miRNA Biomarkers in Breast Cancer Detection and Management.J Cancer 2:116-122,2011.
PubMed
3) YU Z,et al:microRNA,cell cycle,and human breast cancer.Am J Pathol 176:1058-1064,2010.
PubMed
4) Shi M,et al:Metastasis-related miRNAs,active players in breast cancer invasion,and metastasis.Cancer Metastasis Rev 29:785-799,2010.
PubMed
5) Ma L,et al:Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature 449:682-688,2007.
PubMed
6) Negrini M,Calin GA:Breast cancer metastasis:a microRNA story.Breast Cancer Res 10:203,2008.
PubMed
7) Andorfer CA,et al:MicroRNA signatures:clinical biomarkers for the diagnosis and treatment of breast cancer.Trends Mol Med 17:313-319,2011.
PubMed
8) Roth C,et al:Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.Breast Cancer Res 12:R90,2010.
PubMed
9) Hu Z,et al:Serum microRNA profiling and breast cancer risk:the use of miR-484/191 as endogenous controls.Carcinogenesis 33:828-834,2012.
PubMed
10) Gidlof O,et al:Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction,are selectively dependent on renal elimination,and can be detected in urine samples.Cardiology 118:217-226,2011.
PubMed
11) Xu D,et al:miR-22 represses cancer progression by inducing cellular senescence.J Cell Biol 193:409-424,2011.
PubMed
12) Gong C,et al:Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.J Biol Chem 286:19127-19137,2011.
PubMed
P.91 掲載の参考文献
1) Chlebowski RT,et al:Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.JAMA 304(15):1684-1692,2010.
PubMed
2) Stefanick ML,et al:Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.JAMA 295(14):1647-1657,2006.
PubMed
3) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials.Lancet 365(9472):1687-1717, 2005.
 
4) Cuzick J:Aromatase inhibitors for breast cancer prevention.J Clin Oncol 23(8):1636-1643,2005.
PubMed
5) Coombes RC,et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med 251:2461,2004.
 
6) Arimidex,Tamoxifen,Alone or in Combination(ATAC) Trialists'Group:Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial.Lancet Oncol 9(1):45-53,2008.
 
7) Jakesz R,et al:Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years'adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial.Lancet 366(9484):455-462,2005.
PubMed
8) Goss PE,et al:A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.N Engl J Med 349(19):1793-1802,2003.
 
9) Cuzick J,et al:Overview of the main outcomes in breast-cancer prevention trials.Lancet 361(9354):296-300,2003.
PubMed
10) Martino S,et al:Continuing outcomes relevant to Evista:breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.J Natl Cancer Inst 96(23):1751-1761,2004.
 
11) Barrett-Connor E,et al:Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.N Engl J Med 355(2):125-137,2006.
PubMed
12) Vbgel VG,et al:Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes:the NSABP Study of Tamoxifen and Raloxifene(STAR) P-2trial.JAMA 295(23):2727-2741,2006.
 
P.95 掲載の参考文献
1) Bombonati A,Sgroi DC:The molecular pathology of breast cancer progression.J Pathol 223:307-317,2011.
PubMed
2) Lerwill MF:Flat epithelial atypia of the breast.Arch Pathol Lab Med 132:615-621,2008.
PubMed
3) Dupont WD,Page DL:Risk factors for breast cancer in women with proliferative breast disease.N Engl J Med 312:146-151,1985.
PubMed
4) Simpson PT,et al:Molecular evolution of breast cancer.J Pathol 205:248-254,2005.
PubMed
5) Reya T,et al:Stem cells,cancer,and cancer stem cells.Nature 414:105-111,2001.
PubMed
6) Barabe F,et al:Modeling the initiation and progression of human acute leukemia in mice.Science 316:600-604,2007.
PubMed
7) Joshi PA,et al:Progesterone induces adult mammary stem cell expansion.Nature 465:803-807,2010.
PubMed
8) Ginestier C,et al:ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell Stem Cell 1:555-567,2007.
 
9) Lim E,et al:Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.Nat Med 15:907-913,2009.
PubMed
10) Molyneux G,et al:BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.Cell Stem Cell 7:403-417,2010.
PubMed
11) Kenemans P,et al:Oncogenic pathways in hereditary and sporadic breast cancer.Maturitas 49:34-43,2004.
PubMed
12) Lambie H,et al:Prognostic significance of BRCA1 expression in sporadic breast carcinomas.J Pathol 200:207-213,2003.
PubMed
13) Hughes-Davies L,et al:EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.Cell 115:523-535,2003.
PubMed
14) Kenemans P,Bosman A:Breast cancer and post-menopausal hormone therapy.Best Pract Res Clin Endocrinol Metab 17:123-137,2003.
PubMed
15) Hayashi SI,et al:The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:193-202,2003.
PubMed
P.100 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン(1)治療編 2011年版,p186-187,金原出版,2011.
 
2) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン(1)治療編 2011年版,p265-267,金原出版,2011.
 
3) Clarke M,et al:Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-years survival:an overview of the randomized trials.Lancet 366:2078-2106,2005.
 
4) Fowble B,et al:Second cancers after conservative surgery and radiation for states I-II breast cancer:Identifying a subset of women at increased risk.Int J Radiat Oncol Biol Phys 51:679-690,2001.
 
5) Kirova YM,et al:Risk of second malignancies after adjuvant radiotherapy for breast cancer:A large-scale,single-institution review.Int J Radiat Oncol Boil Phys 68:359-363,2007.
 
6) 島田義也ほか:発癌機序 放射線と大腸癌(治療後の二次発癌を含めて).日本臨牀 69:126-131,2011.
 
7) 霞富士夫:両側乳癌.日外会誌 86:266-279,1985.
 
8) Shaitelman SF,et al:Rates of second malignancies after definitive local treatment for ductal carcinoma in situ of the breast.Int J Radiat Oncol Biol Phys 81:1244-1251,2011.
PubMed
9) Stovall M,et al:Dose to the contralatelral breast from radiotherapy and risk of second primary breast cancer in the WECARE study.Int J Radiat Oncol Biol Phys 72:1021-1030,2008.
 
10) Kirova YM,et al:Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.Breast Cancer Res Treat 102:119-126,2010.
 
11) Deutsch M,et al:The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy.Result of National Surgical Adjuvant Breast and Bowel Project(NSABP) clinical trials B-04 and B-06.Cancer 98:1362-1368,2003.
 
12) Inskip PD,et al:Lung cancer risk and radiation dose among women treated for breast cancer.J Nat Cancer Inst 86:983-988,1994.
PubMed
13) Huang J,Mackillop WJ:Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma.Cancer 92:172-180,2001.
PubMed
14) Woodward AH,et al:Lynphangiosarcoma arising in chronic lymphedematous extremities.Cancer 30:562-572,1972.
PubMed
15) 山中光規朗ほか:再発を繰り返した放射線照射後皮膚血管肉腫の1剖検例.癌の臨床 47:321-327,2001.
 
P.108 掲載の参考文献
1) Collaborative Group on Hormonal Factors in Breast Cancer:Familial breast cancer:collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.Lancet 358:1389-1399,2001.
 
2) Miki Y,et al:A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1.Science 266:66-71,1994.
 
3) Wooster R,et al:Identification of the breast cancer susceptibility gene BRCA2.Nature 378:789-792,1995.
PubMed
4) Petrakis NL:Cerumen genetics and human breast cancer.Science 173:347-349,1971.
PubMed
5) Yoshiura K,et al:A SNP in the ABCC11ene is the determinant of human earwax type.Nat Genet 38:324-330,2006.
PubMed
6) Ota I,et al:Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11.Anticancer Res 30:5189-5194,2010.
PubMed
7) Easton DF,et al:Genome-wide association study identifies novel breast cancer susceptibility loci.Nature 447:1087-1093,2007.
PubMed
8) Kiyotani K,et al:Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.Cancer Sci 99(5):995-999,2008.
PubMed
9) Lim HS,et al:Clinical implications of CYP2D6genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.J Clin Oncol 25(25):3837-3845,2007.
 
10) Kiyotani K,et al:Dose-adjustment study of tamoxifen based on CYP2D6genotypes in Japanese breast cancer patients.Breast Cancer Res Treat 131(1):137-145,2012.
 
11) Goetz MP,et al:The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Breast Cancer Res Treat 101(1):113-121,2007.
PubMed
12) Ding L,et al:Genome remodelling in a basal-like breast cancer metastasis and xenograft.Nature 464(7291):999-1005,2010.
 
13) O'Shaughnessy J,et al:Next generation sequencing reveals co-activating events in the MAPK and PI3K/AKT pathways in metastatic triple negative breast cancers.Cancer Res 71(24 Suppl):104S,2011.
 

IV 乳癌の浸潤・転移

P.117 掲載の参考文献
1) Roy R,et al:Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.J Clin Oncol 27:5287-5297,2009.
 
2) Coussens LM,et al:Matrix metalloproteinase inhibitors and cancer:trials and tribulations.Science 295:2387-2392,2002.
PubMed
3) Barbolina MV,Stack MS:Membrane type 1-matrix metalloproteinase:substrate diversity in pericellular proteolysis.Semin Cell Dev Biol 19:24-33,2008.
 
4) Duffy MJ,et al:Cancer invasion and metastasis:changing views.J Pathol 214:283-293,2008.
PubMed
5) Kleer CG,et al:Molecular biology of breast cancer metastasis.Inflammatory breast cancer:clinical syndrome and molecular determinants.Breast Cancer Res 2:423-429,2000.
PubMed
6) AI-Raawi D,et al:Membrane type-1 matrix metalloproteinase(MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2(MMP-2) in inflammatory breast cancer.Int J Clin Exp Med 4(4):265-275,2011.
 
7) Kim HJ,et al:Expression of MT-1 MMP,MMP2,MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.Yonsei Med J 47(3):333-342,20O6.
PubMed
P.122 掲載の参考文献
1) Coleman RE:Skeletal complications of malignancy.Cancer 80:1588-1594,1997.
PubMed
2) Coleman RE:Bisphosphonates:clinical experience.Oncologist 9(Suppl 4):14-27,2004.
 
3) 小林心ほか:転移性乳癌の予後.日本乳癌学会総会,2010.
 
4) 高橋俊二:骨転移に対するRANKL抗体:denosumab.医学のあゆみ 224:33-38,2008.
Medical*Online
5) Yoneda T,Hiraga T:Crosstalk between cancer cells and bone microenvironment in bone metastasis.Biochem Biophys Res Commun 328:679-687,2005.
PubMed
6) Wu JS,et al:Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.Int J Radiat Oncol Biol Phys 55:594-605,2003.
PubMed
7) Kassamali RH,et al:Pain management in spinal metastases:the role of percutaneous vertebral augmentation.Ann Oncol 22:782-786,2010.
PubMed
8) Kohno N,et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized,placebo-controlled trial.J Clin Oncol 23:3314-3321,2005.
 
9) Gnant M,et al:Endocrine therapy plus zoledronic acid in premenopausal breast cancer.N Engl J Med 360:679-691,2009.
PubMed
10) Coleman RE,et al:Breast-cancer adjuvant therapy with zoledronic acid.N Engl J Med 365:1396-1405,2011.
PubMed
11) Yoneda T,et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research,Japan Osteoporosis Society,Japanese Society of Periodontology,Japanese Society for Oral and Maxillofacial Radiology,and Japanese Society of Oral and Maxillofacial Surgeons.J Bone Miner Metab 28:365-383,2010
PubMed
12) Storto G,et al:Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.Bone 39:35-41,2006.
PubMed
13) Stopeck AT,et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,double-blind study.J Clin Oncol 28:5132-5139,2010.
PubMed
14) Takahashi S,et al:Phase I study of dasatinib(BMS-354825) in Japanese patients with solid tumors.Cancer Sci 102:2058-2064,2011.
PubMed
15) Ono K,et al:Involvement of hepatocyte growth factor in the development of bone metastasis of a aylor PJ,et al:Emerging therapies to prevent skeletal morbidity in men with prostate cancer.J Clin Oncol 29:3705-3714,2011.
 
16) Saylor PJ,et al:Emerging therapies to prevent skeletal morbidity in men with prostate cancer.J Clin Oncol 29:3705-3714,2011.
PubMed
17) Previdi S,et al:Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib(ARQ 197) and shRNA c-MET knockdown.Mol Cancer Ther 11:214-223,2012.
PubMed
P.129 掲載の参考文献
1) Hoe AL,et al:Breast liver metastases-incidence,diagnosis and outcome.J R Soc Med 84:714-716,1991.
PubMed
2) Wingo PA,et al:Cancer statistics,1995.CA Cancer J Clin 45:8-30,1995.
PubMed
3) Rubino A,et al:Hepatic metastases from breast cancer.Updates Surg 62:143-148,2010.
PubMed
4) Atalay G,et al:Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era:a retrospective analysis of two prospective,randomised metastatic breast cancer trials.Eur J Cancer 39:2439,2003.
 
5) Fisher B,et al:Twenty-five-year followup of a randomized trial comparing radical mastectomy,total mastectomy,and total mastectomy followed by irradiation.N Engl J Med 347:567-575,2002.
PubMed
6) Fisher B,et a1:Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl JMed 347:1233-1241,2002.
 
7) Insa A,et al:Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer:analysis of 439 patients.Breast Cancer Res Treat 56:67-78,1999.
PubMed
8) Eichbaum MH,et al:Prognostic factors for patients with liver metastases from breast cancer.Breast Cancer Res Treat 96:53-62,2006.
PubMed
9) Brookes M,et al:Metastatic carcinoma of the breast:the appearances of metastatic spread to the abdomen and pelvis as demonstrated by CT.Br J Radiol 80:284-292,2007.
 
10) Baskaran V,et al:Do the progesterone receptors have a role to play in gallbladder cancer? Int J Gastrointest Cancer 35:61-68,2005.
PubMed
11) Nakamura S,et al:Estrogen and progesterone receptors in gallbladder cancer.JPn J Surg 19:189-194,1989.
 
12) Nash JW,et al:The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver.Arch Pathol Lab Med 127:1591-1595,2003.
PubMed
13) Harder J,et al:EGFR and HER2 expression in advanced biliary tract cancer.World J Gastroenterol 15:4511-4517,2009.
PubMed
14) Shimonishi T,et al:Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver.Histopathology 37:55-63,2000.
PubMed
15) Giordano SH,et al:Is breast cancer survival improving? Cancer 100:44-52,2004.
PubMed
16) Hortobagyi GN:Treatment of breast cancer.N Engl J Med 339:974-984,1998.
PubMed
17) Wilcken N,et al:Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer.Cochrane Database Syst Rev:CDOO2747,2003.
PubMed
18) Adam R,et al:Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897-908,2006.
PubMed
19) Hoffmann K,et al:Liver resection for multimodal treatment of breast cancer metastases:identification of prognostic factors.Ann Surg Oncol 17:1546-1554,2010.
PubMed
20) Thelen A,et al:Liver resection for metastases from breast cancer.J Surg Oncol 97:25-29,2008.
PubMed
21) Lermite E,et al:Surgical resection of liver metastases from breast cancer.Surg Oncol 19:e79-84,2010.
 
22) Pocard M,et al:Hepatic resection in metastatic breast cancer:results and prognostic factors.Eur J Surg Oncol 26(2):155-159,2000.
PubMed
23) Caralt M,et al:Hepatic resection for liver metastases as part of the"oncosurgical"treatment of metastatic breast cancer.Ann Surg Oncol 15:2804-2810,2008.
PubMed
24) Yoshimoto M,et al:Surgical treatment of hepatic metastases from breast cancer.Breast Cancer Res Treat 59:177-184,2000.
PubMed
25) Bergenfeldt M,et al:Liver resection and local ablation of breast cancer liver metastases-a systematic review.Eur J Surg Oncol 37:549-557,2011.
PubMed
26) Abbott DE,et al:Resection of liver metastases from breast cancer:Estrogen receptor status and response to chemotherapy before metastasectomy define outcome.Surgery 151:710-716,2012.
PubMed
27) Elias D,et al:An attempt to clarify indications for hepatectomy for liver metastases from breast cancer.Am J Surg 185:158-164,2003.
PubMed
28) Martinez SR,et al:The utility of estrogen receptor,progesterone receptor,and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases.Am J Surg 191(2):281-283,2006.
PubMed
29) d'Annibale M,et al:Liver metastases from breast cancer:the role of surgical treatment.Hepatogastroenterology 52:1858-1862,2005.
PubMed
30) Chua TC,et al:Hepatic resection for metastatic breast cancer:a systematic review.Eur J Cancer 47:2282-2290,2011.
PubMed
31) Mocellin S,et al:Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer:the end of an era?J Clin Oncol 25:5649-5654,2007.
PubMed
32) Tanaka K,et al:Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver.Br J Surg 90:963-969,2003.
 
33) Adam R,et al:Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy:a model to predict long-term survival.Ann Surg 240:644-657,2004.
 
34) Fraschini G,et al:Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer.Cancer Treat Rep 71:1001-1005,1987.
PubMed
35) Ikeda T,et al:Aphase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer:a Japan Clinical Oncology Group(JCOG) study 9113.JCOG Breast Cancer Study Group.JPn J Clin Oncol 29:23-27,1999.
 
36) Maes T,et al:Intra-hepatic Mitomycin C bolus infUsion in the treatment of extensive liver metastases of breast cancer.Breast Cancer Res Treat 110:135-142,2008.
PubMed
37) Shibata T,et al:Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.Cancer 89:276-284,2000.
PubMed
38) Tanaka K,et al:Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver.Surgery 139:263-273,2006.
 
39) Park IJ,et al:Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery.Ann Surg Oncol 15:227-232,2008.
PubMed
40) Ogata Y,et al:Intraoperative thermal ablation therapy for small colorectal metastases to the liver.Hepatogastroenterology 55:550-556,2008.
 
P.134 掲載の参考文献
1) Patanaphan V,et al:Breast cancer:metastatic patterns and their prognosis.South Med J 81:1109-1112,1988.
PubMed
2) 蒔田益次郎ほか:乳癌術後初再発部位と再発時期の検討.乳癌の臨床 19:343-351,2004.
Medical*Online
3) 藤田崇史ほか:乳癌術後患者における孤立性肺腫瘤に対する鑑別診断.乳癌の臨床 24:571-578,2009.
Medical*Online
4) 北田浩二ほか:術中原発性肺癌と診断された術後36年目の乳癌孤立性肺転移の1例.日臨外会誌 66:1303-1307,2005.
 
5) Smid M,et al:Subtypes of breast cancer show preferential site of relapse.Cancer Res 68:3108-3114,2008.
PubMed
6) Driouch K,et al:Confounding effects in"a six-gene signature predicting breast cancer lung metastasis":reply.Cancer Res 69:9507-9511,2009.
 
7) 中川徹:転移性肺腫瘍のCT 形態,HRCT所見及び病理組織像との対比.日本医放会誌 56:1032-1038,1996.
 
8) 塩谷清司ほか:Thin-slice CT画像を用いた孤立性の転移性肺腫瘍の解析.肺癌 35:775-782,1995.
 
9) 菊池真理ほか:乳癌肺転移のMDCTによる画像的特徴.乳癌の臨床 24:579-586,2009.
Medical*Online
10) Yatabe Y,et al:TTF-1 expression in pulmonary adenocarcinomas.Am J Surg Pathol 26:767-773,2002.
PubMed
11) Bhargava R,et al:Mammaglobin vs GCDFP-15:an immunohistologic validation survey for sensitivity and specificity.Am J Clin Pathol 127:103-113,2007.
PubMed
12) Sasaki E,et al:Breast-specific expression of MGB1/mammaglobin:an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers.Mod Pathol20:208-214,2007.
PubMed
13) Staren ED,et al:Pulmonary resection for metastatic breast cancer.Arch Surg 127:1282-1284,1992.
PubMed
14) Planchard D,et al:Uncertain benefit from surgery in patients with lung metastases from breast carcinoma.Cancer 100:28-35,2004.
PubMed
15) Friedel G,et al:Results of lung metastasectomy from breast cancer:prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases.Eur J Cardiothorac Surg 22:335-344,2002.
PubMed
P.138 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2.疫学・診断編2011年版,p156-166,金原出版,2011.
 
2) Schellinger PD, et al:Diagnostic accuracy of MRI compared to CCT in patients with brainmetastases.J Neurooncol 44(3):275-281,1999.
 
3) Gaspar L,et al:Recursive partitioning analysis(RPA) of prognostic factors in three Radiation Therapy Oncology Group(RTOG) brain metastases trials.Int J Radiat Oncol Biol Phys 37(4):745-751,1997.
PubMed
4) Altundag K,et al:Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.Cancer 110(12):2640-2647,2007.
PubMed
5) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン1.治療編2011年版,p96-98,p244-245,p313-316,金原出版,2011.
 
6) Linskey ME,et al:The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases:a systematic review and evidence-based clinical practice guideline.J Neurooncol 96(1):45-68,2010.
PubMed
7) Aoyama H,et al:Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases:a randomized controlled trial JAMA 295(21):2483-2491,2006.
PubMed
8) Kalkanis SN,et al:The role of surgical resection in the management of newly diagnosed brain metastases:a systematic review and evidence-based clinical practice guideline.J Neurooncol 96(1):33-43, 2010.
PubMed
9) Lin NU,et al:CNS metastases in breast cancer.J Clin Oncol 22(17):3608-3617,2004.
PubMed
10) Lien EA,et al:Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.Cancer Res 51:4837-4844,1991.
PubMed
11) Rosner D,et al:Chemotherapy induces regression of brain metastases in breast carcinoma.Cancer 58(4):832-839,1986.
PubMed
12) Dahabreh IJ,et al:Trastuzumab in the adjuvant treatment of early-stage breast cancer:a systematic review and meta-analysis of randomized controlled trials.Oncologist 13(6):620-630,2008.
PubMed
13) Lin NU,et al:Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol 26(12):1993-1999,2008.
PubMed
14) Lin NU,et al:Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.Clin Cancer Res 15(4):1452-1459,2009.
PubMed
P.142 掲載の参考文献
1) Harris M,et al:A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast.Br J Cancer 50:23-30,1984.
 
2) Acs G,et al:Different expression of E-cadherin in ductal and lobular carcinoma of the breast.Mod Pathol 13:17A,2000.
 
3) 芥川篤史ほか:胃転移を来した乳癌の一例.日臨外会誌 59:2808-2812,1998.
 
4) 安本和生:転移性胃癌の頻度.日本医事新報 No.4479:95-97,2010.
 
5) 斎藤大三ほか:転移性胃腫瘍の内視鏡的検討.Progress of Digestive Endoscopy 20:138-142,1982.
 
6) 田邊渉ほか:転移性胃腫瘍28例の検討.倉敷中央病院年報 71:19-24,2008.
Medical*Online
7) 佐野量造:胃疾患の臨床病理,医学書院,1974.
 
8) Weingold AB,Boltouch SM:Extragenital metastasis to the uterus.Am J Obstet Gynecol 82:1267-1272,1961.
 
9) Oda I,et al:Metastaic tumors to the stomach:analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases.Endoscopy 33(6):507-510,2001.
 
10) 北村匡:スキルス胃癌と鑑別を要する腫瘍性疾患.胃と腸 45(4):489-492,2010.
 
11) Cormier WJ,et al:Linitis plastica caused by metastatic lobular carcinoma of breast.Mayo Clin Proc 55:747-753,1980.
PubMed
12) 平野誠ほか:Paclitaxel weekly投与が奏功した乳癌の胃および腹膜転移再発の一例.乳癌の臨床 16:621-626,2001.
 
13) 梅村しのぶ:各臓器,疾患で用いられる抗体とその応用-乳腺.病理と臨床 25(臨時増刊号):180-181,2007.
 
14) 唐橋喜美,松倉史朗:GDP-PETにて検出されず診断に難渋した乳癌胃転移の一例.消化器外科 33:1489-1493,2010.
 
15) Kumar A,Schneider V:Metastasis to the uterus from extrapelvic primary tumor.Int J Gynecol Pathol 12:134,1983.
 
P.145 掲載の参考文献
1) Jayson GC,et al:Carcinomatous meningitis in patients with breast cancer.An aggressive disease variant.Cancer 74:3135-3141,1994.
PubMed
2) Hitchins RN,et al:Aprospective randomized trial of single-agent carcinomatosis.J Clin Oncol 5:1655-1662,1987.
 
3) Grossman SA,et al:Leptomeningial carcinomatosis.Cancer Treat Rev 25:103-119,1999.
 
4) Glantz MJ,et al:Diagnosis,management,and survival of patients with eptomeningeal cancer based on cerebrospinal fluid-flow status.Cancer 75:2919,1995.
PubMed
5) Balm M,et al:Leptomeningeal carcinomatosis.Arch Neurol 53:626-632,1996.
PubMed
6) Boogerd W,et al:Meningeal carcinomatosis in breast cancer,Prognostic factors and influence of treatment.Cancer 67:1685-1695,1991.
PubMed
7) Boogerd W,et al:The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer:a randomised study.Eur J Cancer 40(18):2726-2733,2004.
PubMed
8) Rudnicka H,et al:Breast cancer leptomeningeal metastasis-the role of multimodality treatment.J Neurooncol 84(1):57-62,2007.
PubMed
9) Jaeckle KA,et al:Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.Br J Cancer 84:157-163,2001.
PubMed
10) Bendell JC,et al:Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer 97(12):2972-2977,2003.
PubMed
11) Baculi RH,et al:Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.J Clin Oncol 19:3297-3298,2001.
 
12) Laufman LR,Forsthoefel KF:Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.Clin Breast Cancer 2:235,2001.
 
13) Gutierrez M,et al:Leptomeningeal meningitis related to breast cancer overexpressing HER2:is there a place for a more specific treatment? Bull Cancer 98(4):417-424,2011.
 
14) Abrey LE et al:Aphase II trial of temozolomide for patients with recurrent or progressive brain metastases.J Neurooncol 53:259-265,2001.
PubMed
15) Lin NU,et al:Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.Clin Cancer Res 15(4):1452-1459,2009.
PubMed

V 乳癌の予後因子

P.153 掲載の参考文献
1) Bilimoria KY,et al:Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.J Clin Oncol 27:2946-2953,2009.
PubMed
2) de Boer M,et al:Micrometastases or isolated tumor cells and the outcome of breast cancer.N Engl J Med 361:653-663,2009.
 
3) Fisher B,et al:Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients:findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.J Clin Oncol 6:1076-1087,1988.
 
4) Tamoxifen for early breast cancer:an overview of the randomised trials.Early Breast Cancer Trialis'Collaborative Group.Lancet 351:1451-1467,1998.
 
5) Slamon DJ,et al:Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235:177-182,1987.
PubMed
6) Cobleigh MA,et al:Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 17:2639-2648,1999.
PubMed
7) Dawood S,et al:Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment:an institutional-based review.J Clin Oncol 28:92-98,2010.
PubMed
8) Yerushalmi R,et al:Ki67 in breast cancer:prognostic and predictive potential.Lancet Oncol 11:174-183,2010.
PubMed
9) Sorlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
PubMed
10) Paik S,et al:Amultigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med 351:2817-2826,2004.
PubMed
11) van de Vijver MJ,et al:Agene-expression signature as a predictor of survival in breast cancer.NEngl J Med 347:1999-2009,2002.
 
12) Goldhirsch A et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.Ann Oncol 22:1736-1747,2011.
PubMed
13) Cristofanilli M,et al:Circulating tumor cells,disease progression,and survival in metastatic breast cancer.N Engl J Med 351:781-791,2004.
PubMed
14) Nakamura S,et al:Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.Breast Cancer 17:199-204,2010.
PubMed
15) Yagata H,et al:Evaluation of circulating tumor cells in patients with breast cancer:multi-institutional clinical trial in Japan.Int J Clin Oncol 13:252-256,2008.
PubMed
16) Honma N,et al:Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.J Clin Oncol 26:3727-3734,2008.
PubMed
17) Peters AA,et al:Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.Cancer Res 69:6131-6140,2009.
PubMed
P.157 掲載の参考文献
1) Krag DN,Single RM:Breast cancer survival according to number of nodes removed.Ann Surg Oncol 10:1152-1159,2003.
PubMed
2) Joslyn SA,Konety BR:Effect of axillary lymphadenectomy on breast carcinoma survival.Breast Cancer Res Treat 91:11-18,2005.
PubMed
3) Tausch C,et al:Prognostic value of number of removed lymph nodes,number of involved lymph nodes,and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group(ABCSG).Ann Surg Oncol 19:1808-1817,2012.
 
4) Sosa JA,et al:Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.Ann Surg Oncol 5:140-149,1998.
 
5) Camp RL,et al:A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome.Cancer 88:108-113,2000.
PubMed
6) Moorman PG,et al:Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative breast carcinoma.Cancer 91:2258-2262,2001.
PubMed
7) Blancas I,et al:Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.Ann Oncol 17:1644-1649,2006.
PubMed
8) Vinh-Hung V,et al:Effect of the number of uninvolved nodes on survival in early breast cancer.Oncol Rep 10:363-368,2003.
PubMed
9) Weir L,et al:Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer.J Clin Oncol 20(7):1793-1799,2002.
PubMed
P.161 掲載の参考文献
1) Haupt Y,et al:Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice Cell 65:753-763,1991.
 
2) Smith KS,et al:Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1.Mol Cell 12:393-400,2003.
PubMed
3) Dimri GP,et al:The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells.Cancer Res 62:4736-4745,2002.
PubMed
4) Alkema MJ,et al:Characterization and chromosomal localization of the human proto-oncogene BMI-1.Hum Mol Genet 2:1597-1603,1993.
PubMed
5) Liu S,et al:Hedgehog signaling and Bm-1 regulate self-renewal of normal and malignant human mammary stem cells.Cancer Res 66:6063-6071,2006.
 
6) Datta S,et al:Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways.Cancer Res 67:10286-10295,2007.
 
7) Glinsky GV,et al:Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.J Clin Invest 115:1503-1521,2005.
 
8) Li DW,et al:Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer.J Cancer Res Clin Oncol 136:997-1006,2010.
PubMed
9) Song LB,et al:Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells.Cancer Res 66:6225-6232,2006.
PubMed
10) Kim JH,et al:Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer.Breast 13:383-388,2004.
PubMed
11) Silva J,et al:Implication of polycomb members Bmi-1,Mel-18,and Hpc-2 in the regulation of p161NK4a,p14ARF,h-TERT,and c-Myc expression in primary breast carcinomas.Clin Cancer Res 12:6929-6936,2006.
 
12) Guo BH,et al:Bmi-1 promotes invasion and metastasis,and its elevated expression is correlated with an advanced stage of breast cancer.Mol Cancer 10(1):10,2011.
PubMed
13) Silva J,et al:Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients.Breast Cancer Res 9(4):R55,2007.
PubMed
14) Choi YJ,et al:Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients.Breast Cancer Res Treat 113:83-93,2009.
PubMed
P.165 掲載の参考文献
1) Fisher B,et al:Effect of preoperative chemotherapy on local-region disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol 15(7):2483-2493,1997.
PubMed
2) Buzdar AU,et al:Significantly high pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicine chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol 23(16):3676-3685,2005.
 
3) Semiqlazov V,et al:Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or infiammatory breast cancer participating in the NeOAdjuvant Herceptin(NOAH) study.Eur J Surg Oncol 37(10):856-863,2011.
 
4) Kong X,et al:Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients.Eur J Cancer 47:2084-2090,2011.
PubMed
5) Loibl S,et al:Comparison of survival according to pathological complete response(pCR) in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy with and w/o trastuzumab compared to patients with HER2-negative tumors.S5-4,SABCS2011.
 
6) Fisher B,et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16(8):2672-2685,1998.
PubMed
7) Wolmark N,et al:Preoperative chemotherapy in patients with operable breast cancer:nine-year results from national surgical adjuvant breast and bowel project B-18.J Natl Cancer Inst Monogr 30:96-102,2001.
PubMed
8) Gonzalez-Angulo AM,et al:Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.J Clin Oncol 23(28):7098-7104, 2005.
PubMed
9) Ring AE,et al:Oestrogen receptor status,pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.Br J Cancer 91:2012-2017,2004.
PubMed
10) Tanioka M,et al:Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.Br J Cancer 103:297-302,2010.
PubMed
11) Nagashima T,et al:Tumor reduction rate predicts early recurrence in patients with breast cancer failing to achieve complete response to primary chemotherapy.Breast Cancer 17:125-130.2010.
PubMed
P.169 掲載の参考文献
1) Abate-Shen C:Deregulated homeobox gene expression in cancer:cause or consequence? Nat Rev Cancer 2:777-785,2002.
 
2) Cantile M,et al:In vivo expression of the whole HOX gene network in human breast cancer.Eur J Cancer 39:257-264,2003.
PubMed
3) Garcia-Fernandez J:The genesis and evolution of homeobox gene clusters.Nat Rev Genet 6:881-892,2005.
PubMed
4) Chen F,et al:Analysis of Hoxa7/Hoxb7 mutants suggests periodicity in the generation of the different sets of vertebrae.Mech Dev 77:49-57,1998.
PubMed
5) Wu X,et al:HOXB7,a homeodomain protein,is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66:9527-9534,2006.
PubMed
6) Ma XJ,et al:A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.Cancer Cell 5:607-616,2004.
PubMed
7) Calvo R,et al:Altered HOX and WNT7A expression in human lung cancer.Proc Natl Acad Sci USA 97:12776-12781,2000.
PubMed
8) Nguyen DX,et al:WNT/TCF signaling through LEFI and HOXB9 mediates lung adenocarcinoma metastasis.Cell 138:51-62,2009.
 
9) Hayashida T,et al:HOXB9,a gene overexpressed in breast cancer,promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 107:1100-1105,2010.
PubMed
10) Chiba N,et al:Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses.Proc Natl Acad Sci USA 109:276-2765,2012.
 
11) Seki H,et al:HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients.Ann Surg Oncol 19:1831-1840,2012.
 
12) Sarri6 D,et al:Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.Cancer Res 68:989-997,2008.
 
13) Ganapathy V,et al:Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.Mol Cancer 9:122,2010.
PubMed
14) Millanta F,et al:Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas.Vet Pathol 39:690-696,2002.
PubMed
15) Weidner N,et al:Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma.N Engl J Med 324:1-8,1991.
PubMed
16) Uzzan B,et al:Microvessel density as a prognostic factor in women with breast cancer:a systematic review of the literature and meta-analysis.Cancer Res 64:2941-2955,2004.
PubMed
17) Jain RK:Molecular regulation of vessel maturation.Nat Med 9:685-693,2003.
PubMed
18) Raman V,et al:HOXA5 regulates expression of the progesterone receptor.J Biol Chem 275:26551-26555,2000.
PubMed
19) Lechner JF,et al:Perspective:cell ditferentiation theory may advance early detection of and therapy for lung cancer.Radiat Res 155:235-238,2001.
PubMed
20) Ybshida H,et al:Deregulation of the HOXA10 homeobox gene in endometrial carcinoma:role in epithelial-mesenchymal transition.Cancer Res 66:889-897,2006,
 
21) Naora H,et al:A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.Proc Natl Acad Sci USA 98:4060-4065,2001.
PubMed
22) Miller GJ,et al:Aberrant HOXC expression accompanies the malignant phenotype in human prostate.Cancer Res 63:5879-5888,2003.
PubMed
23) Carrio M,et al:Homeobox D10 induces phenotypic reversion of breast tumor cells in a threedimensional culture model.Cancer Res 65:7177-7185,2005.
 
P.173 掲載の参考文献
1) Rakha EA,et al:Basal-like breast cancer:a critical review.J Clin Oncol 26(15):2568-2581,2008.
PubMed
2) Toyama T,et al:Frequently increased epidermal growth factor receptor(EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.BMC Cancer 8:309,2008.
PubMed
3) Nilsen TW:Mechanisms of microRNA-mediated gene regulation in animal cells.Trends Genet 23(5):243-249,2007.
PubMed
4) Esquela-Kerscher A,Slack FJ:Oncomirs-microRNAs with a role in cancer.Nat Rev Cancer 6(4):259-269,2006.
PubMed
5) Keith B,Simon MC:Hypoxia-inducible factors,stem cells,and cancer.Cell 129(3):465-472,2007.
PubMed
6) Huang X,et al:Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumorinitiation.Mol Cell 35(6):856-867,2009.
 
7) Huang X,et al:MiR-210-micromanager of the hypoxia pathway.Trends Mol Med 16(5):230-237,2010.
PubMed
8) Foekens JA,et al:Four miRNAs associated with aggressiveness of lymph node-negative,estrogen receptor-positive human breast cancer.Proc Natl Acad Sci USA 105(35):13021-13026,2008.
PubMed
9) Camps C,et al:hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer.Clin Cancer Res 14(5):1340-1348,2008.
PubMed
10) Puissegur MP,et al:miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity.Cell Death Differ 18(3):465-478,2011.
PubMed
11) Gee HE,et a1:hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.Cancer 116(9):2148-2158,2010.
 
12) Toyama T,et al:High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients.JPn J Clin Oncol 42:256-263,2012.
PubMed
13) Chan SY,Loscalzo J:MicroRNA-210:a unique and pleiotropic hypoxamir.Cell Cycle 9(6):1072-1083,2010.
PubMed
14) Chan SY,et al:MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2.Cell Metab 10(4):273-284,2009.
PubMed
15) Denko NC:Hypoxia,HIF1 and glucose metabolism in the solid tumour.Nat Rev Cancer 8(9):705-713,2008.
PubMed
P.178 掲載の参考文献
1) Hirano A,et al:Allelic losses of loci at 3p25.1,8p22,13q12,17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer.Clin Cancer Res 7:876-882,2001.
PubMed
2) Hirano A,et al:Allelic losses as prognostic markers for breast cancers.Int J Clin Oncol 6:6-12,2001.
PubMed
3) Ching HC,et al:Integrated analysis of copy number and loss of heterozygosity in primary breast carcinomas using high-density SNP array.Int J Oncol 39:621-633,2011.
PubMed
4) Hawthorn L,et al:Integration of transcript expression,copy number and LOH analysis of infiltrating ductal carcinoma of the breast.BMC Cancer 10:460,2010.
PubMed
5) Fang M,et al:Genomic differences between estrogen receptor(ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.Cancer 117:2024-2034,2011.
PubMed
6) Esteller M,et al:DNA methylation patterns in hereditary human cancers mirnic sporadic tumorigenesis.Hum Mol Genet 10:3001-3007,2001.
 
7) Osorio A,et al:Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.Int J Cancer 99:305-309,2002.
PubMed
8) Bell DW,et al:Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.Cancer Res 62:2741-2743,2002.
PubMed
9) Staff S,et al:Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.Br J Cancer 85:1201-1205,2001.
PubMed
10) Tung N,et al:Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.Breast Cancer Res 12:R95,2010.
PubMed
11) Okada S,et al:Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.Ann Surg Oncol 19:1499-1507,2012.
 
12) Silva JM,et al:Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.Breast Cancer Res Treat 53:9-17,1999.
PubMed
13) Rhiem K et al:Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.Anticancer Res 30:3445-3449,2010.
PubMed
14) Staff S,et al:Haplo-insufflciency of BRCA1 in sporadic breast cancer.Cancer Res 63:4978-4983,2003.
 
15) Tirkkonen M,et al:Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.Cancer Res 57:1222-1227,1997.
PubMed
16) Konishi H,et al:Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.Proc Natl Acad Sci USA 108:17773-17778,2011.
PubMed
17) Cousineau I,Belmaaza A:BRCA1 haploinsufficiency,but not heterozygosity for a BRCA1-truncating mutation,deregulates homologous recombination.Cell Cycle 6:962-971,2007.
 
18) Rennstam K,et al:Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.Genes Chromosomes Cancer 49:78-90,2010.Erratum in:Genes Chromosomes Cancer 49:760-761,2010.
 
19) King TA,et al:Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.Ann Surg Oncol 14:2510-2518,2007.
PubMed
20) 三好康雄:Triple negative乳癌の生物学的特徴-BRCA1変異乳癌の特徴-.Triple negative乳癌(戸井雅和編),p22-29,南山堂,2010.
 
21) Gonzalez R,et al:Detection of loss of heterozygosity at RAD51,RAD52,RAD54 and BRCA1 and BRCA2 loci in breast cancer:pathological correlations.Br J Cancer 81:503-509,1999.
PubMed
22) Hampl JA,et al:Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.Anticancer Res 24:281-290,2004.
PubMed
P.184 掲載の参考文献
1) Scholzen T,Gerdes J:The Ki-67 protein:from the known and the unknown.J Cell Physiol 182:311-322,2000.
PubMed
2) Beckmann MW,et al:Zurich Consensus:German Expert Opinion on the St.Gallen Votes on 15 March 2009(11th International Conference at St.Gallen:Primary Therapy of Early Breast Cancer).Breast Care(Basel) 4:109-116,2009.
PubMed
3) de Azambuja E,et al:Ki-67 as prognostic marker in early breast cancer:a meta-analysis of published studies involving 12,155 patients.Br J Cancer 96:1504-1513,2007.
PubMed
4) Urruticoechea A,et al:Proliferation marker Ki-67 in early breast cancer.J Clin Oncol 23:7212-7220,2005.
PubMed
5) Guarneri V,et al:A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.Ann Oncol 20:1193-1198,2009.
PubMed
6) Fasching PA,et al:Ki67,chemotherapy response,and prognosis in breast cancer patients receiving neoadjuvant treatment.BMC Cancer 11:486,2011.
PubMed
7) 緒方昭彦ほか:術前化学療法後の遺残腫瘍におけるKi-67高発現の再発予測因子としての有用性.第18回日本乳癌学会学術総会 O-052,2010.
 
8) Jacquemie J,et al:Protein cxpression,survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.Breast Cancer Res 13:R109,2011.
 
9) Penault-Llorca F,et al:Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.J Clin Oncol 27:2809-2815,2009.
PubMed
10) Hugh J,et al:Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial.J Clin Oncol 27:1168-1176,2009.
 
11) Viale G,et al;Breast International Group Trial 1-98:Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer:results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.J Clin Oncol 26:5569-5575,2008.
 
12) Dowsett M,et al;IMPACT Trialists Group:Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.J Natl Cancer Inst 99:167-170,2007.
PubMed
13) Smith E,et al;IMPACT Trialists Group:Neoadjuvant treatment of postmenopausal breast cancer with anastrozole,tamoxifen,or both in combination:The Immediate Preoperative Anastrozole,Tamoxifen,or Combined With Tamoxifen(IMPACT) multicenter double-blind randomized trial.J Clin Oncol 23:5108-5116,2005.
 
14) Ellis MJ,et al:Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst 100:1380-1388,2008.
PubMed
15) Cheang MC,et al:Ki67 index,HER2 status,and prognosis of patients with luminal B breast Cancer.J Natl Cancer Inst 101:736-750,2009.
PubMed

VI 乳癌取扱い規約・乳癌診療ガイドライン

P.190 掲載の参考文献
1) Pathology and Genetics Tumours of the Breast and Female Genital Organs(ed by Tavassoeli FA,Devilee P),IARC Press,Lyon,2003.
 
2) UICC(ed by Sobin Let,et al):TNM Classification of Malignant Tumours 7th ed,Wiley-Blackwell,New York,2009.
 
3) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約(第16版),金原出版,2008.
 
4) Institute of Medicine:Guidelines for Clinical Practice:from Development to Use. National Academy Press,Washington DC,1992.
 
5) 中山健夫:診療ガイドライン:現状と今後の展望.Gout and Nucleic Acid Metabolism 33(2):137-147,2007.
 
6) 福井次矢ほか(編),Minds診療ガイドライン選定部会(監修):Minds診療ガイドライン作成の手引き 2007,医学書院,2007.
 
7) 中山健夫:EBMの手法を用いた診療ガイドライン:日本における取り組み・課題と展望.日補完代替医療会誌 2(2):113-125,2005.
 
8) 中山健夫:EBMを用いた診療ガイドライン:作成・活用ガイド,p78-80,金原出版,2004.
 
9) 津谷喜一郎,長澤道行:医師と診療ガイドライン:"professional autonomy"の視点から.日医師会誌 129:1783-1803,2003.
 
10) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン1.薬物療法,金原出版,2004.
 
11) 高塚雄一:乳癌診療ガイドラインの概要.日本臨牀 65(6):175-181,2007.
 
P.194 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理乳癌取扱い規約,第16版,金原出版,2008.
 
2) UICC TNM Classification of Malignant Tumours,7th ed(ed by Sobin LH,et al),Wiley-Blackwell,New York,2009.
 
3) UICC TNM Classification of Malignant Tumours,6th ed(ed by Sobin LH,et al),Wiley-Blackwell,New York,2002.
 
4) 日本乳癌学会(編):臨床・病理乳癌取扱い規約,第15版,金原出版,2004.
 
5) Veronesi U,et al:Rethinking TNM:a breast cancer classification to guide to treatment and facilitate reserch.Breast J 15:291-295,2009.
 
6) Arnone P,et al:The TNM classification of breast cancer:need for change.Updates Surg 62:75-81,2010.
PubMed
P.200 掲載の参考文献
1) Griggs JJ,et al:American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.J Clin Oncol 29:3939-3942,2011.
 
2) Cuzick J,et al:Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer:a meta-analysis of individual patient data from randomised adjuvant trials.Lancet 369:1711-1723,2007.
PubMed
3) Amir E,et al:Tissue confirmation of disease recurrence in patients with breast cancer:Pooled analysis of two large prospective studies.J Clin Oncol 28(Suppl):15s,2010.
 
4) Krueger EA,et al:Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy.Int J Radiat Oncol Biol Phys 49:713-721,2001.
PubMed
5) Anderson PR,et al:Low complication rates are achievable after postmastectomy breast reconstruction and radiation therapy.Int J Radiat Oncol Biol Phys 59:1080-1087,2004.
PubMed
6) Cuzick J,et al:Overview of the main outcomes in breast-cancer prevention trials.Lancet 361:296-300,2003.
PubMed
7) Fagerlin A,et al:Women's interest in taking tamoxifen and raloxifene for breast cancer prevention:response to a tailored decision aid.Breast Cancer Res Treatment 127:681-688,2011.
PubMed
8) Force UPST:Screening for breast cancer:U.S.Preventive Services Task Force recommendation statement.Ann Intern Med 151:716-726,W-236,2009.
 

VII 乳癌治療戦略を目指した基礎研究

P.206 掲載の参考文献
1) Maheswaran S,et al:Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med 359:366-377,2008.
PubMed
2) Chambers AF,et al:Dissemination and growth of cancer cells in metastatic sites.Nat Rev Cancer 2:563-572,2002.
PubMed
3) Paget S:The distribution of secondary growths in cancer of the breast.Lancet 1:571-573,1889.
 
4) Fidler IJ:The pathogenesis of cancer metastasis:the 'seed and soil' hypothesis revisited.Nat Rev Cancer 3:453-458,2003.
PubMed
5) Stoker M,et al:Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.Nature 327:239-242,1987.
PubMed
6) Vega S,et al:Snail blocks the cell cycle and confers resistance to cell death.Genes Dev 18:1131-1143,2004.
PubMed
7) Ono Y,et al:Direct inhibition of the transforming growth factor-beta pathway by protein-bound polysaccharide through inactivation of Smad2 signaling.Cancer Sci 103:317-324,2012.
PubMed
8) Mani SA,et al:The epithelial-mesenchymal transition generates cells with propenies of stem cells.Cell 133:704-715,2008.
PubMed
9) Shipitsin M,et al:Molecular definition of breast tumor heterogeneity.Cancer Cell 11:259-273,2007.
PubMed
10) Gupta PB,et al:Identification of selective inhibitors of cancer stem cells by high-throughput screening.Cell 138:645-659,2009.
PubMed
11) Kudo-Saito C,et al:Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.Cancer Cell 15:195-206,2009.
PubMed
12) Zeng Q,et al:CD146,an epithelial-mesenchymal transition inducer,is associated with triple-negative breast cancer.Proc Natl Acad Sci USA 109:1127-1132,2012.
PubMed
13) Hayashida T,et al:HOXB9,a gene overexpressed in breast cancer,promotes tumorigenicity and lung metastasis.Proc Natl Acad Sci USA 107:1100-1105,2010.
PubMed
14) Seki H,et al:HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients.Ann Surg Oncol 19:1831-1840,2012.
 
P.213 掲載の参考文献
1) Trinchieri G:Biology of natural killer cells.Adv Immunol 47:187-376,1989.
PubMed
2) Robertson MJ,Ritz J:Biology and clinical relevance of human natural killer cells.Blood 76:2421-2438,1990.
PubMed
3) Ishiyama K,et al:Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.Hepatology 43:362-372,2006.
PubMed
4) Ochi M,et al:Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice.Hepatology 39:1321-1331,2004.
PubMed
5) Cullen SP,Martin SJ:Mechanisms of granule-dependent killing.Cell Death Differ 15:251-262,2008.
PubMed
6) Pardo J,et al:The biology of cytotoxic cell granule exocytosis pathway:granzymes have evolved to induce cell death and inflammation.Microbes Infect 11:452-459,2009.
PubMed
7) Kajitani K,et al:Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.Breast Cancer Res Treat 134:139-155,2012.
PubMed
8) Kendrick JE,et al:Tumor necrosis-related apoptosis-inducing ligand(TRAIL) and its therapeutic potential in breast and gynecologic cancers.Gynecol Oncol 106:614-621,2007.
PubMed
9) Ishigami S,et al:Prognostic value of intratumoral natural killer cells in gastric carcinoma.Cancer 88:577-583,2000.
PubMed
10) Villegas FR,et al:Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.Lung Cancer 35:23-28,2002.
PubMed
11) Helms MW,et al:IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.Cancer Immunol Immunother 59:1325-1334,2010.
PubMed
12) Pegram HJ,et al:Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.Cancer Immunol Immunother 59:1235-1246,2010.
PubMed
13) Iliopoulou EG,et al:Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.Cancer Immunol Immunother 59:1781-1789,2010.
 
14) Milani V,et al:Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy-a case report.J Transl Med 7:50,2009.
PubMed
15) Mahalingam D, et al:TRAIL receptor signaling and modulation:Are we on the right TRAIL? Cancer Treat Rev 35:280-288,2009.
PubMed
P.217 掲載の参考文献
1) Harada N,et al:Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exon I and promoters,and switching of tissue-specific exons I in carcinogenesis.Proc Natl Acad Sci USA 90:11312-11316,1993.
PubMed
2) Miller WR:Aromatase activity in breast tissue.J Steroid Biochem Mol Biol 39:783-790,1991.
 
3) Bolufer P,et al:Aromatase activity and estradiol in human breast cancer:its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.J Clin Oncol 10:438-446,1992.
PubMed
4) Chetrite GS,et al:Comparison of estrogen concentrations,estrone sulfatase and aromatase activities in normal,and in cancerous,human breast tissues.J Steroid Biochem Mol Biol 72:23-27,2000.
PubMed
5) Bulun SE,et al:Regulation of aromatase expression in estrogen-responsive breast and uterine disease:from bench to treatment.Pharmacol Rev 57:359-383,2005.
PubMed
6) Giguere V,et al:Isoform-specific amino-terminal domains dictate DNA-binding properties of RORα,anovel family of orphan hormone nuclear receptors.Genes Dev 8:538-553,1994.
 
7) Dai J,et al:Transcriptional repression of RORα activity in human breast cancer cells by melatonin.Mol Cell Endocrinol 176:111-120,2001.
 
8) Odawara H,et al:Activation of aromatase expression by retinoic acid receptor-related orphan receptor(ROR) alpha in breast cancer cells:identification of a novel ROR response element.J Biol Chem 284:17711-17719,2009.
PubMed
9) Zhao Y,et al:Characterization of the sequences of the human CYP19(aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes Mol Endocrinol 9:340-349,1995.
PubMed
10) 小田原宏樹ほか:乳腺組織のアロマターゼ発現におけるRORαとGRの相互関係. 乳癌基礎研究 20:11-15,2011.
 
11) Lau P,et al:Exogenous expression of a dominant negative RORα1 vector in muscle cells impairs differentiation:RORα1 directly interacts with p300 and myoD.Nucleic Acids Res 27:411-420,1999.
 
12) Gold DA,et al:RORα coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways.Neuron 40:1119-1131,2003.
 
13) Dzhagalov I,et al:Lymphocyte development and function in the absence of retinoic acid-related orphan receptor α.J Immunol 173:2952-2959,2004.
 
14) Lipton A,et al:Prognostic value of breast cancer aromatase.Cancer 70:1951 -1955,1992.
 
15) Silva MC,et al:Intratumoral aromatase as a prognostic factor in human breast carcinoma.Cancer Res 49:2588-2591,1989.
PubMed
P.225 掲載の参考文献
1) Carninci P,et al:The transcriptional landscape of the mammalian genome.Science 309:1559-1563,2005.
PubMed
2) Lee RC,et al:The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell 75:843-854,1993.
 
3) Lagos-Quintana M,et al:Identification of novel genes coding for small expressed RNAs.Science 294:853-858,2001.
PubMed
4) Liu CG,et al:An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.Proc Natl Acad Sci USA 101:9740-9744,2004.
PubMed
5) Lu DP,et al:PCR-based expression analysis and identification of microRNAs.J RNAi Gene Silencing 1:44-49,2005.
PubMed
6) Lu C,et al:MicroRNAs and other small RNAs enriched in the Arabidopsis RNA-dependent RNA polymerase-2 mutant.Genome Res 16:1276-1288,2006.
PubMed
7) Sato F,et al:Intra-platform repeatability and inter-platform comparability of microRNA microarray technology.PLoS One 4:e5540,2009.
PubMed
8) 東レ(株):3D-GeneのmiRNA配列に対する検出特異性,2012.[http://www.3d-gene.com/technical/tec_OO1_07.html]
 
9) Xi Y,et al:Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples.RNA 13:1668-1674,2007.
PubMed
10) Mitchell PS,et al:Circulating microRNAs as stable blood-based markers for cancer detection.Proc Natl Acad Sci USA 105:10513-10518,2008.
PubMed
11) Hanke M,et al:Arobust methodology to study urine microRNA as tumor marker:microRNA-126 and microRNA-182 are related to urinary bladder cancer.Urol Oncol 28:655-661,2010.
 
12) Shi M,et al:Metastasis-related miRNAs,active players in breast cancer invasion,and metastasis.Cancer Metastasis Rev 29:785-799,2010.
PubMed
13) Sorlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
PubMed
14) Blenkiron C,et al:MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.Genome Biol 8:R214,2007.
PubMed
15) Adams BD,et al:The micro-ribonucleic acid(miRNA) miR-206 targets the human estrogen receptor-alpha(ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.Mol Endocrinol 21:1132-1147,2007.
PubMed
16) Adams BD,et al:The role of miR-206 in the epidermal growth factor(EGF) induced repression of estrogen receptor-alpha(ERalpha) signaling and a luminal phenotype in MCF-7 breast cancercells.Mol Endocrinol 23:1215-1230,2009.
 
17) Ferracin M,et al:MicroRNAs:toward the clinic for breast cancer patients.Semin Oncol 38:764-775,2011.
PubMed
18) Maillot G,et al:Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.Cancer Res 69:8332-8340,2009.
PubMed
19) Shibahara Y,et a1:Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f,a microRNA targeting CYP19A1.J Pathol 227:357-366,2012.
 
20) Kovalchuk O,et al:Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.Mol Cancer Ther 7(7):2152-2159,2008.
PubMed
21) Scott GK,et al:Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.J Biol Chem 282:1479-1486,2007.
PubMed
22) Iorio MV,et al:microRNA-205 regulates HER3 in human breast cancer.Cancer Res 69:2195-2200,2009.
PubMed
23) Ichikawa T,et al:Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.PLoS One 7:e31422,2012.
 
24) Yan LX,et al:MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage,lymph ode metastasis and patient poor prognosis.RNA 14:2348-2360,2008.
 
25) Qian B,et al:High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.Breast Cancer Res Treat 117:131-140,2009.
PubMed
26) Camps C,et al:hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer.Clin Cancer Res 14:1340-1348,2008.
PubMed
27) Heneghan HM,et al:Circulating microRNAs as novel minimally invasive biomarkers for breast cancer.Ann Surg 251:499-505,2010.
PubMed
28) 米国国立衛生研究所(NIH) ClinicalTrials.gov.[http://clinicaltrials.gov/]
 
29) 大学病院医療情報ネットワーク(UMIN) UMIN Clinical Trials Registry.[http://www.umin.ac.jp/ctr/]
 
30) Kozomara A,Griffiths-Jones S:miRBase:integrating microRNA annotation and deep-sequencing data.Nucleic Acids Res 39:D152-157,2011.
PubMed
P.231 掲載の参考文献
1) Perou CM,et al:Molecular portraits of human breast tumours.Nature 406:747-752,2000.
PubMed
2) Sorlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
PubMed
3) Weigelt B,et al:Breast cancer molecular profiling with single sample predictors:a retrospective analysis.Lancet Oncol 11:339-349,2010.
PubMed
4) Doane AS,et al:An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.Oncogene 25:3994-4008,2006.
PubMed
5) Mackay A,et al:Microarray-based class discovery for molecular classification of breast cancer:analysis of interobserver agreement.J Natl Cancer Inst 103:662-673,2011.
PubMed
6) Desmedt C,et al:Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.Clin Cancer Res 14:5158-5165,2008.
PubMed
7) Bianchini G,et al:Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and-negative cancers.J Clin Oncol 28:4316-4323,2010.
PubMed
8) van't Veer LJ,et al:Gene expression profiling Predicts clinical outcome of breast cancer.Nature 415:530-536,2002.
PubMed
9) van de Vijver MJ,et al:Agene-expression signature as a predictor of survival in breast cancer.N Engl J Med 347:1999-2009,2002.
 
10) Paik S,et al:Amultigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med 351:2817-2826,2004.
PubMed
11) Paik S,et al:Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.J Clin Oncol 24:3726-3734,2006.
PubMed
12) Sotiriou C,et al:Gene expression profiling in breast cancer:understanding the molecular basis of histologic grade to improve prognosis.J Natl Cancer Inst 98:262-272,2006.
PubMed
13) Reis-Filho JS,Pusztai L:Gene expression profiling in breast cancer:classification,prognostication,and prediction.Lancet 378:1812-1823,2011.
PubMed
14) Geyer FC,et al:Molecular classification of estrogen receptor-positive/luminal breast cancers.Adv Anat Pathol 19:39-53,2012.
 
15) Simon RM,et al:Use of archived specimens in evaluation of prognostic and predictive biomarkers.J Natl Cancer Inst 101:1446-1452,2009.
PubMed
P.236 掲載の参考文献
1) Perou CM,et al:Molecular portraits of human breast tumours.Nature 406:747-752,2000.
PubMed
2) Prat A,Perou CM:Mammary development meets cancer genomics.Nat Med 15:842-844,2009.
PubMed
3) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22:1736-1747,2011.
PubMed
4) Hammond ME,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.J Clin Oncol 28:2784-2795,2010.
 
5) Wolff AC,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol 25:118-145,2007.
 
6) Cheang MC,et al:Ki67 index,HER2 status,and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst 101:736-750,2009.
PubMed
7) Chia SKL,et al:Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor(PAM50) for adjuvant tamoxifen in premenopausal breast cancer:Results from the NCIC CTG MA.12 randomized trial.J Clin Oncol 28:suppl;abstr 508,2010.
 
8) Parker JS,et al:Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol 27:1160-1167,2009.
PubMed
9) Bastien RRL,et al:Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+breast cancers:A direct comparison to Oncotype DX.J Clin Oncol 29:suppl;abstr 503,2011.
 
10) Fearon ER,Vogelstein B:A genetic model for colorectal tumorigenesis.Cell 61:759-767,1990.
PubMed
11) Perera FP,Weinstein IB:Molecular epidemiology:recent advances and future directions.Carcinogenesis 21:517-524,2000.
PubMed
12) Weinstein IB:Cancer.Addiction to oncogenes-the Achilles heal of cancer.Science 297:63-64,2002.
PubMed
13) Weinstein IB,Joe AK:Mechanisms of disease:Oncogene addiction-a rationale for molecular targeting in cancer therapy.Nat Clin Pract Oncol 3:448-457,2006.
PubMed
14) Sharma SV,Settleman J:Oncogene addiction:setting the stage for molecularly targeted cancer therapy.Genes Dev 21:3214-3231,2007.
PubMed
15) Kaelin WG Jr:The concept of synthetic lethality in the context of anticancer therapy.Nat Rev Cancer 5:689-698,2005.
PubMed
P.242 掲載の参考文献
1) 野水整,阿部力哉:乳癌多発家系-家族性乳癌の臨床的検討.癌の臨床 33:477-481,1987.
 
2) Anderson DE,Badzioch MD:Familial breast cancer risks.Effects of prostate and other cancers.Cancer 72(1):114-119,1993.
PubMed
3) 土屋敦雄ほか:本邦における遺伝性乳癌の統計.外科 58:146-151,1996.
 
4) 野水整ほか:家族性乳癌よりみた両側乳癌.乳癌の臨床 6:522 -523,1992.
 
5) Stopfer JE,et al:Genetic Testing and Counseling Issues.In:Hereditary Breast Cancer(ed by Isaacs C,Rebbeck TR),p153-177,Informa Healthcare,New York,2008.
 
6) Pierce LJ,et al:Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.J Clin Oncol 24(16):2437-2443,2006.
 
7) Miki Y,et al:Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1.Science 266:66-71,1994.
 
8) Wooster R,et al:Identification of the breast cancer susceptibility gene BRCA2.Nature 378:789-792,1995.
PubMed
9) Liu S,et al:BRCA1 regulates human mammary stem/progenitor cell fate.Proc Natl Acad Sci USA 105:1680-1685,2008.
PubMed
P.247 掲載の参考文献
1) Clarke MF,et al:Cancer stem cells-perspectives on current status and future directions:AACR Workshop on cancer stem cells.Cancer Res 66:9339-9344,2006.
PubMed
2) O'Brien CA,et al:Cancer stem cells and self-renewal.Clin Cancer Res 16:3113-3120,2010.
PubMed
3) Sorlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
PubMed
4) Al-Hajj M,et al:Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA 100:3983-3988,2003.
PubMed
5) Ginestier C,t al:ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell Stem Cell 1:555-567,2007.
 
6) Shafee N,et al:Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Cancer Res 68:3243-3250,2008.
PubMed
7) Ishimoto T,et a1:CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.Cancer Cell 19:387-400,2011.
 
8) Weiss RB,et al:Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide,methotrexate,and fluorouracil-based adluvant chemotherapy:a study by the Cancer and Leukemia Group B.J Clin Oncol 21:1825-1835,2003.
 
9) Kalluri R,Weinberg RA:The basics of epithelial-mesenchymal transition.J Clin Invest 119:1420-1428,2009.
PubMed
10) Mani SA,et al:Mesenchyme Forkhead 1(FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.Proc Natl Acad Sci USA 104:10069-10074,2007.
 
11) Mani SA,et al:The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell 133:704-715,2008.
PubMed
12) Mego M,et al:Molecular mechanisms of metastasis in breast cancer-clinical applications.Nat Rev Clin Oncol 7:693-701,2010.
PubMed
13) Sun YF,et al:Circulating tumor cells:advances in detection methods,biological issues,and clinicalrelevance.J Cancer Res Clin Oncol 137:1151-1173,2011.
 
14) Anborgh PH,et al:Role of the metastasis-promoting protein osteopontin in the tumour microenvironment.J Cell Mol Med 14:2037-2044,2010.
PubMed
15) MUller A,et al:Involvement of chemokine receptors in breast cancer metastasis.Nature 410:50-56,2001.
PubMed
16) Malanchi I,et al:Interactions between cancer stem cells and their niche govern metastatic colonization.Nature 481:85-89,2012.
 
17) Tsuji T,et al:Epithelial-mesenchymal transition and cell cooperativity in metastasis.Cancer Res 69:7135-7139,2009.
PubMed

VIII 乳癌の検査・診断

P.254 掲載の参考文献
1) 蒔田益次郎:乳癌診療の最前線 診断乳管内視鏡.癌の臨床 46:563-570,2000.
 
2) 日本乳癌学会ホームページ[http://www.jbcs.gr.jp/T_kiyakuhenkou.html]
 
3) NCCN guideline[http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf]
 
4) 日本乳癌学会(編):乳癌診療ガイドライン 2疫学・診断編,p149,金原出版,2011.
 
P.258 掲載の参考文献
1) Smith RA,et al:The randomized trials of breast cancer screening:what have we learned? Radiol Clin North Am 42:793-806,2004.
PubMed
2) 厚生労働省がん検診に関する検討会.老人保健事業に基づく乳がん検診及び子宮がん検診の見直しについて-がん検診に関する検討会中間報告(2005年3月).[http://www.mhlw.go.jp/shingi/2004/04/sO426-3.html](2012.1.15.引用)
 
3) 飯沼武ほか:マンモグラフィ併用検診の有効性と問題点 40-49歳女性の2年間隔マンモグラフィ検診の有効性.日乳癌検診会誌 13:47-57,2004.
 
4) Ohuchi N,et al:Randomized controlled trial on effectiveness of ultrasonography screening for breast cancer in women aged 40-49(J-START):research design.JPn J Clin Oncol 41:275-277,2011.
PubMed
5) ACR Practice Guideline for the Performance of Contrast-Enhanced Magnetic Resonance Imaging(MRI) of the Breast.American College of Radiology,2008.[http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/breast/mri_breast.aspx](2012.1.15.引用)
 
6) Mann RM,et al:Breast MRI:guidelines from the European Society of Breast Imaging.Eur Radiol 18:1307-1318,2008.
PubMed
7) Yabuuchi H,et al:Detection of non-alpable breast cancer in asymptomatic women by using unen-hanced diffusion-weighted and T2-weighted MR imaging:comparison with mammography and dynamic contrast-enhanced MR imaging.Eur Radio 21:11-17,2011.
 
8) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン (2)疫学・診断編2011年版,金原出版,2011.
 
9) US Preventive Services Task Force:Screening for breast cancer:U.S.preventive services task force recommendation statement.Ann Intern Med 151:716-726,2009.
PubMed
10) Feoli F,et al:Fine needle aspiration cytology of the Breast:impact of experience on accuracy,using standardized cytologic criteria.Acta Cytol 52:145-151,2008.
PubMed
11) Pisano ED,et al:Diagnostic performance of digital versus film mammography for breast-cancer screening.N Engl J Med 353:1773-1783.2005.
PubMed
12) Nakano S,et al:Real-time virtual sonography,a coordinated sonography and MRI system that uses magnetic navigation,improves the sonographic identification of enhancing lesions on breast MRI.Ultrasound Med Biol 38:42-49,2012.
PubMed
13) Mann RM,et al:MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast:a review of existing literature.Breast Cancer Res Treat 107:1-14,2008.
PubMed
14) Hathaway PB,et al:Value of combined FDG-PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer:preliminary experience.Radiology 210:807-814,1999.
 
15) Bruening W,et al:Systematic review:comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions.Ann Intern Med l52:238-246,2010.
 
P.273 掲載の参考文献
1) 遠藤登喜子ほか:乳腺硬化性腺症およびその関連病変と乳癌の画像診断.臨床放射線 50:1649-1658,2005.
 
2) 高橋かおる:構築の乱れ(architectual distortion)を呈する病変.臨床放射線 54:1317-1325,2009.
 
3) 日本乳癌学会(編):臨床・病理乳癌取扱い規約(第16版),金原出版,2006.
 
4) 市原周:硬化性病変と関連病変.乳腺病理学 Breast Pathology,名古屋大学出版会,2000.
 
5) Mann RM:The effectiveness of MR imaging in the assessment of invasive lobular carcinoma of the breast.Magn Reson Imaging Clin N Am 18(2):259-276,2010.
PubMed
6) McGhan LJ,et al:Use of preoperative magnetic resonance imaging for invasive lobular cancer:good,better,but maybe not the best? Ann Surg Oncol 17(Suppl 3):255-262,2010.
PubMed
7) Farshid G,Rush G:Assessment of 142 stellate lesions with imaging features suggestive of radial scar discovered during Population-based screening for breast cancer.Am J Surg Pathol 28(12):1626-1631,2004.
PubMed
8) Sloane Jp,Mayers MM:Carcinoma and atypical hyperplasia in radial scars and complex sclerosing lesions:importance of lesion size and patient age.Histopathology 23:225-231,1993.
PubMed
9) Ichihara S,Aoyama H:Intraductal carcinoma of the breast arising in sclerosing adenosis.Pathol Int 44:722-726,1994.
PubMed
10) Oberman HA,Markey BA:Noninvasive carcinoma of the breast presenting in adenosis.Mod Pathol 4:31-35,1991.
PubMed
11) Moritani S,et al:Topographical,morphological and immunohistochemical characteristics of carcinoma in sitza of the breast involving sclerosing adenosis.Two distinct topographical patterns and histological types of carcinoma in situ.Histopathology 58:835-846,2011.
PubMed
12) Jensen RA,et al:Invasive breast cancer risk in women with sclerosing adenosis.Cancer 64:1977-1983,1989.
PubMed
P.277 掲載の参考文献
1) (社)日本医学放射線学会,(社)日本放射線技術学会(編):マンモグラフィガイドライン第3版,p45-50, p71-72,医学書院,2010.
 
2) Nagashima T,et al:Ultrasound Demonstration of Mammographically Detected Microcalcifications in Patients with Ductal Carcinoma in situ of the Breast.Breast Cancer 12:216-220,2005.
PubMed
3) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2疫学・診断編2011年版,p181-183,金原出版,2011.
 
4) 高橋かおる:マンモトーム生検.日本臨牀 65(増刊号6):265-268,2007.
Medical*Online
5) Iwase T,et al:Present state of and problems with core needle biopsy for non-palpable breast lesions.Breast Cancer 13:32-37,2006.
PubMed
P.283 掲載の参考文献
1) Fletcher SW,et al:Report of the international workshop on screening for the breast cancer.J Natl Cancer Inst 85:644-656,1993.
 
2) Kerlikowske K et al:Efficacy of screening mammography:a meta-analysis.JAMA 273:149-154,1995.
PubMed
3) 橋本秀行ほか:乳房超音波検査を用いた乳癌検診-千葉県における現状と課題-.日乳癌検診会誌 17:37-45,2008.
Medical*Online
4) (社)日本医学放射線学会/(社)日本放射線技術学会(編):マンモグラフィガイドライン(第3版),医学書院,2010.
 
5) 遠藤登喜子:乳癌検診の精度管理のあゆみと今後の課題.日乳癌検診会誌 18:107-114,2009.
Medical*Online
P.287 掲載の参考文献
1) Vuoto HD,et al:Bilateral breast carcinoma:clinical characteristics and its impact on survival.Breast J 16:625-632,2010.
PubMed
2) Healey EA,et al:Contralateral breast cancer:clinical characteristics and impact on prognosis.J Clin Oncol 11:1545-1552,1993.
PubMed
3) Saphner T,et al:Annual hazard rates of recurrence for breast cancer after primary therapy.J Clin Oncol 14:2738-2746,1996.
PubMed
4) Schootman M,et a1:Prognosis of metachronous contralateral breast cancer according to stage at diagnosis:the importance of early detection.Breast Cancer Res Treat 99:91-95,2006.
 
5) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2.疫学・診断編(2011年版),金原出版,2011.
 
6) Chaudary MA,et al:Bilateral primary breast cancer:aprospective study of disease incidence.Br JSurg 71:711-714,1984.
 
7) Huo D, et al:Concordance in histological and biological parameters between first and second primary breast cancers.Cancer 117:907-915,2011.
PubMed
8) Janschek E,et al:Contralateral breast cancer:molecular differentiation betWeen metastasis and second primary cancer.Breast Cancer Res Treat 67:1-8,2001.
PubMed
9) Dawson LA,et al:Evolving perspectives in contralateral breast cancer.Eur J Cancer 34:2000-2009,1998.
PubMed
10) Metcalfe K,et al:Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.J Clin Oncol 22:2328-2335,2004.
PubMed
11) Tokunaga M,et al:Incidence of female breast cancer among atomic bomb survivors,1950-1985.Radiat Res 138:209-223,1994.
PubMed
12) Elkin EB.et al:Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma:a multi-institutional,matched cohort study.J Clin Oncol 29:2466-2473,2011.
PubMed
13) Morrow M,et al:MRI for breast cancer screening,diagnosis,and treatment.Lancet 378:1804-1811,2011.
PubMed
14) NCCN Clinical Practice Guidelines in Oncology.Available at:www.nccn.org.Accessed January 10,2012.
 
15) Brennan ME,et al:Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer:systematic review and meta-analysis of incremental cancer detection and impact on surgical management.J Clin Oncol 27:5640-5649,2009.
PubMed
P.289 掲載の参考文献
1) Akashi-Tanaka S,et al:Diagnostic value of contrast-enhanced computed tomography for diagnosing the intraductal component of breast cancer.Breast Cancer Res Treat 49:79-86,1998.
PubMed
2) Akashi-Tanaka S,et al:The role of computed tomography in the selection of breast cancer treatment.Breast Cancer 10(3):198-203,2003.
PubMed
3) 明石定子:CT/MRI.乳癌診療ハンドブック改訂2版(福富隆志編),p67-78,中外医学社,2009.
 
4) Fischer U,et al:The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer.Eur Radiol 14(10):1725-1731,2004.
PubMed
5) Solin U,et al:Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ.J Clin Oncol 26(3):386-391,2008.
PubMed
6) Turnbull L,et al:Comparative effectiveness of MRI in breast cancer(COMICE) trial:a randomised controlled trial.Lancet 375(9714):563-571,2010.
 
7) Peters NH,et al:Preoperative MRI and surgical management in patients with nonpalpable breast cancer:the MONET-randomised controlled trial. Eur J Cancer 47(6):879-886,2011.
PubMed
8) Akashi-Tanaka S,et al:Evaluation of the Usefulness of Breast CT Imaging in Delineating Tumor Extent and Guiding Surgical Management:A Prospective Multi-Institutional Study.Ann Surg 256:157-162,2012.
PubMed
9) Uematsu T,et al:Value of Three-Dimensional Helical CT Image-Guided Planning for Made-to-Order Lumpectomy in Breast Cancer Patients.Breast J 10(1):33-37,2004.
PubMed
10) Akashi-Tanaka S:Preoperative CT evaluation of intraductal spread of breast cancer and surgical treatment.Breast Cancer,2011.[Epub ahead of print]
 
P.295 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン4.検診・診断2008年版,金原出版,2008.
 
2) American College of Radiology:ACR Practice Guideline for the Performance of Contrast-Enhanced Magnetic Resonance Imaging(MRI) of the Breast(ed by Reston VA),American College of Radiology,2008.
 
3) Mann RM,et al:Breast MRI;guidelines from the European Society of Breast Imaging. ur Radiol 18:1307-1318,2008.
 
4) 中野正吾ほか:乳腺画像診断におけるreal-time virtual sonography(RVS)の実際とその役割-超音波とMRI画像情報の融合-.日本臨牀 65:304-309,2007.
Medical*Online
5) Turnbull L,et al:Comparative effectiveness of MRI in breast cancer(COMICE) trial:a randomized controlled trial.Lancet 375:563-571,2010.
 
6) 磯本一郎:仰臥位撮像乳房MRIの有用性.日獨医報 55(2):104-116,2010.
 
7) 岡崎稔ほか:MRI,乳管内視鏡などの新しい診断法.乳房温存療法のすべて(福田護編),p62-67,メジカルビュー社,1994.
 
8) 戸崎光宏:乳房MRIの位置づけ,読影方法,今後の展望.日獨医報 54(1):22-26,2009.
 
9) The ACR Breast Imaging Reporting and Data System(BI-RADS),4th ed(ed by Reston VA),American College of Radiology,2003.
 
10) 石山公一ほか:乳腺造影MRIの撮像法と診断法.INNERVISION 26(12):94-97,2011.
Medical*Online
P.301 掲載の参考文献
1) 芳賀駿介ほか:腋窩リンパ節郭清からみた乳房温存手術の根治性に関する病理組織学的検討.日外会誌 90(6):907-913,1989.
 
2) 芳賀駿介ほか:乳癌に対する乳房温存療法の適応と手技.日外会誌 93(9):1202-1205,1992.
 
3) 芳賀駿介ほか:特集癌治療におけるMinimally Invasive Surgery乳房温存手術としての乳房円状部分切除術.癌の臨床 45(5):409-412,1999.
 
4) 山田理恵子ほか:乳癌の拡がり診断からみたMDCTの有用性-癌体積を含めた検討-.第18回日本乳癌学会総会抄録集,2010.
 
5) 住吉一浩ほか:乳癌の拡がり診断に関するmultidetector-row CT所見と病理組織所見の比較検討.日臨外会誌 67(7):1463-1472,2006.
 
6) 明石定子:MD-CTの有用性.日本臨牀 64:491-495,2006.
Medical*Online
7) 明石定子:CT.日本臨牀 58(増刊:乳癌の診断と治療):66-70,2000.
 
8) 酒村智子ほか:乳腺造影CTと病理学的診断.日本臨牀 65:348-352,2007.
Medical*Online
9) 明石定子:256列MDCTによる乳癌の画像診断.映像情報medical 40:232-235,2008.
Medical*Online
P.304 掲載の参考文献
1) International Breast Cancer Consensus Conference:Image-detected breast cancer:state of the art diagnosis and treatment.International Breast Cancer Consensus Conference.J Am Coll Surg 193:297-302,2001.
PubMed
2) Parker SH,et al:Stereotactic breast biopsy with biopsy gun.Radiology 176:741-747,1990.
PubMed
3) Parker SH,Klaus AJ:Performing a breast biopsy with a directional,vacuum-assisted biopsy instrument.Radiographics 17(5):1233-1252,1997.
PubMed
4) 岩瀬拓士ほか:新しい生検法(2)ステレオタクティック 乳房針生検.乳癌の臨床 16:576-582,2001.
 
5) 五味直哉ほか:マンモトーム生検の有用性.乳癌の臨床 17:114-123,2002.
 
6) 五味直哉ほか:マンモトーム生検の有用性.治療学 39:178-181,2005.
Medical*Online
P.316 掲載の参考文献
1) Nakano S,et al:Detection of enhancing lesions on contrast-enhanced MRI of the breast using real-time virtual sonography;fusion of MRI and sonography data.Breast Cancer Res Treat 106:S13,2007.
 
2) Nakano S,et al:Fusion of MRI and sonography image for breast cancer evaluation using real-time virtual sonography with magnetic navigation:first experience.JPn J Clin Oncol 39:552-559,2009.
PubMed
3) Nakano S,et al:Real-time virtual sonography,a coordinated sonography and MRI system that uses magnctic navigation,improves the sonographic identification of enhancing lesions on breast MRI.Ultrasound Med Biol 38:42-49,2012.
PubMed
4) Fausto A,et al:A new method to combine contrast-enhanced magnetic resonance imaging during live ultrasound of the breast using volume navigation technique:A study for evaluating feasibility,accuracy and reproducibility in healthy volunteers.Eur J Radiol 81:e332-337,2012.
PubMed
5) Chang JM,et al:Evaluation of tumor extent in breast cancer patients using real-time MR navigated ultrasound:Preliminary study.Eur J Radiol,2012.[Epub ahead of print]
 
6) Houssami N,et al:Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging:systematic review and meta-analysis in detection of multifocal and multicentric cancer.J Clin Oncol 26:3248-3258,2008.
 
7) LaTrenta LR,et al:Breast lesions detected with MR imaging:utility and histopathologic importance of identification with US.Radiology 227:856-861,2003.
PubMed
8) Beran L,et al:Correlation of targeted ultrasound with magnetic resonance imaging abnormalities ofthe breast.Am J Surg 190:592-594,2005.
 
9) Shin JH,et al:Targeted ultrasound for MR-detected lesions in breast cancer patients.Korean J Radiol 8:475-483,2007.
PubMed
10) Demartini WB,et al:Utility of targeted sonography for breast lesions that were suspicious on MRI.AJR Am J Roentgenol 192:1128-1134,2009.
PubMed
11) Meissnitzer M,et al:Targeted ultrasound of the breast in women with abnormal MRI findings for whom biopsy has been recommended.AJR Am J Roentgenol 193:1025-1029,2009.
PubMed
12) Destounis S,et al:Community-based practice experience of unsuspected breast magnetic resonance imaging abnormalities evaluated with second-look sonography.J Ultrasound Med 28:1337-1346,2009.
PubMed
13) Carbognin G,et al:Utility of second-look ultrasound in the management of incidental enhancing lesions detected by breast MR imaging.Radiol Med 115:1234-1245,2010.
PubMed
14) Abe H,et al:MR-directed("Second-Look") ultrasound examination for breast lesions detected initially on MRI:MR and sonographic findings.AJR Am J Roentgenol 194:370-377,2010.
PubMed
15) Tozaki M,Fukuda K:Supine MR mammography using VIBE with parallel acquisition technique for the planning of breast-conserving surgery:clinical feasibility.Breast 15:137-140,2006.
PubMed
16) Siegler P,et al:Supine breast MRI.J Magn Reson Imaging 34:1212-1217,2011.
PubMed
17) Yamamoto S,et al:Sentinel lymph node detection in breast cancer patients by real-time virtual sonography constructed with three-dimensional computed tomography-lymphography.Breast J 16:4-8,2010.
PubMed
18) Yamamoto S,et al:Prospective ultrasonographic prediction of sentinel lymph node metastasis breal-time virtual sonography constructed with three-dimensional computed tomography-lymphography in breast cancer patients.Breast Cancer 19:77-82,2011.
 
P.320 掲載の参考文献
1) Ishikawa Y,et al:Triple-negative breast cancer:Histological subtypes and immunohistochemical and clinicopathological features.Cancer Sci 102(3):656-662,2011.
PubMed
2) Kojima Y,Tsunoda H:Mammography and ultrasound features of triple-negative breast cancer.Breast Cancer 18:146-151,2011.
PubMed
3) Ko ES.et al:Triple-negative breast cancer:correlation between imaging and pathological findings.Eur Radiol 20:1111-1117,2010.
PubMed
4) 日本乳腺甲状腺超音波診断会議(編):乳房超音波診断ガイドライン改訂第2版,南江堂,2008.
 
5) 日本乳癌学会(編):第4章 組織学的治療効果の判定基準.臨床・病理乳癌取扱い規約(第16版),金原出版,2008.
 
6) Loo CE,et al:Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy:relevance of breast cancer subtype.J Clin Oncol 29:660-666,2011.
PubMed
7) Perou CM,et al:Molecular portraits of human breast tumours.Nature 406:747-752,2000.
PubMed
8) Lehmann BD,et al:Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest 121(7):2750-2767,2011.
PubMed
P.325 掲載の参考文献
1) 厚生労働省老健局老人保健課長:がん予防重点健康教育及びがん検診実施のための指針,2004.
 
2) 楠木哲朗:3Dマンモグラフィシステムの撮影条件の最適化と臨床使用.映像情報メディカル 43(12):1023-1025,2011.
 
3) 白岩美咲ほか:3Dマンモグラフィの撮像条件の基礎的検討-乳房切除標本による画像評価-.第70回日本医学放射線学会総会:cypos,2011.
 
4) Bakic PR,et al:Dose requirements in stereoradiography.Proceedings of SPIE 4682,126,2002.
 
5) 白岩美咲ほか:3Dマンモグラフィの撮像条件の検討-房切除標本による診断能評価-.第19回日本乳癌学会学術総会抄録集,2011.
 
6) Getty DJ,et al:Stereoscopic digital mammography:Improved accuracy of lesion detection in breast cancer screening.Proceedings of the International Workshop on Digital Mammography,p74-79,2008.
 
P.329 掲載の参考文献
1) Wang LV,Wu HI:Biomedical Optics:Principles and Imaging,Wiley-Interscience,Hoboken,2007.
 
2) Frangioni JV:New technologies for human cancer imaging.J Clin Oncol 26:4012-4021,2008.
PubMed
3) Viacava P,et al:Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.J pathol 204:140-146,2004.
 
4) Uzzan B,et al:Microvessel density as a prognostic factor in women with breast cancer:a systematic review of the literature and meta-analysis.Cancer Res 64:2941-2955,2004.
PubMed
5) Makris A,et al:Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma.Cancer 85:1996-2000,1999.
PubMed
6) Soliman H,et al:Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in woman with locally advanced breast cancer.Clin Cancer Res 16:2605-2614,2010.
PubMed
7) Zhu Q,et al:Early-stage invasive breast cancers:Potential role of optical tomography with US localization in assisting diagnosis.Radiology 256:367-378,2010.
PubMed
8) Roblyer D,et al:Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.Proc Natl Acad Sci USA 108:14626-14631,2011.
PubMed
9) Manohar S,et al:Initial results of in vivo non-invasive cancer imaging in the human breast using near-infrared photoacoustics.Opt Express 15:12277-12285,2007.
PubMed
10) Ermilov SA,et al:Laser optoacoustic imaging system for detection of breast cancer.J Biomed Opt 14:024007,2009.
PubMed
11) Erpelding TN,et al:Sentinel lymph nodes in the rat:Noninvasive photoacoustic and US imaging with a clinical US system.Radiology 256:102-110,2010.
PubMed
P.334 掲載の参考文献
1) 日本乳癌学会:全国乳がん患者登録調査報告-暫定版-第40号 2009年次症例.
 
2) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2.疫学・診断編2011年版,金原出版,2011.
 
3) 徐樹明ほか:仰臥位撮像法によるMR mammographyの検討.東医大誌 68(1):53-62,2010.
Medical*Online
4) Balleyguier C,et al:New potential and applications of contrast-enhanced ultrasound of the breast:Own investigations and review of the literature.Eur J Radiol 69(1):14-23,2009.
 
5) Forsberg F,et al:Breast lesions:imaging with contrast-enhanced subharmonic US-initial experience.Radiology 244(3):718-726,2007.
PubMed
6) Du J,et al:Microvascular architecture of breast lesions:evaluation with contrast-enhanced ultrasonographic micro flow imaging.J Ultrasound Med 27(6):833-842,2008.
PubMed
7) 位藤俊一ほか:体表臓器におけるレボビスト造影エコー法.Innervision 17:138-141,2002.
Medical*Online
8) 位藤俊一:超音波造影剤の応用.臨床放射線 54:1355-1360,2009.
 
9) 平井都始子ほか:乳腺腫瘍に対するソナゾイド造影超音波の初期経験.映像情報メディカル 43:201-205,2011.
 
P.344 掲載の参考文献
1) 荻野充利ほか:B-モード超音波(US)で検出される非浸潤性乳管癌(DCIS)について.第19回日本乳癌学会学術総会プログラム抄録集,p268,2011.
 
2) 日本乳腺甲状腺超音波診断会議(編集):腫瘤像非形成性病変.乳房超音波診断ガイドライン改訂第2版,p71-81,南江堂,2008.
 
3) 荻野充利ほか:腫瘤像非形成性の石灰化病変に対する超音波(US)診断能について.第17回日本乳癌学会学術総会プログラム抄録集,p295,2009.
 
4) 荻野充利ほか:腫瘤像非形成性の石灰化病変に対する超音波(US)診断能について.シンポジウム:局所的非対称性陰影 腫瘤像非形成性病変.第19回日本乳癌画像研究会プログラム抄録集,p35,2010.
 
5) 荻野充利ほか:マンモグラフィ(MMG)で石灰化を認めた腫瘤像非形成性病変に対するB-モード超音波(US)のアプローチ法.第18回日本乳癌学会学術総会プログラム抄録集,p308,2010.
 
6) 坂本吾偉(監修):非浸潤性乳管癌.乳腺の組織型診断とその病態,p10-24,じほう,2006.
 
7) 武部晃司ほか:非触知乳癌の診断における超音波検査及び穿刺吸引細胞診の有用性.香川臨細胞誌 23:3-9,2011.
 
8) 荻野充利ほか:B-モード超音波(US)による乳腺スクリーニング検査の現況と課題.第8回日本乳癌学会近畿地方会プログラム抄録集,p47,2010.
 
9) 佐久間浩:非浸潤性乳管癌の超音波画像.超音波検査技術 29(1):54-55,2004.
Medical*Online
10) 荻野充利ほか:病理からみた非浸潤性乳管癌のB-モード超音波(US)像について.第20回日本乳癌学会学術総会プログラム抄録集,p247,2012.
 
P.348 掲載の参考文献
1) 山口正秀ほか:FDG-PET/CTによる乳癌リンパ節転移診断の検討.京府医大誌 117:7-13,2008.
 
2) Peare R,et al:The use of FDG-PET in assessing axillary lymph node status in breast cancer:a systematic review and meta-analysis of the literature.Breast Cancer Res Treat 123:281-290,2010.
PubMed
3) Cooper KL,et al:Positron emission tomography(PET) for assessment of axillary lymph node status in early breast cancer:A systematic review and meta-analysis.Eur J Surg Oncol 37:187-198,2011.
PubMed
4) 大地哲也ほか:乳癌診療におけるFDG-PET検査.臨床外科 65:192-199,2010.
 
5) 石井要ほか:PET-CT検査による乳癌リンパ節転移診断.乳癌の臨床 25:163-167,2010.
Medical*Online
6) Rousseau C,et al:FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.Eur J Nucl Med Mol Imaging 38:1029-1036,2011.
PubMed
7) Keam B,et al:Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.Breast Cancer,2012.[Epub ahead of print]
 
P.353 掲載の参考文献
1) Rosen EL,et al:Detection of primary breast carcinoma with a dedicated,large-field-of-view FDG PET mammography device:initial experience.Radiology 234:527-534,2005.
PubMed
2) Raylman RR,et al:The positron emission mammography/tomography breast imaging and biopsy system(PEM/PET):design,construction and phantom-based measurements.Phys Med Biol 53:637-653,2008.
PubMed
3) MacDonald L,et al:Clinical imaging characteristics of the positron emission mammography camera:PEM FIex Solo II.J Nucl Med 50:1666-1675,2009.
 
4) Tai YC,et al:Virtual-pinhole PET.J Nucl Med 49:471-479,2008.
 
5) Bowen SL,et al:Initial characterization of a dedicated breast PET/CT scanner during human imaging.J Nucl Med 50:1401-1408,2009.
PubMed
6) Furuta M,et al:Basic evaluation of a C-shaped breast PET scanner.In:Proceedings of IEEE Nuclear Science Symposium Conference Record,p2548-2552,Orland,2009.
 
P.358 掲載の参考文献
1) Fenaroli P,et al:Axillary sentinel node biopsy under local anesthesia in early breast cancer.Ann Oncol 11:1617-1618,2000.
PubMed
2) Luini A et al:Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma.Arch Surg 137:1157-1160,2002.
PubMed
3) Smidt ML,et a1:Sentinel lymphnode biopsy performed under local anesthesia is feasible.Am J Surg 187:684-687,2004.
 
4) Luini A,et al:The sentinel node biopsy under local anesthesia in breast cancer:advantages and problems,how the technique influenced the activity of a breast surgery department;update from the European Institute of Oncology with more than 1000 cases.Breast 16:527-532,2007.
PubMed
5) Van Berio CL,et al:Ambulatory sentinel node biopsy under local anaesthesia for patients with early breast cancer.Eur J Surg Oncol 29:383-385,2003.
 
6) 廣川高久ほか:早期乳癌手術の低侵襲化にともなうDay Surgery化への安全性試験.乳癌の臨床 25(5):569-574,2010.
Medical*Online
7) Weaver DL,et al:Effect of occult metastases on survival in node-negative breast canver.N Engl J Med 364:412-421,2011.
 
8) Giuliano AE,et al:Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randmized clinical trial.JAMA 305:569-575,2011.
 
9) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン1治療編2011年版,金原出版,2011.
 
10) Buchholz TA,et al:Statement of the science concerning locoregional treatment after preoperative chemotherapy for breast cancer:a National Cancer Institute conference.J Clin Oncol 26:791-797,2008.
PubMed
11) 戸井雅和ほか:センチネルリンパ節.CANCER BOARD乳癌 1(1):12-18,2008.
Medical*Online
12) 木下貴之ほか:術前化学療法後のセンチネルリンパ節生検の現状と展望.乳癌の臨床 24(1)71-76,2009.
Medical*Online
P.364 掲載の参考文献
1) Krag DN,et al:Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial.Lancet Oncol 11:927-933,2010.
PubMed
2) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン (1)治療編2011年版,金原出版,2011.
 
3) Viale G,et al:Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy.Ann Surg 241(2):319-325,2005.
PubMed
4) Giuliano AE,et al:Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial.JAMA 305(6):569-575,2011.
PubMed
5) 中村清吾ほか:センチネルリンパ節生検に対する多施設共同臨床確認試験における安全性と同定率に関する報告.乳癌の臨床 24(2):271-277,2009.
Medical*Online
6) Kurosumi M:Significance and problems of histopathological examination and utility of real-time reverse transcriptase-polymerase chain reaction method for the detection of sentinel lymph node metastasis in breast cancer.Breast Cancer 14:342-349,2007.
PubMed
7) Fougo JL,et al:Validating the MSKCC nomogram and a clinical decision rule in the prediction of non-sentinel node metastases in a Portuguese population of breast cancer patients.Breast 20:134-140, 2011.
 
8) Wada N,et al:Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lympf node.Eur J Surg Oncol 32:29-33,2006.
 
9) Ponzone R,et al:Comparison of two models for the prediction of nonsentinel node metastases in breast cancer.Am J Surg 193:686-692,2007.
PubMed
10) Schrenk P,et al:Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 92:707-713,2005.
PubMed
11) Van Zee KJ,et al:A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.Ann Surg Oncol 10:1140-1151,2003.
PubMed
12) Hwang RF,et al:Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer.Ann Surg Oncol 10:248-254,2003.
PubMed
13) Degnim AC,et al:Nonsentinel node metastasis in breast cancer patients:assessment of an existing and a new predictive nomogram.Am J Surg 190:543-550,2005.
 
14) Pal A,et al:A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive.Br J Surg 193:686-692,2008.
 
15) Kohrt HE,et al:New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients.BMC Cancer 8:66,2008.
PubMed
P.368 掲載の参考文献
1) Cabanas RM:An approach for the treatment of penile carcinoma.Cancer 39:456-466,1977.
PubMed
2) Morton DL,et al:Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Surg 127:392-399,1992.
PubMed
3) Giuliano AE,et al:Lymphatic mapping and sentinel lymphadenectomy for breast cancer.Ann Surg 220:391-398,1994.
PubMed
4) Noguchi M,et al:A multicenter valiation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society.Breast Cancer Res Treat 63:31-40,2000.
 
5) Cox CE,et al:Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer.Annu Rev Med 51:525-542,2000.
PubMed
6) Kim T,et al:Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma:A metaanalysis.Cancer 106:4-16,2006.
PubMed
7) Morrow M,et al:Learning sentinel node biopsy:Result of a prospective randomized trial of two techniques.Surgery 126:714-722,1999.
PubMed
8) McMasters KM,et al:Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy:a model for implementation of new surgical techniques.Ann Surg 234:292-300,2001.
 
9) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン 1治療編2011年版,p205-206,金原出版,2011.
 
10) Giuliano AE,et al:Sentinel lymphadenectomy in breast cancer.J Clin Oncol 15:2345-2350,1997.
PubMed
11) Motomura K,et al:Sentinel node biopsy in breast cancer patients with clinically negative lymphnodes.Breast Cancer 6:259-262,1999.
PubMed
12) 堀口淳ほか:乳癌センチネルリンパ節生検-色素法と色素・RI併用法の比較検討-.北関東医学 54:105-108,2004.
 
13) 吉永康照ほか:早期乳癌に対するセンチネルリンパ節生検による腋窩郭清省略の検討.福岡大医紀 34:97-101,2007.
 
14) 吉村吾郎ほか:色素法による乳癌センチネルリンパ節生検-feasibility studyとobservation studyの成績-.和歌山医学 58:10-13,2007.
 
15) 勝木健文ほか:当科における色素法単独による乳癌センチネルリンパ節生検feasibility studyの成績.日外科系連会誌 34:549-555,2009.
 
P.372 掲載の参考文献
1) Lyman GH,et al:American Society of Clinical Oncology:American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol 23:7703-7720,2005.
 
2) Kitai T,et al:Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer.Breast Cancer 12:211-215,2005.
PubMed
3) Tagaya N,et al:Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer.Am J Surg 195:850-853,2008.
PubMed
4) Sugie T,et al:A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer.Cancers 2:713-720,2010.
PubMed
5) Tsujimoto M,et al:One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients.Clin Cancer Res 13:4807-4816,2007.
PubMed
6) Sugie T,et al:Validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph node in early stage breast cancer in comparison with the dye method.J Clin Oncol 29:15s,2010.
 
7) 北島政樹,久保敦司:Sentinel Node Navigation-癌治療の新しい展開-.金原出版,2002.
 
8) Murawa D,et al:Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence.Br J Surg 96:1289-1294,2009.
PubMed
P.376 掲載の参考文献
1) Shimazu K,et al:Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma.Cancer 100:2555-2561,2004.
PubMed
2) Mamounas EP,et al:Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer:results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol 23(12):2694-2702,2005.
PubMed
3) Classe JM,et al:Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer:results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante,a French prospective multicentric study.J Clin Oncol 27(5):726-732,2009.
PubMed
4) Hunt KK,et al:Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.Ann Surg 250:558-566,2009.
PubMed
5) Xing Y,et al:Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.Br J Surg 93(5):539-546,2006.
PubMed
6) Kelly AM,et al:Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis.Acad Radiol 16(5):551-563,2009.
PubMed
7) van Deurzen CH,et al:Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients:a systematic review.Eur J Cancer 45(18):3124-3130,2009.
PubMed
8) Kim T,et al:Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma:a metaanalysis.Cancer 106(1):4-16,2006.
PubMed
9) Shimazu K,et al:Intraoperative frozen section analysis of sentinel lymph node in breast cancer patients treated with neoadjuvant chemotherapy.Ann Surg Oncol 15(6):1717-1722,2008.
PubMed
10) Rubio IT,et al:Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.Ann Surg Oncol 17(1):235-239,2010.
PubMed
11) Ollila DW,et al:Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers.Am J Surg 190(3):371-375,2005.
PubMed
12) Cox CE,et al:Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.Ann Surg Oncol 13(4):483-490,2006.
PubMed
13) Khan A,et al:Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.Ann Surg Oncol 12(9):697-704,2005.
PubMed
14) Jones JL,et al:A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy:timing is important.Am J Surg 190(4):517-520,2005.
PubMed
15) Goldhirsch A,et al:Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.Ann Oncol 20(8):1319-1329,2009.
PubMed
P.380 掲載の参考文献
1) Schwartz GF,et al:Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22,2001,Philadelphia,Pennsylvania.Cancer 94:2542-2551,2002.
 
2) Kuehn T,et al:A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance.Cancer 103:451-461,2005.
PubMed
3) Giuliano AE,et al:Lymphatic mapping and sentinel lymphadenectomy for breast cancer.Ann Surg 220:391-398,1994.
PubMed
4) Borgstein PJ,et al:Intradermal blue dye to identify sentinel lymph-node in breast cancer.Lancet 384:149-157,1997.
 
5) Krag DN,et al:Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe.Surg Oncol 2:335-339,1993.
PubMed
6) Suga K,et al:Interstitial CT lymphography-guided localization of breast sentinel lymph node:preiminary results.Surgery 133:170-179,2003.
 
7) Minato M,et al:3-Dimensional computed tomography lymphography-guided identification of sentinel lymph node in breast cancer patients using subcutaneous injection of nonionic contrast medium:a clinical trial.J Comput Assist Tomogr 28:46-51,2004.
PubMed
8) Tangoku A,et al:Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer.Surgery 135:258-265,2004.
PubMed
9) Yamashita K,Shimizu K:Video-assisted breast surgery and sentinel lymph node biopsy guided by 3D-CT lymphography.Surg Endosc 22:392-397,2008.
PubMed
10) Yamashita K,Shimizu K:Evaluation of sentinel lymph node metastasis alone guided by three-dimensional computed tomographic lymphography in video-assisted breast surgery.Surg Endosc 23:633-640,2009.
PubMed
11) Yamashita K,Shimizu K:Video-assisted breast surgery can sample the second and third sentinel nodes to omit axillary node dissection for sentinel-node positive patients.Surg Endosc 23:1574-1580,2009.
PubMed
12) Yamashita K,Shimizu K:Transaxillary retromammary route approach of video-assisted breast surgery enables the innerside breast cancer to be resected for breast-conserving surgery.Am J Surg 196:578-581,2008.
PubMed
13) Yamashita K,Shimizu K:Five axillary node groups beyond sentinel node observed by 3D-CT lymphography,evaluated for avoiding axillary dissection with sentinel node metastasis.Annual Meeting 2008 of American Society of Clinical Oncology,Abstract 595,2008.
 
P.384 掲載の参考文献
1) Tsujimoto M,et al:One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients.Clin Cancer Res 13(16):4807-4816,2007.
PubMed
2) Visser M,et al:Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer.Int J Cancer 1228(11):2562-2567,2008.
 
3) Coltrera MD,et al:Markers for dysplasia of the upper aerodigestive tract.Suprabasal expression of PCNA,p53,and CK19 in alcohol-fixed,embedded tissue.Am J Pathol 141(4):817-825,1992.
PubMed
4) Chu PG, Weiss LM:Keratin expression in human tissues and neoplasms.Histopathology 40:403-439,2002.
PubMed
5) Notomi T,et al:Loop-mediated isothermal amplification of DNA.Nucleic Acids Res 28(12):E63,2000.
PubMed
6) Tamaki Y,et al:Molecular detection of lymph node metastases in breast cancer patients:results of a multicenter trial using the one-step nucleic acid amplification assay.Clin Cancer Res 15(8):2879-2884.2009.
PubMed
7) McGhan LJ,et al:The changing landscape of axillary surgery:Which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol,2011.[Epub ahead of print]
 
8) Ponzone R,et al:Comparison of two models for the prediction of nonsentinel node metastases in breast cancer.Am J Surg 193:686-692,2007.
PubMed
P.389 掲載の参考文献
1) Usami S,et al:Reliability of prognostic factors in breast carcinoma determined by core needle biopsy.JPn J Clin Oncol 37:250-255,2007.
PubMed
2) 園尾博司,森谷卓也:日本の乳癌取扱い規約と世界の規約との違い TNM分類,組織学的分類,RECISTを中心に.外科治療 103:457-463,2010.
Medical*Online
3) Yang M,et al:Microinvasive ductal carcinoma(T1mic) of the breast.The clinicopathological profile and immunohistochemical features of 28 cases.Pathol Int 53:422-428,2003.
PubMed
4) Tsuda H,et al:Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy.Japan National Surgical Adju-vant Study of Breast Cancer(NSAS-BC) Pathology Section.Jpn J Clin Oncol 28:486-491,1988.
 
5) Ito M,et al:Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer.Breast Cancer 14:381-387,2007.
PubMed
6) Mohammed RA,et al:Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma:findings from a large case series with long-term follow-up.J Clin Pathol 223:358-365,2011.
 
7) Kurebayashi J,et al:The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races.Breast 16:S72-S77,2007.
PubMed
8) Umemura S,et al:Recommendations for'adequate evaluation of hormone receptors'a report of the task force of the Japanese Breast Cancer Society.Oncol Rep 24:299-304,2010.
PubMed
9) Umemura S,et al:What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.Am J Clin Pathol 130:883-891,2008.
PubMed
10) Nishimura R,et al:Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.Breast Cancer 17:269-275,2010.
PubMed
11) 森谷卓也:温存手術における切除断端の評価法について教えてください.Cancer Board乳癌 2:108-109,2009.
Medical*Online
12) Komoike Y,et al:Ipsilateral breast tumor recurrence(IBTR) after breast-conserving treatment for early breast cancer:risk factors and impact on distant metastases.Cancer 106:35-41,2006.
PubMed
13) Yiu CC,et al:Presence of extensive intraductal component in patients undergoing breast conservative surgery predicts presence of residual disease in subsequent completion mastectomy.Clin Med J 122:900-905,2009.
 
14) 森谷卓也:乳癌に対する病理学的治療効果の判定法について教えてください.Cancer Board乳癌 3:150-151,2010.
Medical*Online
15) 森谷卓也ほか:病理との付き合い方 病理医からのメッセージ 病理組織診断 正確な診断結果を得るための検体提出方法.Medicina 42:1107-1111,2005.
 
P.395 掲載の参考文献
1) Page DL et al:Atypical hyperplastic lesions of the female:A long-term follow-up study.Cancer 55:2698-2708,1985.
PubMed
2) Tavassoli FA,et al:Lobular neoplasia.In:World Health Organization Classification of Tumours.Pathology and Genetics of Tumours of the Breast and Female Genital Organs(ed by Tavassoli FA,Devilee P),p60-62,IARC Press,Lyon,2003.
 
3) Haagensen CD:Lobular neoplasia(lobular carcinoma in situ).In:Diseases of the Breast,3rd ed,p239,WB Saunders Company,Philadelphia,1986.
 
4) Simpson PT,et al:The diagnosis and management of pre-invasive breast disease:Pathology of atypical lobular hyperplasia and lobular carcinoma in situ.Breast Cancer Res 5:258-262,2003.
PubMed
5) Douglas S,et al:Lobular neoplasia:frequency and association with other breast lesions.Diagn Pathol 6:74,2011.
 
6) Zou D,et al:Epigenetic silencing in non-neoplastic epithelia identhies E-cadherin(CDH1) as a target for chemoprevention of lobular neoplasia.J Pathol 218:265-272,2009.
PubMed
P.400 掲載の参考文献
1) 森谷鈴子:非浸潤性小葉癌.乳腺病理カラーアトラス(土屋眞一編),p98-99,文光堂,2008.
 
2) Li CI,et al:Changing incidence of lobular carcinoma in situ.Breast Cancer Res Treat 75:259-268,2002.
PubMed
3) Esserman LE,et al:Should the extent of lobular neoplasia on core biopsy influence the decision for excision? Breast J 13:55-61,2007.
PubMed
4) Frykberg ER:Lobular carcinoma in situ of the breast.Breast J 5:296-303,1999.
PubMed
5) Fentiman IS:The dilemma of in situ carcinoma of the breast.Int J Clin Prac 55:680-683,2001.
 
6) 日本乳癌学会乳癌診療ガイドライン:[https://www.jbcsguideline.jp/algorithm/index.html#category_noninvasive]
 
7) Hussain M,Cunnick GH:Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast-A review.Eur J Surg Oncol 37:279-289,2011.
PubMed
P.404 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン 1治療編,金原出版,2011.
 
2) Bonnefoi H,et al:Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy:a substudy if the EORTC 10994/BIG 00-01 clinical trial.Lancet Oncol 8:1071-1078,2007.
PubMed
3) Qureshi NA,et al:Imprint cytology of needle core-biopsy specimens of breast lesions:Is it a useful adjunt to rapid assessment breast clinics? Breast 16:81-85,2007.
PubMed
4) Masood S,et al:Diagnostic value of imprint cytology during image-guided core biopsy in improving breast health care.Ann Clin Lab Sci 41:8-13,2011.
PubMed
5) Kulkarni D,et al:The use of core biopsy imprint cytology in the'one-stop'breast clinic.Eur J Surg Oncol 35:1037-1040,2009.
PubMed
6) Dayal S,et al:Imprint cytology from core biopsies increases the sensitivity of fine needle aspiration(FNA) in breast cancer patients.Magy Seb 64:59-62,2011.
PubMed
P.408 掲載の参考文献
1) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of radiotherapy and of differences in the extent of surgery for early breast cancer of local recurrence and 15-year survival:an overview of the randomized trials.Lancet 366:2087-2106,2005.
 
2) Veronesi U,et al:Conservation approaches for the management of stage I/II carcinoma of the breast:Milan Cancer Institute trials.World J Surg 18:70-75,1994.
 
3) Singleraty SE:Surgical margin in patients with early-stage breast cancer treated with breast conservation therapy.Am J Surg 184:383-393,2002.
 
4) 日本乳癌学会学術委員会:乳房温存療法ガイドライン,教育広報社,1999.
 
5) Kasumi F,et al:CIH-Tokyo experience with breast-conserving surgery without radiotherapy:6.5 year follow up results of 1,462 patients.Breast J 12:181-190,2006.
 
6) Klimberg VS,et al:Assessing margin status.Surg Oncol 8:77-84,1999.
PubMed
7) 佐藤一彦ほか:乳癌センチネルリンパ節生検の手技.外科治療 83:264-269,2000.
Medical*Online
8) Lyman GH,et al:American Society of Clinical Oncology.American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol 23:7703-7720,2005.
 
9) Cserni G,et al:Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer.Br J Surg 91:1245-1252,2004.
PubMed
10) Weaver DL,et al:Effect of occult metastases on survival in node-negative breast cancer.N Engl J Med 364:412-421,2011.
PubMed
11) Takeshita T,et al:Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients:serial step section analysis with long-term follow-up.Ann Surg Oncol 19:1160-116,2012.
 
P.411 掲載の参考文献
1) Early Breast Cancer Trialists'Collaborative Group:Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival:an overview of the randomized trials.Lan-cet 365:1687-1717,2005.
 
2) Slamon DJ,et al:Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235:177-182,1987.
PubMed
3) Wolff AC,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol 25:118-145,2007.
 
4) Sorlie T,et al:Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA 100:8418-8423,2003.
PubMed
5) Rastogi P,et al:Preoperative chemotherapy:updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.J Clin Oncol 26:778-785,2008.
 
6) Wolmark N,et a1:Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr 30:96-102,2001.
 
7) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約,第16版,p75,金原出版,2008.
 
8) Symmans WF,et a:Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol 25:4414-4422,2007.
 
9) Ring AE,et al:Oestrogen receptor status,pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.Br J Cancer 91:2012-2017,2004.
PubMed
10) von Minckwitz G,et al:Results from the German neoadjuvant meta-analysis.J Clin Oncol 29:Issues 15S,87s, Abstract No.1028,2011.
 
11) Dowsett M,et al:Assessment of Ki67 in breast cancer:recommendations from the International Ki67 in Breast Cancer working group.J Natl Cancer Inst 103:1656-1664,2011.
 
12) Ellis MJ,et al:Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst 100:1380-1388,2008.
PubMed
13) Dowsett M,et al:Endocrine therapy,new biologicals,and new study designs for presurgical studies in breast cancer.J Natl Cancer Inst Monogr 43:120-123,2011.
PubMed
14) Ellis MJ,et al:Randomized phase II neoadjuvant comparison between letrozole,anastrozole,and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer:clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031.J Clin Oncol 29:2342-2349,2011.
PubMed
P.417 掲載の参考文献
1) Yamaguchi R, et al:Comparison of the accuracy of breast cytological diagnosis at seven institutions in southern Fukuoka prefecture,Japan. JPn J Clin Oncol 42:21-28,2012.
PubMed
2) 日本乳癌学会(編):第二部 細胞診および針穿刺の報告様式.臨床病理 乳癌取扱い規約,第15版,p64-74,金原出版,2004.
 
3) Singh N, Wells A:Assessment of accuracy in breast cytology.Cytopathology 12:211-218,2001.
 
4) Yamaguchi R, et al:Evaluation of inadequate,indeterminate,false-negative and false-positive cases in cytological examination for breast cancer according to histological type.Diagn Pathol 7(1):53,2012.
 
5) 秋保伸彦ほか:乳腺穿刺吸引細胞診15470例の再検討-新報告様式導人による変化-.日臨細胞会誌 46:323-331,2007.
 
6) 越川卓ほか:乳腺細胞診の新報告様式.臨床検査 51:85-90,2007.
 
7) Yamaguchi R,et al:Cytological features of myxomatous fibroadenoma of the breast.Diagn Cytopathol 40:316-320,2012.
PubMed
8) 山口倫,土屋眞一:細胞診の有用性と問題点.癌診療指針のための病理診断プラクティス 乳癌(青笹克之,黒住昌史編),p17-25,中山書店,2011.
 
9) 山口倫:乳腺細胞診の現状とさらなる精度向上のために.乳癌の臨床 26:43-48,2011.
Medical*Online
P.421 掲載の参考文献
1) Wolff AC,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.ArchPathol Lab Med 131:18-43,2007.
 
2) トラスツズマブ病理部会:HER2検査ガイド第3版,2009.
 
3) 増田しのぶほか:HER2検査の精度管理.病理と臨床,p353-359,文光堂,2011.
 
4) Shah S,Chen B:Testing for HER2 in Breast Cancer:A Continuing Evolution.Patholog Res Int,Article ID903202,2011.
PubMed
5) Dybdal N,et al:Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immllnohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.Breast Cancer Res Treat 93:3-11,2005.
PubMed
6) Iorfida M,et al:HER2-negative(1+)breast cancer with unfavorable prognostic features:to FISH or not to FISH? Ann Oncol,2012.[Epub ahead of print].
PubMed
7) Tong LC,et al:The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor,progesterone receptor,and HER2 expression in invasive breast cancer:a prospectivestudy.Am J Surg Pathol 35:545-552,2011.
 
8) Umemura S,et al:What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.Am J Clin Pathol 130:883-891,2008.
PubMed
P.426 掲載の参考文献
1) Slamon DJ,et al:Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235:177-182,1987.
PubMed
2) Ross JS,et al:The HER-2/neu gene and protein in breast cancer 2003:biomarker and target oftherapy.Oncologist 8:307-325,2003.
 
3) Cobleigh MA et al:Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 17:2639-2648,1999.
PubMed
4) Wolff AC,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol 25:118-145,2007.
 
5) Carbone A et al:Delineation of HER2 gene status in breast carcinoma by silver in situ hybridizationis reproducible among laboratories and pathologists.J Mol Diagn 10:527-536,2008.
 
6) Isola L,et a1:Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.Clin Cancer Res 15:4793-4798,2004.
 
7) Saez A,et al:HER-2 gene amplification by chromogenic in situ hybridization(CISH) compared with fluorescence in situ hybridization(FISH) in breast cancer-A study of two hundred cases.Breast 15:519-527,2006.
PubMed
8) Horii R,et al:Comparison of dual color in situ hybridization and fiuorescence in situ hybridizationin HER2 gene amplification in breast cancer.Am J Surg Pathol(in submitted).
 
P.432 掲載の参考文献
1) Gerdes J,et al:Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.Am J Pathol 138:867-873,1991.
PubMed
2) Urruticoechea A,et al:Proliferation marker Ki-67 in early breast cancer.J Clin Oncol 23:7212-7220, 2005.
PubMed
3) Cuzick J,et al:Prognostic Factors and Biomarkers-Clinical Testing and Validation Prognostic Value of a Combined ER,PgR,Ki67,HER2 Immunohistochemical(IHC4) Score and Comparisonwith the GHI Recurrence Score-Results from TransATAC.Cancer Res 69(24 Suppl):74,2009.
 
4) Allred DC,et al:Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol 11:155-168,1998.
PubMed
5) 黒住昌史:乳癌におけるホルモンレセプター状況の免疫組織化学的判定.診断病理 20:311-317,2003.
Medical*Online
6) Wolff AC,et al:American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol 25:118-145,2007.
 
7) de Azambuja E,et al:Ki-67 as prognostic marker in early breast cancer:a meta-analysis of published studies involving 12,155 patients.Br J Cancer 96:1504-1513,2007.
PubMed
8) Goldhirsch A et al:Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.Ann Oncol 20:1319-1329,2009.
PubMed
9) Jalava P,et al:Ki67 immunohistochemistry:a valuable marker in prognostication but with a risk of misclassification:proliferation subgroups formed based on Ki67 immunoreactivity and standardizedmitotic index.Histopathology 48:674-682,2006.
PubMed
10) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer2011.Ann Oncol 22:1736-1747,2011.
 
11) Cheang MC,et al:Ki67 index,HER2 status,and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst 101:736-750,2009.
PubMed
12) Dowsett M,et al:Assessment of Ki67 in breast cancer:recommendations from the International Ki67 in Breast Cancer working group.J Natl Cancer Inst 103:1656-1664,2011.
 
P.437 掲載の参考文献
1) Gerdes J,et al:Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.Am J Pathol 138:867-873,1991.
PubMed
2) Toi M,et al:Ki67 index changes,pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.Cancer Sci 102:858-865,2011.
PubMed
3) Ellis MJ,et al:Randomized phase II neoadjuvant comparison between letrozole,anastrozole,and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer:clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031.J Clin Oncol 29:2342-2349,2011.
PubMed
4) Masuda N,et al:A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.J Clin Oncol 29:2011(suppl;abstr 558).
 
5) Dowsett M,et al:Biomarker changes during neoadjuvant anastrozole,tamoxifen,or the combination:influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists.J Clin Oncol 23:2477-2492,2005.
 
6) Dowsett M,et al;IMPACT Trialists Group:Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.J Natl Cancer Inst 99:167-170,2007.
PubMed
7) Ellis MJ,et al:Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst 100:1380-1388,2008.
PubMed
8) Cheang MC,et al:Ki67 index, HER2 status,and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst 101:736-750,2009.
PubMed
9) Viale G,et al;Breast International Group Trial 1-98:Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer:results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.J Clin Oncol 26:5569-5575,2008.
 
10) Bago-Horvath Z,et al;Austrian Breast and Colorectal Cancer Study Group:Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.Clin Cancer Res 17:7828-7834,2011.
 
P.442 掲載の参考文献
1) Sorlie T,et al:Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 98:10869-10874,2001.
PubMed
2) Goldhirsch A, et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer2011.Ann Oncol 22:1736-1747,2011.
 
3) Sotiriou C,Pusztai L:Gene-expression signatures in breast cancer.N Engl J Med 360:790-800,2009.
PubMed
4) Badve S,Nakshatri H:Oestrogen-receptor-positive breast cancer:towards bridging histopathological and molecular classifications.J Clin Pathol 62:6-12,2009.
PubMed
5) Hisamatsu Y,et al:Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.Ann Surg Oncol 19:1145-1152,2012.
 
6) Carroll JS,Brown M:Estrogen receptor target gene:an evolving concept.Mol Endocrinol 20:1707-1714,2006.
PubMed
7) Hurtado A,et al:FOXA1 is a key determinant of estrogen receptor function and endocrine response.Nat Genet 43:27-33,2011.
PubMed
8) Lupien M,et al:FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.Cell 132:958-970,2008.
PubMed
9) Badve S,et al:FOXA1 expression in breast cancer-correlation with luminal subtype A and survival.Clin Cancer Res 13:4415-4421,2007.
PubMed
10) Mehta RJ,et al:FOXA1 is an independent prognostic marker for ER-positive breast cancer.Breast Cancer Res Treat 131:881-890,2012.
PubMed
11) Ademuyiwa FO,et al:Expression of Forkhead-box protein A1,a marker of luminal A type breastcancer,parallels low Oncotype DX 21-gene recurrence scores.Mod Pathol 23:270-275,2010.
 
P.447 掲載の参考文献
1) 金井好克:癌のアミノ酸トランスポーターと代謝制御.細胞工学 30:41-46,2011.
 
2) Kanai Y,et al:Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen(CD98).J Biol Chem 273:23629-23632,1998.
 
3) Yanagida O,et al:Human L-type amino acid transporter 1(LAT1):characterization of function and expression in tumor cell lines.Biochim Biophys Acta 1514:291-302,2001.
 
4) Fuchs BC,Bode BP:Amino acid transporters ASCT2 and LAT1 in cancer:partners in crime? Semin Cancer Biol 15:254-266,2005.
PubMed
5) Xu D,Hemler ME:Metabolic activation-related CD147-CD98 complex.Mol Cell Proteomics 4:1061-1071,2005.
PubMed
6) Kaira K,et al:Fluorine-18-alph-amethyltyrosine positron emission tomography for diagnosis and staging of lung cancer:a clinicopathologic sUldy.Clin Cancer Res 13:6369-6378,2007.
 
7) Kaira K,et al:Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT:a clinicopathologicalstudy.Int J Cancer 124:1152-1160,2009.
PubMed
8) Nawashiro H,et al:L-type amino acid transporter 1 as a potential molecular target in human astrocy tictumors.Int J Cancer 119:484-492,2006.
 
9) Yamauchi K,et al:System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.Cancer Lett 276:95-101,2009.
 
10) Oda K,et al:L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.Cancer Sci 101:173-179,2010.
PubMed
11) Imai H,et al:L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.Histopathology 54:804-813,2009.447
 
12) Sakata T,et al:L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.Pathol Int 59:7-18,2009.
PubMed
13) Furuya M,et al:Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis.Cancer Sci 103:382-389,2012.
PubMed
14) Esseghir S,et al:Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.J Pathol 210:420-430,2006.
PubMed
15) Bartlett JM,et al:Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.Breast Cancer Res 12:R47,2010.
PubMed
P.453 掲載の参考文献
1) Matsumoto R,et al:Human ecalectin,a variant of human galectin-9,is a novel eosinophil chemoattractant produced by T lymphocytes.J Biol Chem 273:16976-16984,1998.
 
2) Irie A,et al:Galectin-9 as a prognostic factor with anti-metastatic potential in breast cancer.Clin Caner Res 11:2962-2968,2005.
 
3) Nishi N,et al:Development of highly stable galectins:truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins.FEBS Lett 579:2058-2064,2005.
PubMed
4) Nobumoto A,et al:Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices.Glycobiology 18:735-744,2008.
PubMed
5) Kashio Y,et al:Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway.J Immunol 170:3631-3636,2003.
PubMed
6) Lu LH,et al:Characterization of galectin-9-induced death of Jurkat T cells.J Biochem 141:157-172,2007.
 
7) Zhu C,et al:The Tim-31igand galectin-9 negatively regulates T helper type 1 immunity.Nat Immunol 6:1245-1252,2005.
PubMed
8) Seki M,et al:Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts.Arthritis Rheum 56:3968-3976,2007.
PubMed
9) Reddy PB,et al:Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency.J Immunol 187:5745-5755,2011.
PubMed
10) Sharma S,et al:T cell immunoglobulin and mucin protein-3(Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses.Proc Natl Acad Sci USA 108:19001-19006,2011.
 
11) Kadowaki T,et al:Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages.Clin Immunol 142:296-307,2012.
PubMed
12) Nagahara K,et al:Galectin-9 increases Tim-3+dendritic cells and CD8+T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.J Immunol 181:7660-7669,2008.
PubMed
P.458 掲載の参考文献
1) Lapidot T,et al:A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.Nature 367:645-648,1994.
PubMed
2) Al-Hajj M,et al:Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA 100:3983-3988,2003.
PubMed
3) Ginestier C,et al:ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell Stem Cell 1:555-567,2007.
 
4) Tanei Tet al:Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.Clin Cancer Res 15:4234-4241,2009.
 
5) Rouzier R,et al:Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes,J Clin Oncol 20:1304-1310,2002.
PubMed
6) Hennessy BT,et al:Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.J Clin Oncol 23:9304-9311,2005.
PubMed
7) Sakakibara M,et al:Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.Ann Surg Oncol 16:2470-2478,2009.
PubMed
8) Sakakibara M,et al:Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer.Cancer,2011.[Epub ahead of print]
 
P.463 掲載の参考文献
1) 紅林純一:乳癌の腫瘍マーカー.乳腺疾患-state of arts(伊藤良則,戸井雅和編),p156-158,医歯薬出版,2004.
 
2) Harris L,et al:American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol 25:5287-5312,2007.
 
3) 厚生労働省:平成22年国民生活基礎調査.
 
4) 平成22年度がん研究開発費「がん検診の評価とあり方に関する研究」班:有効性評価に基づく前立腺がん検診ガイドラインERSPC・PLCOに関する更新ステートメント,2011.
 
5) 野村文夫:疾患プロテオミクス.遺伝子分析科学(日本臨床検査同学院遺伝子分析科学認定士制度委員会編),p70-72,宇宙堂,2011.
 
6) Tirumalai RS,et al:Characterization of the low molecular weight human serum proteome.Mol Cell Proteomics 2:1096-1103,2003.
PubMed
7) Kadowaki M,et al:Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.J Cancer Res Clin Oncol 137:1105-1115,2011.
PubMed
8) 門脇正美ほか:早期乳癌に対する血清診断マーカーの探索.乳癌の臨床 24:768-769,2009.
Medical*Online
P.469 掲載の参考文献
1) Asahara T,et a1:Isolation of putative progenitor endothelial cells for angiogenesis.Science 275:964-967,1997.
 
2) Shi Q,et al:Evidence for circulating bone marrow-derived endothelial cells.Blood 92:362-367,1998.
PubMed
3) Mancuso P,et al:Validation of a standardized method for enumerating circulating endothelial cells and progenitors:flow cytometry and molecular and ultrastructural analyses.Clin Cancer Res 15:267-273,2009.
PubMed
4) Ali AM,et al:Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients.Eur J Cancer 47:2265-2272,2011.
PubMed
5) Mancuso P,et al:Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.Blood 97:3658-3661,2001.
PubMed
6) Goon PK,et al:Circulating endothelial cells and circulating progenitor cells in breast cancer:relationship to endothelial damage/dysfunction/apoptosis,clinicopathologic factors,and the Nottingham Prognostic Index.Neoplasia 11:771-779,2009.
PubMed
7) Smirnov DA,et al:Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.Cancer Res 66:2918-2922,2006.
PubMed
8) Furstenberger G,et al:Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.Br J Cancer 94:524-531,2006.
PubMed
9) Naik RP,et al:Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.Breast Cancer Res Treat 107:133-138,2008.
PubMed
10) Shaked Y,et al:Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents.Cancer Cell 14:263-273,2008.
PubMed
11) Bertolini F,et al:Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.Cancer Res 63:4342-4346,2003.
PubMed
12) Calleri A,et al:Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.Clin Cancer Res 15:7652-7657,2009.
PubMed
13) Dellapasqua S,et al:Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.J Clin Oncol 26:4899-4905,2008.
PubMed
14) Bidard FC,et al:Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.Ann Oncol 21:1765-1771,2010.
PubMed
15) Gao D,et al:Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.Science 319:195-198,2008.
PubMed
P.473 掲載の参考文献
1) Kawano A,et al:Prognostic factors for stage IV hormone receptor-positive primary metastaticbreast cancer.Breast Cancer,2011.[Epub ahead of print]
 
2) Ravdin PM,et al:Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen:results of a prospective Southwest Oncology Group study.J Clin Oncol 10:1284-1291,1992.
 
3) Stuart-Harris R,et al:The prognostic significance of single hormone receptor positive metastatic breast cancer:an analysis of three randomised phase III trials of aromatase inhibitors.Breast 18:351-355,2009.
PubMed
4) Neumeister V,Rimm D:Is ALDH1 a good method for definition of breast cancer stem cells? Breast Cancer Res Treat 123:109-111,2010.
PubMed
5) Jeter CR,et al:NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.Oncogene 30:3833-3845,2011.
PubMed
6) Hashimoto K et al:Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.Oncology 82:168-174,2012.
PubMed
7) Shigekawa T,et al:FOXP1,estrogen-inducible transcription factor,modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.Horm Cancer 2:286-297,2011.
PubMed
8) 清水千佳子ほか:IV期乳癌における内分泌療法効果予測因子の検討-ホルモン抵抗性の克服に向けて-.第19回日本乳癌学会総会抄録集,2011.
 
9) Toi M,et al:Ki67 index changes and pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.Cancer Sci 102:858-865,2011.
PubMed
10) Smith IE,et al:Neoadjuvant treatment of postmenopausal breast cancer with anastrozole,tamoxifen,or both in combination:the Immediate Preoperative Anastrozole,Tamoxifen,or Combined with Tamoxifen(IMPACT) multicenter double-blind randomised trial.J Clin Oncol 23:5108-5116,2005.
 
11) Jones RL,Smith IE:Neoadjuvant treatment for early-stage breast cancer:opportunities to assess tumour response.Lancet Oncol 7:869-874,2006.
PubMed
12) Generali D,et al:Phosphorylated ER-alpha,HIF-1alpha and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.J Clin Oncol 27:227-234,2009.
PubMed
13) Amir E,et al:Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.J Clin Oncol 30:587-592,2012.
PubMed
14) Hirata T,et al:Change in hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.Br J Cancer 101:1529-1536, 2009.
 
15) Ellis MJ,et al:Randomized phase II neoadjuvant comparison between letrozole,anastrozole,and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer:clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031.J Clin Oncol 29:2342-2349,2011.
PubMed
P.479 掲載の参考文献
1) Ando Y,et al:Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity:apharmacogenetic analysis.Cancer Res 60:6921-6926,2000.
PubMed
2) 佐井君江ほか:日本人がん患者のイリノテカン個別化医療実現に向けて:UGT1A1遺伝子多型(*28及び*6)の意義について.薬学雑誌 128:575-584,2008.
 
3) Yao L,et al:The association betWeen TA-repeat polymorphism in the promoter region of UGT1A1 and breast cancer risk:a meta-analysis.Breast Cancer Res Treat 122:879-882,2010.
 
4) Sai K,et al:UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.Clin Pharmacol Ther 75:501-515,2004.
PubMed
5) 市川渡ほか:塩酸イリノテカンとUGTIA1遺伝子多型.大腸癌Frontier 2:44-48,2009.
 
6) Sunakawa Y, et al:UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.Cancer Chemother Pharmacol 68:279-284,2011.
PubMed
7) 田中麻子,小谷一夫:UGT1A1遺伝子多型検査の臨床意義と運用.日本遺伝カウンセリング学会誌 30:79-82,2009.
Medical*Online
8) ファーマコゲノミクス検査の運用指針,2010.[http://www.jslm.org/others/news/genomics101201.pdf].
 
9) 日本医学会:医療における遺伝学的検査・診断に関するガイドライン,2011.[http://jams.med.or.jp/guideline/genetics-diagnosis.html].
 
10) 渡邉淳,島田隆:ゲノム情報を医療現場で適切に利用するための課題-日本医科大学付属病院での試み.ファルマシア 46:415-420,2010.
 
11) 尾上雅英ほか:薬剤師が発信するがん薬物療法のエビデンス 第1回 イリノテカン塩酸塩の代謝の個体差を探る.月間薬事 51:97-103,2009.
 
P.485 掲載の参考文献
1) Meindl A,et al:Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.Nat Genet 42:410-414,2010.
PubMed
2) van der Groep P,et a1:Pathology of hereditary breast cancer.Cell Oncol 34:71-88,2011.
 
3) Meindl A,et al:Hereditary breast and ovarian cancer:new genes,new treatments,new concepts.Dtsch Arztebl Int 108:323-330,2011.
PubMed
4) Ford D,et al:Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.Am J Hum Genet 57:1457-1462,1995.
PubMed
5) Risch HA,et al:Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances:a kincohort study in Ontario,Canada.J Natl Cancer Inst 98:1694-1706,2006.
 
6) Antoniou A,et al:Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history:a combined analysis of 22 studies.Am J Hum Genet 72:1117-1130,2003.
 
7) Spearman AD,et al:Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.J Clin Oncol 26:5393-5400,2008.
PubMed
8) Lustbader ED,et al:Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.Am J Hum Genet 51:344-356,1992.
PubMed
9) Varley JM:Germline TP53 mutations and Li-Fraumeni syndrome.Hum Mutat 21:313-320,2003.
 
10) Nagy R,et al:Highly penetrant hereditary cancer syndromes.Oncogene 23:6445-6470,2004.
PubMed
11) Krutilkova V,et al:Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.Eur J Cancer 41:1597-1603,2005.
PubMed
12) Gonzalez KD,et al:Beyond Li Fraumeni Syndrome:clinical characteristics of families with p53 germline mutations.J Clin Oncol 27:1250-1256,2009.
PubMed
13) Nelen MR,et al:Localization of the gene for Cowden disease to chromosome 10q22-23.Nat Genet 43:114-116,1996.
 
14) Nusbaum R,et al:Susceptibility to breast cancer:hereditary syndromes and low penetrance ganes.Breast Dis 27:21-50,2006.
 
15) Nelen MR et al:Novel PTEN mutations in patients with Cowden disease:absence of clear genotype-phenotype correlations.Eur J Hum Genet 7(3):267-273,1999.
PubMed

IX 乳癌の治療戦略

P.492 掲載の参考文献
1) https://www.jbcsguideline.jp/
 
2) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン治療編2011年版,金原出版,2011.
 
3) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン疫学・診断編2011年版,金原出版,2011.
 
P.497 掲載の参考文献
1) Veronesi U,et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.N Engl J Med 347:1227-1232,2002.
PubMed
2) Fisher B,et al:Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med 347:1233-1241,2002.
PubMed
3) Katipamula R,et al:Trends in mastectomy rates at the Mayo Clinic Rochester:effect of surgical year and preoperative magnetic resonance imaging.J Clin Oncol 27:4082-4088,2009.
 
4) Uematsu T,et al:Comparison of magnetic resonance imaging,multidetector row computed tomography,ultrasonography,and mammography for tumor extension of breast cancer.Breast Cancer Res Treat 112:461-474,2008.
PubMed
5) 厚生労働科学研究費補助金「がん臨床研究事業」標準的な乳房温存療法の実施要項の研究班:乳房温存療法ガイドライン医療者向け-「標準的な乳房温存療法の実施要項の研究」班に基づく治療指針.金原出版,2005.
 
6) Oura S,et al:Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size.Breast Cancer 14:48-54,2007.
 
7) Elliott LF,Hartrampf CR Jr:Breast reconstruction:progress in the past decade.World J Surg 14:763-775,1990.
PubMed
8) Krag DN,et al:Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial.Lancet Oncol 11:927-933,2010.
PubMed
9) Giuliano AE,et al:Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial.JAMA 305:569-575,2011.
PubMed
P.501 掲載の参考文献
1) 玉木康博ほか:乳癌に対する内視鏡補助下手術.日本臨牀 68:1349-1353,2010.
Medical*Online
2) 山形基夫ほか:内視鏡下円状部分切除と郭清術.日鏡外会誌 6:45-51,2001.
 
3) 福間英輔ほか:内視鏡下乳房全摘術の遠隔成績と術式適応.日内視鏡外会誌 10:171-178,2005.
 
4) 山形基夫ほか:内視鏡下乳房温存手術.臨床外科 60:1481-1490,2005.
 
5) 喜島祐子ほか:遊離真皮脂肪片移植による乳房温存術後一期的再建.日臨外会誌 66:7-12,2010.
 
6) 大内憲明ほか:乳癌患者のQOL向上をめざした新しい乳房温存手術:Lateral Tissue Flapを用いた一期的再建法.日外会誌 99(臨時増刊):494,1998.
 
7) 矢野健二:有茎広背筋皮弁による乳房再建.乳房・乳頭の再建と整容(矢野健二編),p23-32,克誠堂出版,2010.
 
8) 佐武利彦ほか:穿通枝皮弁による乳房再建.乳房・乳頭の再建と整容(矢野健二編).p79-92,克誠堂出版,2010.
 
9) 岩平佳子:Tissue expansion法と乳房インプラントによる乳房再建.乳房・乳頭の再建と整容(矢野健二編),p114-122,克誠堂出版,2010.
 
10) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2011年版-1治療編,金原出版,2011.
 
P.503 掲載の参考文献
1) Veronesi U,et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.N Engl J Med 347:1227-1232,2002.
PubMed
2) Fisher B,et al:Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med 347:1233-1241,2002.
PubMed
3) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366:2087-2106,2005.
 
4) Yi M,et al:Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.Ann Surg 253:572-579,2011.
PubMed
5) Nishimura S,et al:Classification of ipsilateral breast tumor recurrence after breast-conserving therapy:new primary cancer allows a good prognosis.Breast Cancer 12:112-117,2005.
PubMed
6) Komoike Y,et al:Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors.Breast Cancer 12:104-111,2005.
PubMed
7) Panet-Raymond V,et al:Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence.Cancer 117:2035-2043,2011.
PubMed
8) Punglia RS,et al:Local therapy and survival in breast cancer.N Engl J Med 356:2399-2405,2007.
PubMed
9) Sanpaolo P,et al:Prognostic value of breast cancer subtypes on breast cancer specific survival,distant metastases and local relapse rates in conservatively managed early stage breast cancer:a retrospective clinical study.Eur J Surg Oncol 37:876-882,2011.
PubMed
10) VOduc KD,et al:Breast cancer subtypes and the risk of local and regional relapse.J Clin Oncol 28:1684-1691,2010.
PubMed
11) Robertson C,et al:Surveillance mammography for detecting ipsilateral breast tumor recurrence and metachronous contralateral breast cancer:a systematic review.Eur Radiol 21:2484-2491,2011.
PubMed
12) Kubota K,et al:Power Doppler and gray-scale sonography standardized by BI-RADS for the differentiation of benign postoperative lesion and local recurrence after breast-conserving therapy.Oncol Rep 26:1357-1362,2011.
PubMed
13) Kim SJ,et al:The detection of recurrent breast cancer in patients with a history of breast cancer surgery:comparison of clinical breast examination,mammography and ultrasonography.Acta Radiol 52:15-20,2011.
PubMed
14) Chen SL,Martinez SR:The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence.Am J Surg 196:495-499,2008.
PubMed
15) Anderson SJ,et al:Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.J Clin Oncol 27:2466-2473,2009.
PubMed
P.510 掲載の参考文献
1) Kaur N,et al:Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer.Ann Surg Oncol 12:1-7,2005.
PubMed
2) Petit JY,et al:One hundred and eleven cases of breast conservation treatment with simultaneous reconstruction at the European Institute of Oncology(Milan).Tumori 88:41-47,2002.
PubMed
3) Smith ML,et al:Reduction mammaplasty:Its role in breast conservation therapy for early-stage breast cancer.Ann Plast Surg 41:234-239,1998.
PubMed
4) Shestak KC,et al:Partial mastectomy and breast reduction as a valuable treatment option for patients with macromastia and carcinoma of the breast.Surg Gynecol Obstet 177:54-56,1993.
PubMed
5) Berry MG,et al:Oncoplastic breast surgery:a review and systematic approach.J plast Reconstr Aesthet Surg 63:1233-1243,2010.
PubMed
6) Kijima Y,et al:Oncoplastic surgery for Japanese patients with ptotic breasts.Breast Cancer 18:273-281,2011.
PubMed
7) Kijima Y,et al:Oncoplastic surgery in Japanese patients with breast cancer close to the areola:partial mastectomy using periareolar mammoplasty.Case Reports in Surgery,Volume 2011,Article ID 121985,5pages,2011.
 
8) Kijima Y,et al:Oncoplastic surgery for Japanese patients with breast cancer of the lower pole.Surg Today 41:1461-1465,2011.
PubMed
9) Kijima Y,et al:Oncoplastic surgery in a Japanese patient with breast cancer in the lower inner quadrant area:partial mastectomy using horizontal reduction mammoplasty.Breast Cancer,2010(inpress).
 
10) Kijima Y,et al:Oncoplastic surgery after mammary reduction and mastopexy for bilateral breast cancer lesiols.Report of a case.Surg Today 38:335-339,2008.
PubMed
11) Kijima Y,et al:Oncoplastic surgery combining partial mastectomy with breast reconstruction using a free nipple-areola graft for ductal carcinoma in situ in a ptotic breast:report of a case.Surg Today 41:390-395,2011.Gasperoni C,et al:A personal technique:mammaplasty with J scar.Ann Plast Surg 48:124-130,2002.
 
12) Gasperoni C,et al:A personal technique:mammaplasty with J scar.Ann Plast Surg 48:124-130,2002.
 
13) Audretsch W,et al:Onco-plastic surgery:"target"volume reduction(BCT-mastopexy),lumpectomy reconstruction(BCT-reconstruction) and flap-supported operability in breast cancer.Proceedings 2nd European Congress on Senology, October 2-6,1994,Vienna,Bologna,Monduzzi,p139-157,1994.
 
14) Hoffmann J,Wallwiener D:Classifying breast cancer surgery:a novel,complexity-based system for oncological,oncoplastic and reconstructive procedures,and proof or principle by analysis of 1225 operations in 1166 patients.BMC Cancer 9:108,2009.
PubMed
15) 喜島祐子:整容性からみた乳房温存治療ハンドブック(矢形寛ほか編),第1版,メディカル・サイエンス・インターナショナル,p16,図1-7,2010.
 
P.514 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン-2 疫学・診断編,金原出版,2011.
 
2) Turnbull L,et al:Comparative effectiveness of MRI in breast cancer(COMICE) trial:a randomised controlled trial.Lancet 375:563-571,2010.
 
3) American College of Radiology:Breast Imaging Reporting and Data System(BI-RADS),4th ed,American College of Radiology,Reston,VA,USA,2003.
 
4) Tozaki M,Fukuma E:1H MR spectroscopy and diffusion-weighted imaging of the breast:are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol 193:840-849,2009.
PubMed
5) ACR practice guideline for the performance of contrast enhanced magnetic resonance imaging of the breast.[www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/breast.aspx]
 
6) Mann RM,et al:Breast MRI:guidelines from the European Society of Breast Imaging.Eur Radiol 18:1307-1318,2008.
PubMed
7) Tozaki M,et al:Magnetic resonance-guided vacuum-assisted breast biopsy:results in 100 Japanese women.Jpn J Radiol 28:527-533,2010.
PubMed
8) Tozaki M,Fukuda K:High-Spatial-Resolution MRI of non-masslike breast lesions:interpretation model based on BI-RADS MRI descriptors.AJR Am J Roentgenol 187:330-337,2006.
 
9) Tozaki M,et al:Breast MRI using the VIBE sequence:Clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement.AJR Am J Roentgenol 187:313-321,2006.
PubMed
10) Tozaki M:BI-RADS-MRI terminology and evaluation of intraductal carcinoma and ductal carcinoma in situ.Breast Cancer,2011.[Epub ahead of print]
 
11) Ogawa T,et al:New preoperative MRI marking technique for a patient with ductal carcinoma in situ.Breast Cancer 15:309-314,2008.
PubMed
12) Yamashiro N,et al:Preoperative MRI marking technique for the planning of breast-conserving surgery.Breast Cancer 16:223-238,2009.
PubMed
13) Sakamoto N,et al:Early results of an endoscopic nipple-sparing mastectomy for breast cancer.Ann Surg Oncol 16:3406-3413,2009.
PubMed
14) Tozaki M,et al:Breast-conserving surgery after chemotherapy:value of MDCT for determining tumor distribution and shrinkage pattern.AJR Am J Roentgenol 186:431-439,2006.
PubMed
15) Kuhl CK,et al:MRI for diagnosis of pure ductal carcinoma in situ:a prospective observational study.Lancet 370:485-492,2007.
PubMed
P.518 掲載の参考文献
1) Cady B,et al:The new era in breast cancer:invasion,size,and nodal involvement dramatically decreasing as a result of mammographic screening.Arch Surg 131(3):301-308,1996.
PubMed
2) Lovrics PJ,et al:The relationship between surgical factors and margin status after breast conservation surgery for early stage breast cancer.Am J Surg 197(6):740-746,2008.
PubMed
3) Acosta JA,et al:Surgical margins after needle-localization breast biopsy.Am J Surg 170(6):643-645,1995.
PubMed
4) Gajdos C,et al:Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics.Ann Surg 235(2):246-251,2002.
PubMed
5) Papa MZ,et al:The effect of anesthesia type on needle localization breast biopsy:another point of view.Am J Surg 171(2):242 -243,1996.
 
6) Luini A,et al:Radioguided surgery of occult breast lesions.Eur J Cancer 34(1):204-205,1998.
PubMed
7) Homer MJ,et al:Needle localization of occult breast lesions with a curved-end retractable wire:technique and pitfalls.Radiology 161:547-548,1986.
PubMed
8) Davis PS,et al:Migration of breast biopsy localization wire.AJR Am J Roentgenol 150:787-788,1988.
PubMed
9) Homer MJ:Transection of the localization hooked wire during breast biopsy.AJR Am J Roentgenol 141:929-930,1983.
PubMed
10) Gray RS,et al:Randomized prospective evaluation of a novel technique for biopsy or lumpectomy of nonpalpable breast lesions:radioactive seed versus wire localization.Ann Surg Oncol 8(9):711-715,2001.
PubMed
11) Lovrics PJ,et al:Systematic review of radioguided surgery for non-palpable breast cancer.Eur J Surg Oncol 37(5):388-397,2011.
PubMed
12) Sajid MS,et al:Comparison of radioguided occult lesion localization(ROLL) and wire localization for non-palpable breast cancers:Ameta-analysis.J Surg Oncol,2011.
 
13) Monti S,et al:Occult breast lesion localization plus sentinel node biopsy(SNOLL):experience with 959 patients at the European Institute of Oncology.Ann Surg Oncol 14(10):2928-2931,2007.
PubMed
14) Feggi L,et al:An original approach in the diagnosis of early breast cancer:use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation.Eur J Nucl Med 28:1589-1596,2001.
PubMed
15) Lavoue V,et al:Simplified technique of radioguided occult lesion localization(ROLL) plus sentinel lymph node biopsy(SNOLL) in breast carcinoma.Ann Surg Oncol 15(9):2556-2561,2008.
PubMed
P.521 掲載の参考文献
1) Clarke M,et al:Effects of radiotherapy and of differences in the extent of surgery for early breastcancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366:2087-2106,2005.
 
2) Komoike Y,et al:Ipsilateral breast tumor recurrence(IBTR) after breast-conserving treatment for early breast cancer:risk factors and impact on distant metastases.Cancer 1O6:35-41,2006.
 
3) Ishitobi M,et al:Ipsilateral breast tumor recurrence(IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy:Risk factors of IBTR and validation of the M.D.Anderson Prognostic Index.Cancer,2012.(in press)
 
4) Berry DA,et al:Effect of screening and adjuvant therapy on mortality from breast cancer.N Engl J Med 353:1784-1792,2005.
 
5) Nishimura R et al:Investigation of factors related to periods to ipsilateral breast tumor recurrence after breast-conserving surgery and measures for preventing recurrence in early breast cancer.Breast Cancer 13:152-158,2006.
PubMed
6) Gage I,et al:Skin recurrences after breast-conserving therapy for early-stage breast cancer.J Clin Oncol 16:480-486,1998.
PubMed
7) Clemons M,et al:Management of recurrent locoregional breast cancer:oncologist survey.Breast 12:328-337,2003.
PubMed
8) Chen SL,Martinez SR:The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence.Am J Surg 196:495-499,2008.
PubMed
9) Houssami N,et al:Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.JAMA 305:790-799,2011.
PubMed
10) Komoike Y,et al:Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors.Breast Cancer 12:104-111,2005.
PubMed
11) Alpert TE,et al:Ipsilateral breast tumor recurrence after breast conservation therapy:outcomes of salvage mastectomy vs.salvage breast-conserving surgery and prognostic factors for salvage breast preservation.Int J Radiat Oncol Biol Phys 63:845-851,2005.
PubMed
12) Gentilini O,et al:When can a second conservative approach be considered for ipsilateral breast tumour recurrence? Ann Oncol 18:468-472,2007.
PubMed
13) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン2011年度版,p192-194,金原出版2011.
 
14) Ishitobi M,et al:Repeat lumpectomy for ipsilateral breast tumor recurrence after breast-conserving treatment.Oncology 81:381-386,2011.
PubMed
15) Recht A,et al:Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 19:1539-1569,2001.
 
16) Nielsen HM,et al:Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis.An analysis of patients from the DBCG 82 b & c randomization trials.Radiother Oncol 79:147-155,2006.
 
17) van der Pol CC,et al:Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence.Ann Surg Oncol 16:3414-3421,2009.
PubMed
18) Willner J,et al:Locoregional recurrence of breast cancer following mastectomy:always a fatal event? Results of univariate and multivariate analysis.Int J Radiat Oncol Biol Phys 37:853-863,1997.
PubMed
19) Ballo MT,et al:Local-regional control of recurrent breast carcinoma after mastectomy:does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys 44:105-112,1999.
PubMed
20) Wapnir IL,et al:Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancertrials.J Clin Oncol 24:2028-2037,2006.
 
21) Newman LA,et al:Presentation,management and outcome of axillary recurrence from breast cancer.Am J Surg 180:252-256,2000.
PubMed
22) Rutgers EJ:Sentinel node biopsy:interpretation and management of patients with immunohistochem-istry-positive sentinel nodes and those with micrometastases.J Clin Oncol 26:698-702,2008.
 
23) Smidt ML,et al:Axillary recurrence after a negative sentinel node biopsy for breast cancer:incidence and clinical significance.Ann Surg Oncol 12:29-33,2005.
PubMed
24) Veronesi U,et al:Axillary metastases in breast cancer patients with negative sentinel nodes:a follow-up of 3548 cases.Eur J Cancer 45:1381-1388,2009.
PubMed
25) Anderson SJ,et al:Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.J Clin Oncol 27:2466-2473,2009.
PubMed
P.527 掲載の参考文献
1) 佐貫潤一ほか:3次元皮下留置マーカーを使用した乳房部分切除術.外科 65:1815-1819,2011.
 
2) Klein JA:The tumescent technique for liposuction surgery.Am J Cosmet Surg 4:263-267,1987.
 
3) 南雲吉則ほか:経乳輪的皮下乳腺全摘術とインプラントを用いた同時再建.手術 57:41-45,2003.
 
4) 佐貫潤一ほか:傍乳輪切開と欠損部充填法による乳房温存手術.手術 63:1457-1462,2009.
 
P.531 掲載の参考文献
1) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン (1)治療編,2011年度版,金原出版,2011.
 
2) 林論史ほか:DCIS 109例の臨床的検討.乳癌の臨床 24:503-507,2009.
 
3) Dunne C,et al:Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ.J Clin Oncol 27:1615-1620,2009.
PubMed
4) Ansari B,et al:Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast.Br J Surg 95:547-554,2008.
PubMed
5) Intra M,et al:Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast.The experience of the European institute of oncology on 854 patients in 10 years.Ann Surg 247:315-319,2008.
 
6) Lyman GH,et al:American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol 23:7703-7720,2005.
 
7) Fisher B,et al:Lumpectomy and radiation therapy for the treatment of intraductal breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-17.J Clin Oncol 16:441-452,1998.
PubMed
8) Silverstein MJ,et al:Aprognostic index for ductal carcinoma in situ of the breast.Cancer 77:2267-2274,1996.
 
9) Silverstein MJ:The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.Am J Surg 186:337-343,2003.
 
10) Julien Jp,et al:Radiotherapy in breast-conserving treatment for ductal carcinoma in situ:first results of the EORTC randomized phase III trial 10853.EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.Lancet 355:528-533,2000.
PubMed
11) Houghton J,et al:Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK,Australia,and New Zealand:randomized controlled trial.Lancet 362:95-102,2003.
PubMed
12) Emdin SO,et al:SweDCIS:Radiotherapy after sector resection for ductal carcinoma in situ of the breast.Results of a randomized trial in a population offered mammography screening.Acta Oncol 45:536-543,2006.
 
13) Monteau A,et al:Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery:treatment with reexcision or radiotherapy with increased dosage.Int J Radiat Oncol Biol Phys 75:1021-1028,2009.
 
14) Fisher B,et al:Tamoxifen in treatment of intraductal breast cancer:National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.Lancet 353:1993-2000,1999.
PubMed
P.536 掲載の参考文献
1) Fisher B,et al:Prevention of invasive breast cancer in women with ductal carcinoma in situ:an update of the national surgical adjuvant breast and bowel project experience.Semin Oncol 28(4):400-418,2001.
PubMed
2) Bijker N,et al:Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ:ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.J Clin Oncol 24(21):3381-3387,2006.
 
3) Cuzick J,et al:Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial.Lancet Oncol 12(1):21-29,2011.
PubMed
4) Holmberg L,et al:Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.J Clin Oncol 26(8):1247-1252,2008.
PubMed
5) Correa C,et al:Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.J Natl Cancer Inst Monogr 2010(41):162-177,2010.
PubMed
6) Goodwin A et al:Post-operative radiotherapy for ductal carcinoma in situ of the breast.Cochrane Database Syst Rev(3):CDOOO563,2009.
PubMed
7) NCCN:Guidelines,version 1,2012.
 
8) Early Breast Cancer Trialist's Collaborative Group(EBCTCG);Darby S,et al:Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet 378(9804):1707-1716,2011.
 
9) Hughes KS,et al:Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.N Engl J Med 351(10):971-977,2004.
 
10) Whelan TJ,et al:Long-term results of hypofractionated radiation therapy for breast cancer.N Engl J Med 362(6):513-520,2010.
PubMed
11) Smith BD,et al:Fractionation for whole breast irradiation:an American Society for Radiation Oncology(ASTRO) evidence-based guideline.Int J Radiat Oncol Biol Phys 81(1):59-68,2011.
PubMed
12) 大川智彦ほか:ガイドラインに関する臨床研究 乳房温存療法における手術術式に対応した乳房照射法.乳癌の診療 13:843-855,1998.
 
13) Romestaing P,et al:Role of a 10-Gy boost in the conservative treatment of early breast cancer:results of a randomized clinical trial in Lyon,France.J Clin Oncol 15(3):963-968,1997.
 
14) Bartelink H,et al:Impact of a higher radiation dose on local control and survival in breast-conservingtherapy of early breast cancer:10-year results of the randomized boost versus no boost EORT 22881-10882 trial.J Clin Oncol 25(22):3259-3265,2007
 
P.541 掲載の参考文献
1) Clarke M,et al:Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366:2087-2106,2005.
PubMed
2) 日本乳癌学会(編):早期浸潤性乳癌に対する乳房温存手術後放射線療法.科学的根拠に基づく乳癌診療ガイドライン1.治療編,p265-267,金原出版,2011.
 
3) 日本乳癌学会:全国乳がん患者登録調査報告-確定版-第39号 2008年次症例.[http://www.crsu.org/breast_registration/analyses/2008/Report_2008.pdf](2012年1月8日参照)
 
4) Hughes KS,et al:Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.N Engl J Med 351:971-977,2004.
 
5) Whelan TJ,et al:Long-term results of hypofractionated radiation therapy for breast cancer.N Engl J Med 362:513-520,2010.
PubMed
6) Chen PY,et al:Four-year efficacy,cosmesis,and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation.Int J Radiat Oncol Biol Phys 76:991-997,2010.
PubMed
7) Arthur DW,et al:APhase II trial of brachytherapy alone after lumpectomy for select breast cancer:tumor control and survival outcomes of RTOG 95-17.Int J Radiat Oncol Biol Phys 72:467-473,2008.
 
8) Vicini F,et al:Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation.Int J Radiat Oncol Biol Phys 79:808-817,2011.
PubMed
9) Veronesi U,et al:Intraoperative radiotherapy during breast conserving surgery:a study on 1,822 cases treated with electrons.Breast Cancer Res Treat 124:141-151,2010.
 
10) Vaidya JS,et al:Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer(TARGIT-A trial):an international,prospective,randomised,non-inferiority phase 3 trial.Lancet 376:91-102,2010.
PubMed
11) Sawaki M,et al:Aphase I study of intraoperative radiotherapy for early breast cancer in Japan.World J Surg 33:2587-2592,2009.
 
12) Sawaki M,et al:Phase I/II study of intraoperative radiotherapy for early breast cancer in Japan.Breast Cancer;On line DOI 10.1007/s 12282-011-0294-1(Epub ahead of print:2011/07/23).
 
13) Smith BD,et al:Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology(ASTRO).Int J Radiat Oncol Biol Phys 74:987-1001,2009.
PubMed
P.546 掲載の参考文献
1) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366(9503):2087-2106,2005.
 
2) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of radiotherapy and surgery in early breast cancer.N Engl J Med 333:1444-1455,1995.
 
3) Van de Steene J,et al:Adjuvant radiotherapy for breast cancer significantly improves overall survival:the missing link.Radiother Oncol 55(3):263 -272,2000.
 
4) Cuzick J,et al:Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.J Clin Oncol 12(3):447-453,1994.
PubMed
5) Olson JE,et al:The role of radiotherapy in the management of operable locally advanced breast carcinoma:results of a randomized trial by the Eastern Cooperative Oncology Group.Cancer 79(6):1138-1149,1997.
PubMed
6) Overgaard M,et al:Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy.Danish Breast Cancer Cooperative Group 82b Trial.N Engl J Med 337:949-955,1997.
 
7) Ragaz J,et al:Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.N Engl J Med 337(14):956-962,1997.
PubMed
8) Hojris I,et al:Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy:analysis of DBCG 82b and 82c randomised trials.Radiotherapy Committee of the Danish Breast Cancer Cooperative Group.Lancet 354(9188):1425-1430,1999.
PubMed
9) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer:an overview of the randomised trials.Lancet 355(9217):1757-1770,2000.
 
10) Shervin MS,et al:Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women.Cancer 2011:doi:10.1002/cncr.26081.
 
11) Harris JR,et al:Consensus Statement on postmastectomy radiation therapy.Int J Radiat Oncol Biol Phys 44(5):989-990,1999.
PubMed
12) Pierce LJ:Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer.J Natl Cancer Inst Monogr (30):117-124,2001.
PubMed
13) Recht A,et al:Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 19(5):1539-1569,2001.
 
14) Gebski V,et al:Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses:a clinical perspective.J Natl Cancer Inst 98(1):26-38,2006.Erratum in:J Natl Cancer Inst 98(12):876,2006.
 
15) Danish Breast Cancer Cooperative Group:Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy:long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.J Clin Oncol 24(15):2268-2275,2006.
 
16) Gnant M,et al:St.Gallen 2011:Summary of the Consensus Discussion.Breast Care(Basel) 6(2):136-141,2011.
PubMed
17) 科学的根拠に基づく乳癌診療ガイドライン 1.治療編2011年版(日本乳癌学会編),金原出版,2011.
 
18) Shikama N,et al:Patterns of care study:comparison of process of post-mastectomy radiotherapy(PMRT) in Japan and the USA.JPn J Clin Oncol 33(10):518-521,2003.
PubMed
19) Shikama N,et al:Patterns of care study for postmastectomy radiotherapy in Japan:its role in monitoring the patterns of changes in practice.JPn J Clin Oncol 36(8):499-503,2006.
PubMed
20) NCCN腫瘍学臨床ガイドライン乳癌(2011年,第2版)[http://www.jccnb.net/guideline/images/gl_2011_2.pdf].
 
21) 金森修一ほか:Stage III乳癌の温存乳房に対する放射線治療.臨床放射線 53:442-448,2008.
 
22) Vu TT,et al:Variability in radiation oncologists'opinion on the indication of a bolus in post-mastectomy radiotherapy:an international survey.Clin Oncol(R Coll Radiol) 19(2):115-119,2007.
 
23) Freedman GM,et al:Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys 46(4):805-814,2000.
PubMed
24) Chen RC,et al:Internal mammary nodes in breast cancer:diagnosis and implications for patient management-a systematic review.J Clin Oncol 26(30):4981-4989,2008.
PubMed
25) Yako-Suketomo H,Katanoda K:Time trends in breast cancer mortality between 1950 and 2008 in Japan,USA and Europe based on the WHO mortality database.JPn J Clin Oncol 41(10):1240,2011.
PubMed
P.550 掲載の参考文献
1) Schaake-Koning C,et al:Adjuvant chemo-and hormonal therapy in locally advanced breast cancer:a randomized clinical study.Int J Radiat Oncol Biol Phys 11(10):1759-1763,1985.
PubMed
2) Rubens RD,et al:Locally advanced breast cancer:the contribution of cytotoxic and endocrine treatment to radiotherapy.An EORTC Breast Cancer Co-operative Group Trial(10792).Eur J Cancer Clin Oncol 25(4):667-678,1989.
PubMed
3) Perloff M,et al:Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma:a cancer and Leukemia Group B study.J Clin Oncol 6(2):261-269,1988.
 
4) Low JA et al:Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.J Clin Oncol 22(20):4067-4074,2004.
PubMed
5) Lerouge D,et al:Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer:updated results in a series of 120 patients.Int J Radiat Oncol Biol Phys 59(4):1062-1073,2004.
 
6) Karasawa K,et al:The role of chemoradiotherapy in patients with unresectable T4 breast tumors.Breast Cancer,2012.[Epub ahead of print]
 
7) Hirowatari H,et al:Full dose capecitabine with local radiotherapy is one of the treatment options for inoperable T4 breast cancer.Jpn J Radiol 29(3):222-225.2011.
PubMed
8) Karasawa K,et al:Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.Breast Cancer 10(3):268-274,2003.
PubMed
9) Bellon JR,et al:Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.Int J Radiat Oncol Biol Phys 48(2):393-397,2000.
 
10) Formenti SC.et al:Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer:a phase I/II trial.J Clin Oncol 21(5):864-870,2003.
 
11) Kao J,et al:Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer:results from two consecutive phase I/II trials.Int J Radiat Oncol Biol Phys 61(4):1045-1053,2005.
PubMed
12) Koukourakis MI,et al:Hypofractionated accelerated radiotherapy with cytoprotection colnbined with trastuzumab,liposomal doxorubicine,and docetaxel in c-erbB-2-positive breast cancer.Am J Clin Oncol 28(5):495-500,2005.
 
13) Genet D,et al:Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer:long-term follow-up.Br J Cancer 97(7):883-887,2007.
PubMed
14) Shanta V,et al:Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai,South India,1990-1999.Int J Radiat Oncol Biol Phys 70(1):51-58,2008.
PubMed
P.556 掲載の参考文献
1) 三橋紀夫:放射線治療の有害事象.がん・放射線療法2010(大西洋編),p93-108,篠原出版社,2010.
 
2) Cox JD,et al:Toxicity criteria of the Radiation Therapy Oncology Group(RTOG) and the European Organization for Research and Treatment of Cancer(EORTC).Int J Radiat Oncol Biol Phys 31(5):1341-1346,1995.
PubMed
3) 関根広ほか:電離放射線の発汗機能に及ぼす影響,発汗学 9(1):2-5,2002.
Medical*Online
4) 淡河恵津世:放射線皮膚炎に対するマネージメント.これからの乳癌診療 2009-2010,p136-141,2009.
 
5) 淡河恵津世:整容性からみた乳房温存治療ハンドブック(矢形寛編),p192-202,メディカル・サイエンス・インターナショナル,2010.
 
6) 淡河悦代ほか:HR-CTを用いた乳房温存術後切線照射における肺野経時的変化. 日本医放会誌 58:331-337,1998.
 
7) Ogo E,et al:A survey of radiaion-induced bronchiolitis obliterance organizing pneumonia syndrome after breast-conserving therapy in Japan.Int J Radiat Oncol Biol Phys 71(1):123-131,2007.
 
8) 淡河恵津世ほか:乳房温存術後放射線治療中および直後における肺障害についての検討.臨床放射線 56:113-120,2011.
 
9) Ogo E,et al:The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy.Radiother Oncol 97(1):95-100,2010.
PubMed
10) Katayama N,et al:Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy.Int J Radiat Oncol Biol Phys 73 (4):1049-1054,2009.
PubMed
11) Cuzick J,et al:Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.J Clin Oncol 12(3):447-453,1994.
PubMed
12) Horton JK,et al:Radiosensitization of chemotherapy-refractory,locally advanced or locally recurrent breast cancer with trastuzumab:a phase II trial.Int J Radiat Oncol Biol Phys 76(4):998-1004,2010.
PubMed
P.561 掲載の参考文献
1) Bedwinek JM,et al:Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer.Int J Radiat Oncol Biol Phys 7:581-585,1981.
PubMed
2) Bedwinek JM:Radiation therapy of isolated local-regional recurrence of breast cancer:decisions regarding dose,field size,and elective irradiation of uninvolved sites.Int J Radiat Oncol Biol Phys 19:1093-1095,1990.
 
3) Buchholz TA,Strom EA:Radiation therapy for locoregional recurrence after mastectomy.In:Radiation Oncology,9th ed(ed by CoxJD,Ang KK),p390-391,Elsevier,Philadelphia,2010.
 
4) Schwaibold F,et al:The results of radiation therapy for isolated local regional recurrence after mastectomy.Int J Radiat Oncol Biol Phys 21:299-310,1991.
PubMed
5) Koscielny S,Tubiana M:The link between local recurrence and distant metastases in human breast cancer.Int J Radiat Oncol Biol Phys 43:11-24,1999.
PubMed
6) Willner J,et al:Locoregional recurrence of breast cancer following mastectomy:always a fatal event? results of univariate and multivariate analysis.Int J Radiat Oncol Biol Phys 37:853-863,1997.
PubMed
7) Toonkel LM,et al:The significance of local recurrence of carcinoma of the breast.Int J Radiat Oncol Biol Phys 9:33-39,1983.
PubMed
8) Janjan NA,et al:Management of locoregional recurrent breast cancer.Cancer 58:1552-1556,1986.
PubMed
9) Halverson KJ,et al:Isolated local-regional recurrence of breast cancer following mastectomy:radiotherapeutic management.Int J Radiat Oncol Biol Phys 19:851-858,1990.
 
10) Kuo SH,et al:Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence.Int J Radiat Oncol Biol Phys 72:1456-1464,2008.
PubMed
11) Hortobagyi GN:Can we cure limited metastatic breast cancer? J Clin Oncol 20:620-623,2001.
 
12) Ballo MT,et al:Local-regional control of recurrent breast carcinoma after mastectomy:does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys 44:105-112,1999.
PubMed
13) Halverson KJ,et al:Survival following locoregional recurrence of breast cancer:univariate and multivariate analysis.Int J Radiat Oncol Biol Phys 23:285-291,1992.
PubMed
14) Olivotto IA,et al:Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer.J Clin Oncol 21:851-854,2003.
PubMed
15) Reddy JP,et al:Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer.Int J Radiat Oncol Biol Phys 80:1453-1457,2011.
PubMed
P.565 掲載の参考文献
1) Earashi M,et al:Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision.Breast Cancer 14(1):39-47,2007.
PubMed
2) Oura S,et al:Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size.Breast Cancer 14(1):48-54,2007.
 
3) Yamamoto N,et al:Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer:Evaluation with MRI and vacuum-assisted core needle biopsy and safety management.Breast Cancer 18(1):3-9,2011.
PubMed
4) Manenti G,et al:Small breast cancers:in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system.Radiology 251(2):339-346,2009.
PubMed
5) Nagashima T,et al:Surrounding rim formation and reduction in size after radiofrequency ablation for primary breast cancer.Jpn J Radiol 27(5):197-204,2009.
PubMed
6) Nakamura S,et al:Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy.Breast Cancer 14(2):123-130,2007.
 
7) Seki K,et al:Histopathological effect of radiofrequency ablation therapy fbr primary breast cancer,with special reference to changes in cancer cells and stromal structure and a comparison with enzyme histochemistry.Breast Cancer 18(1):18-23,2011.
 
8) Tsuda H,et al:A histopathological study for evaluation of therapeutic effects of radiofrequency ablation in patients with breast cancer.Breast Cancer 18(1):24-32,2011.
PubMed
P.569 掲載の参考文献
1) Colleoni M,et al:Expression of ER,PgR,HER1,HER2,and response:a study of preoperative chemotherapy.Ann Oncol 19:465-472,2008.
 
2) Kaufmann M,et al:Preoperative(neoadjuvant) systemic treatment of breast cancer.Breast 14(6):576-581,2005.
PubMed
3) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22:1736-1747,2011.
PubMed
4) Kong X,et al:Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients.Eur J Cancer 47(17):2084-2090,2011.
 
5) Fisher B,et al:Effect of preoperative chemotherapy on the outcome of women with operable breastcancer.J Clin Oncol 15(7):2672-2685,1998.
 
6) Rastogi P,et al:Preoperative chemotherapy:updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.J Clin Oncol 26(5):778-785,2008.
 
7) Amat S,et al:High prognostic significance of residual disease after neoadjuvant chemotherapy:a retrospective study in 710 patients with operable breast cancer.Breast Cancer Res Treat 94(3):255-263,2005.
 
8) Ezzat AA,et al:Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer:analysis of 126 patients.Br J Cancer 90(5):968-974,2004.
PubMed
9) Liedtke C,et al:Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer.J Chn Oncol 26(8):1275-1281,2008.
 
10) Toi M,et al:Phase II study of preoperable sequential FEC and docetaxel predicts of pathological response and disease free survival.Breast Cancer Res Treat 110(3):531-539,2008.
 
11) von Minckwitz G,et al:Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:the GEPARDUO study of the German Breast Group.J Clin Oncol 23(12):2676-2685,2005.
 
12) von Minckwitz G,et al:Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer:Phase III GeparQuattro study.J Clin Oncol 28(12):2015-2023,2010.
PubMed
13) Andre F,et al:HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.Breast Cancer Res Treat 108(2):183-190,2008.
PubMed
14) Chang HR et al:Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.Cancer 116(18):4227-4237,2010.
PubMed
15) Frasci G,et al:Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple negative large operable breast cancer.Ann Oncol 20(7):1185-1192,2009.
 
P.574 掲載の参考文献
1) Wolmark N,et al:Preoperative chemotherapy in patients with operable breast cancer:nine-years results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr 30:96-102,2001.
PubMed
2) van Nes JG,et al:Preoperative chemotherapy is safe in early breast cancer,even after 10 years of follow-up;clinical and translational results from the EORTC trial 10902.Breast Cancer Res Treat 115(1):101-113,2009.
PubMed
3) National Comprehensive Cancer Network:Clinical Practice in Guidelines in Oncology,Version 2,2011.
 
4) Goldhirsch A,et al:Strategy for subtypes-dealing with the diversity of breast cancer:highlights ofcthe St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22(8):1736-1747,2011.
 
5) Albain KS,et al:Prognostic and predictive value of the 21-gene recurrence score assay in post menopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy;A retrospective analysis of a randomised trial.Lancet Oncol 11:55-65,2010.
 
6) Straver ME,et al:The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat 119:551-558,2010.
PubMed
7) Parker JS,et al:Supervised risk predictor if breast cancer based on intrinsic subtypes.J Clin Oncol 27:1160-1167,2009.
PubMed
8) Bear HD,et al:Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project B-27.J Clin Oncol 24:2019-2027,2006.
 
9) van Deurzen CH,et al:Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients:a systematic review.Eur J Cancer 45:3124-3130,2009.
PubMed
10) Fisher B,et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672-2685,1998.
PubMed
11) Hennessy BT,et al:Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.J Clin Oncol 23(36):9304-9311,2005.
PubMed
12) von Minckwitz G,et al:Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol 30:1746-1804,2012.
 
13) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival;An overview of the randomised trials.Lancet 365:1687-1717,2005.
 
14) Symmans WF,et al:Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.J Clin Oncol 25(28):4414-4422,2007.
PubMed
15) Ellis MJ,et al:Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst 100(19):1380-1388,2008.
 
P.580 掲載の参考文献
1) Marcom PK,et al:The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in subset of HER2 positive and ER positive advanced breast cancers.Breast Cancer Res Treat 102(1):43-49,2007.
PubMed
2) Kaufman B,et al:Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopousal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM Study.J Clin Oncol 27(33):5529-5537,2009.
 
3) Miller K,et al:Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 357(26):2666-2676,2007,
PubMed
4) Robert NJ,et al:RIBBON-1:randomized,bouble blind,placebo-controlled,phase III trial of chemotherapy with or without bevacizumab(B) for first-line treatment of HER2-negative locally recur-rent or metastatic breast cancer(MBC).J Clin Oncol 27(15 Suppl):1005,2009.
 
5) Sjostron J,et al:Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure:a randomized phase III study with crossover on progression by the Scandivian Breast Group.Eur J Cancer 35(8):1194-1201,1999.
PubMed
6) Nabholtz JM,et al:Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.304 Study Group.J Clin Oncol 17(5):1413-1424,1999.
 
7) Welves C,et al:Updated survival analysis of phase III study(EMBRACE) of eribulin mesylate versus treatment of physician's choice in subjected with locally recurrence or metastatic breast cancer previously treatment with an anthracycline and taxane.San Antonio Breast Cancer Symposium abstract,p6-14,2010.
 
8) Di Leo A,et al:Phase III,double-blind,randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.J Clin Oncol 26(34):5544-5552,2008.
PubMed
9) Cameron D,et al:Aphase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analysis.Breast Cancer Res Treat 112(3):533-543,2008.
 
10) O'Shaughnessy J,et al:A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy.J Clin Oncol(Meeting Abstract) 26(15 Suppl):1015,2008.
 
P.585 掲載の参考文献
1) Kaufmann M,et al:Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.Ann Surg Oncol 19:1508-1516,2012.
 
2) Fisher B,et al:Presence of growth stimulating factor in serum following primary tumor removal in mice.Cancer Res 49:1996-2001,1989.
PubMed
3) Perez CA,et al:Management of locally advanced carcinoma of the breast.I.Noninflammatory.Cancer 74(Suppl 1):453-465,1994.
 
4) Touboul E,et al:Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery.Radiother Oncol 25:167-175,1992.
PubMed
5) Hortobagyi GN, et al:Induction chemotherapy for stage III primary breast cancer.In:Adjuvant Therapy for Cancer(ed by Salmone SE),p419-428,Grune & Stratton,Orland,1987.
 
6) Early breast cancer trialists'collaborative group:Polychemotherapy for early breast cancer,an overview of randomised trial.Lancet 352:930-942,1998.
 
7) Wilson WH,et al:Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer:a phase I/II trial of 96-hour infusion.J Clin Oncol 12:1621-1629,1994.
PubMed
8) Ravdin PM,et al:Phase II trial of docetaxel advanced anthracycline-resistant or anthracenedione-resistant breast cancer.J Clin Oncol 13:2879-2885,1995.
 
9) Smith IC,et al:Neoadjuvant chemotherapy in breast cancer:Significantly enhanced response with docetaxel.J Clin Oncol 20:1456-1466,2002.
PubMed
10) Bear HD,et al:The effect on tumor response of adding preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27.J Clin Oncol 21:4165-4174,2003.
PubMed
11) Fisher B,et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672-2685,1998.
PubMed
12) Von Minckwitz G,et al:Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:the GEPARDUO study of the German Breast Group.J Clin Oncol 23:2676-2685,2005.
 
13) http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf#search=NCCN guideline breast cancer'.
 
14) Early B reast Cancer Trialist's Collaborative Group:Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer.N Engl J Med 319:1681-1692,1988.
 
15) Schabel FM:Concepts for systemic treatment of micrometastasis.Cancer 30:15-24,1975.
 
16) Pierce LJ,et al:The effect of systemic therapy on local-regional control in locally advanced breast cancer.Int J Radiat Oncol Biol Phys 23:949-960,1992.
 
17) Rustogi A,et al:Management of locally advanced breast cancer:Evolusion and current practice.J Cancer Res Ther 1:21-30,2005.
 
18) Chen AM,et al:Breast conservation treatment after neoadjuvant chemotherapy in locally advanced breast cacner:The M.D.Anderson Cancer Center experience.J Clin Oncol 22:2303-2312,2004.
 
19) Burstein HJ,et al:Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer:a pilot study.J Clin Oncol 21:46-53,2003.
PubMed
20) Bllzdar AU,et al:Significantly higher pathologic complete remission rate after neoadjuvant chemotherapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol 23:3676-3685,2005.
 
21) Buzdar AU,et al:Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil,epirubicin,and cyclophosphamide thermotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer:an update of the initial randomized study population and date of additional patients treated with the same regimen.Clin Cancer Res 13:228-233,2007.
 
22) Gianni L,et al:Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer(the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet 375:377-384,2010.
 
23) Untch M,et al:Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer:results from the GeparQuattro study.J Clin Oncol 28(12):2024-2031,2010.
PubMed
24) Baselga J,et al:Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial.Lancet 379(9816):633-640,2012.
PubMed
25) Gianni L,et al:Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer(NeoSphere):a randomised multicentre,open-label,phase 2 trial.Lancet Oncol 13(1):25-32,2012.
PubMed
26) von Minckwitz G,et al:Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.N Engl J Med 366(4):299-309,2012.
PubMed
27) http://www.jbcrg.jp/
PubMed
28) Gianni L,et al:Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women locally advanced breast cancer.J Clin Oncol 29:7265-7277,2005.
PubMed
29) Straver ME,et al:The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat 119(3):551-558,2010.
PubMed
30) Sano H,et al:Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer novel marker genes and prediction model using the expression levels.Breast Cancer 19(1):37-45,2012.
 
P.589 掲載の参考文献
1) O'Shaughnessy JA,et al:Randomized,open-label,phase II trial of oral capecitabine(Xeloda) vs.a reference arm of intravenous CMF(cyclophosphamide,methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.Ann Oncol 12(9):1247-1254,2001.
 
2) Bajetta E,et al:Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.J Clin Oncol 23(10):2155-2161,2005.
PubMed
3) Ershler WB:Capecitabine monotherapy:safe and effective treatment for metastatic breast cancer.Oncologist 11(4):325-335,2006.
PubMed
4) O'Shaughnessy J,et al:Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phase III trial results.J Clin Oncol 20(12):2812-2823,2002.
PubMed
5) Michalaki V,et al:Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer:phase II results.Anticancer Drugs 20(3):204-207,2009.
PubMed
6) Blum JL,et al:Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.Clin Breast Cancer 7(6):465-470,2007.
PubMed
7) Schwartzberg LS,et al:Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.Clin Breast Cancer 12(2):87-93,2012.
PubMed
8) Schaller G,et al:Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.J Clin Oncol 25(22):3246-3250,2007.
PubMed
9) Geyer CE,et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med 355(26):2733-2743,2006.
PubMed
10) Miles D,et al:Combining capecitabine and bevacizumab in metastatic breast cancer:A comprehensive review.Eur J Cancer 48(4):482-491,2012.
PubMed
11) Saek T,et al:A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group,Breast Cancer Working Group.Breast Cancer 11(2):194-202,2004.
 
12) Sato N,et al:The cumulative dose of previous treatment does not relate to efficacy of S-1 in patients with taxane resistant breast cancer.Breast Cancer Res Treat 88(Suppl 1):abstract 1078,2004.
 
13) Yamamoto D,et al:Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network(JBCRN) 04-1 trial.Anticancer Res 30(9):3827-3831,2010.
PubMed
P.595 掲載の参考文献
1) Tanaka M,et al:Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer:a phase II study.Anticancer Drugs 21(4):453-458,2010.
PubMed
2) 岡本康:進行・再発乳癌に対するカペシタビンとシクロホスファミド併用療法の第2相臨床試験.第18回日本乳癌学会学術総会プログラム抄録集,p326[O-193],2010.
 
3) 前川陽子:進行再発乳癌に対するXC(ゼローダ,エンドキサン)療法の有用性に関する検討.第19回日本乳癌学会学術総会プログラム抄録集,p318[P-0084],2010.
 
4) 宮国孝男:当科における進行再発乳癌に対するcapecitabine・cyclophosphamide併用療法の検討.第18回日本乳癌学会学術総会プログラム抄録集,p360[O-330],2010.
 
5) 新山秀昭:両側乳癌術後,頭蓋骨転移による顔面神経麻痺発症例に対し,capecitabine,cyclophosphamide,medroxyprogesterone acetate(MPA)併用療法を行った再発乳癌の一例.日臨外会誌 70(増刊号):904,2009.
 
6) 越田佳朋:再発乳癌に対するゼローダ・エンドキサンXC療法,ゼローダ・エンドキサン・ヒスロンXCMp療法.第17回日本乳癌学会学術総会プログラム抄録集,p376[A-184],2009.
 
7) von Minckwitz G,et al:Trastuzumab beyond progression:overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.Eur J Cancer 47(15):2273-2281,2011.
PubMed
8) Ueno T:A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in poostmenopausal patients with estrogen receptor-positive breast cancer(JBCRG07):The efficacy and its correlation with circulating endothelial cells.J Clin Oncol 29(15)(Suppl):74(618),2011.
 
9) 堀泰祐ほか:進行・再発乳癌(first line therapy)に対する5'-DFUR+CPA+MPA(DMpC療法)とCAF+MPA療法のrandomized Controlled Trial-京滋乳癌研究会第10次研究最終成績報告-.癌治療と宿主 14(3):227-236,2002.
 
10) Jones SE,et al:Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.J Clin Oncol 23(24):5542-5551,2005.
PubMed
11) Leonard R,et al:Optimizing the management of HER2-negative metastatic breast cancer with capecitabine(Xeloda).Semin Oncol 31(Suppl 10):21-28,2004.
 
12) Alexandre J,et al:Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.J Clin Oncol 18(3):562-573,2000.
 
13) Sjostrom J,et al:Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure:a randomised phase III study with crossover on progression by the Scandinavian Breast Group.Eur J Cancer 35(8):1194-1201,1999.
PubMed
14) Dieras V,et al:Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.Semin Oncol 22(4 Suppl 8):33-39,1995.
 
15) Nabholtz J,et al:Multicenter,randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.J Clin Oncol 14(6):1858-1867,1996.
PubMed
P.600 掲載の参考文献
1) Bonadonna G:Evolving concepts in the systemic adjuvant treatment of breast cancer,Cancer Res 52:2127-2137,1992.
PubMed
2) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Polychemotherapy for early breast cancer:an overview of the randomised trials.Lancet 352:930-942,1998.
 
3) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomisedtrials.Lancet 365:1687-1717,2005.
 
4) Henderson IC,et al:Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol 21:976-983,2003.
PubMed
5) Goldhirsch A,et al:Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007.Ann Oncol 18:1133-1144,2007.
PubMed
6) Jones SE,et al:Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.J Clin Oncol 24:5381-5387,2006.
PubMed
7) http://clinicaltrials.gov/
 
8) http://www.jbcrg.jp/clinicaltrials/index.php
 
9) Kawaguchi K,et al:Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers:a multi-institution survey.Breast Cancer Res Treat 130:627-634,2011.
PubMed
10) 柏葉匡寛ほか:臨床エビデンスからの視点によるTC療法の展開.Cancer Board 乳癌 3(1):28-38,2010.
Medical*Online
11) Takabatake D,et al:Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.JPn J Clin Oncol 39(8):478-483,2009.
PubMed
P.604 掲載の参考文献
1) Prat A,et al:Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.Breast Cancer Res 12(5):R68,2010.
PubMed
2) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22(8):1736-1747,2011.
PubMed
3) Rouzier R,et al:Breast cancer molecular subtypes respond differently to preoperative chemotherapy.Clin Cancer Res 11(16):5678-5685,2005.
PubMed
4) Carey LA,et al:The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res 13(8):2329-2334,2007.
PubMed
5) de Ronde JJ,et al:Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.Breast Cancer Res Treat 119(1):119-126,2010.
PubMed
6) Bhargava R,et al:Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy:a single institutional experience with 359 cases.Cancer 116(6):1431-1439,2010.
PubMed
7) Parker JS,et al:Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol 27(8):1160-1167,2009.
PubMed
8) Paik S,et al:A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med 351(27):2817-2826,2004.
PubMed
9) Paik S,et al:Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.J Clin Oncol 24(23):3726-3734,2006.
PubMed
10) Albain KS,et al:Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy:a retrospective analysis of a randomised trial.Lancet Oncol 11(1):55-65,2010,
PubMed
11) Knauer M,et al:The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.Breast Cancer Res Treat 120(3):655-661,2010.
PubMed
12) Harbeck N,et al:Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer.J Clin Oncol 27(15 Suppl):511,2009.
 
13) Schneider BP,et al:Genomic associations with taxane-induced neuropathy by a genome-side association study(GWAS) in E5103.J Clin Oncol 29(15 Suppl):1000,2011.
 
14) Rutgers E,et al:The EORTC 10041/BIG O3-04 MINDACT trial is feasible:results of the pilot phase.Eur J Cancer 47(18):2742-2749,2011.
 
P.612 掲載の参考文献
1) Hudis CA:Trastuzumab-mechanism of action and use in clinical practice.N Engl J Med 357:39-51,2007.
PubMed
2) Miller TW,et al:Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.J Clin Oncol 29:4452-4461,2011.
PubMed
3) Iwase H,et al:Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.Breast Cancer 17:118-124,2010.
PubMed
4) Kaufman B,et al:Trastuzumab plus anastrozole versus anastrozole alone for the treatment of pos menopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study.J Clin Oncol 27:5529-5537,2009.
 
5) Johnston S,et al:Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol 27:5538-5546,2009.
PubMed
6) 戸井雅和,山城大泰:HER2と抗HER2標的治療乳癌レビュー2009,p21-27,メディカルレビュー社,2009.
 
7) Andersson M,et al:Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the HERNATA study.J Clin Oncol 29:264-271,2011.
PubMed
8) 日本乳癌学会(編):乳癌診療ガイドライン治療編,金原出版,2011.
 
9) von Minckwitz G,et al:Trastuzumab beyond progression:overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.Eur J Cancer 47:2273-2281,2011.
PubMed
10) Gori S,et al:Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.Ann Oncol,2011.[Epub ahead of print]
 
11) Cameron D,et al:Aphase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses.Breast Cancer Res Treat 112:533-543,2008.
 
12) Di Leo A,et al:Phase III,double-blind,randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.J Clin Oncol 26:5544-5552,2008.
PubMed
13) Ono M,et al:Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer.Int J Clin Oncol 14:48-52,2009.
PubMed
14) Blackwell KL,et al:Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive,trastuzumab-refractory metastatic breast cancer.J Clin Oncol 28:1124-1130,2010.
 
15) Baselga J,et al:Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med 366:109-119,2011.
PubMed
16) Gianni L,et al:Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer(NeoSphere):a randomised multicentre,open-label,phase 2 trial.Lancet Oncol 13:25-32,2012.
PubMed
P.618 掲載の参考文献
1) Toi M,et al:Vascular endothelial growth factor:its prognostic,predictive,and therapeutic implications.Lancet Oncol 2:667-673,2001.
PubMed
2) Cobleigh MA,et al:Aphase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.Semin Oncol 30:117-124,2003.
 
3) Miller K,et al:Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 357:2666-2676,2007.
PubMed
4) Mnes DW,et al:Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol 28:3239-3247,2010.
 
5) Robert NJ,et al:RIBBON-1:randomized,double-blind,placebo-controlled,phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative,locally recurrent or metastatic breast cancer.J Clin Oncol 29:1252-1260,2011.
 
6) Brufsky AM,et al:RIBBON-2:a randomized,double-blind,placebo-controlled,phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol 29:4286-4293,2011.
PubMed
7) Aogi K,et al:First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer:efficacy and safety results from a large,open-label,single-arm Japanese study.Breast Cancer Res Treat 129:829-838,2011.
PubMed
8) O'Shaughnessy J,et al:Ameta-analysis of overall survival data from three randomized trials of bevacizumab(BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer(MBC).J Clin Oncol 28(Suppl):Abstr 1005,2010.
 
9) von Minckwitz G,et al:Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.N Engl J Med 366:299-309,2012.
PubMed
10) Bear HD,et al:Bevacizumab added to neoadjuvant chemotherapy for breast cancer.N Engl J Med 366:310-320,2012.
PubMed
11) Chang HY,et al:Robustness,scalability,and integration of a wound-response gene expression signature in predicting breast cancer survival.Proc Natl Acad Sci USA 102:3738-3743,2005.
PubMed
12) Jubb AM,Harris AL:Biomarkers to predict the clinical efficacy of bevacizumab in cancer.Lancet Oncol 11:1172-1183,2010.
PubMed
13) Schneider BP,et al:Association of vascular endotheHal growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer:ECOG 2100.J Clin Oncol 26:4672-4678,2008.
 
14) Chun YS,et al:Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.JAMA 302:2338-2344,2009.
PubMed
15) Shaked Y,et al:Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents.Cancer Cell 14:263-273,2008.
PubMed
16) Montero AJ,Vbgel C:Fighting fire with fire:rekindling the bevacizumab debate.N Engl J Med 366:374-375,2012.
 
17) Jain RK:Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy.Science 307:58-62,2005.
PubMed
18) Yanagisawa M,et al:Bevacizumab improves the delivery and efficacy of paclitaxel.Anticancer Drugs 21:687-694,2010.
PubMed
19) Burstein HJ:Bevacizumab for advanced breast cancer:all tied up with a RIBBON? J Clin Oncol 29:1232-1235,2011.
PubMed
20) http://www.fda.gov/NewsEvents/Newsroom/ucm279485.htm
 
21) Broglio KR,Berry DA:Detecting an overall survival benefit that is derived from progression-free survival.J Natl Cancer Inst 101:1642-1649,2009.
PubMed
22) Saad ED,et al:Overall survival and post-progression survival in advanced breast cancer:a review of recent randomized clinical trials.J Clin Oncol 28:1958-1962,2010.
PubMed
23) Montero AJ,et al:Acost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.Breast Cancer Res Treat 132:747-751,2012.
 
24) Burstein HJ,et al:Phase II study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.J Clin Oncol 26:1810-1816,2008.
 
25) Barrios CH,et al:Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Breast Cancer Res Treat 121:121-131,2010.
PubMed
26) Isaacs C,et al:Phase I/II stUdy of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.Breast Cancer Res Treat 125:137-143,2011.
PubMed
27) Moreno-Aspitia A,et al:Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes:North Central Cancer Treatment Group and Mayo Clinic Trial N0336.J Clin Oncol 27:11-15,2009.
PubMed
28) Taylor SK,et al:Aphase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma:a trial of the Princess Margaret Hospital phase II consortium.Oncologist 15:810-818,2010.
PubMed
P.625 掲載の参考文献
1) Peto R,et al:Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials.Lancet 379:432-444,2012.
 
2) Arteaga CL,et al:Treatment of HER2-positive breast cancer:current status and future perspectives.Nat Rev Clin Oncol 9:16-32,2011.
PubMed
3) Pegram MD,et al:Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.J Natl Cancer Inst 96:739-749,2004.
PubMed
4) Inoue K et al:Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-posi-tive metastatic breast cancer:the JO17360 Trial Group.Breast Cancer Res Treat 119:127-136,2010.
 
5) Untch M,et al;HERA Study Team:Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.Ann Oncol 19:1090-1096,2008.
 
6) Prat A,Perou CM:Deconstructing the molecular portraits of breast cancer.Mol Oncol 5:5-23,2011.
PubMed
7) Baselga J,et al:Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial.Lancet 379:633-640,2012.
PubMed
8) Gianni L,et al:Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer(NeoSphere):a randomised multicentre,open-label,phase 2 trial.Lancet Oncol 13:25-32,2012.
PubMed
9) Giani L,et al:Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer(the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet 375:377-384,2010.
 
10) Toi M,et al:Ki67 index changes,pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.Cancer Sci 102:858-865,2011.
PubMed
11) Baselga J,et al:Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.J Clin Oncol 27:2630-2637,2009.
PubMed
12) Baselga J,et al:Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.N Engl J Med 366:520-529,2011.
PubMed
13) Perez EA,Spano JP:Current and emerging targeted therapies for metastatic breast cancer.Cancer 118:3014-3025,2012.
PubMed
14) Masuda N,et al:Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer(STAGE):a double -blind,randomised phase 3 trial.Lancet Oncol 13:345-352,2012.
 
15) Goncalves R,et al:Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer.Nat Rev Clin Oncol 9:223-229,2012.
PubMed
16) Miller K,et a1:Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 357:2666-2676,2007.
 
17) Aogi K,et al:First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer:efficacy and safety results from a large,open-label,single-arm Japanese study.Breast Cancer Res Treat 129:829-838,2011.
PubMed
18) Bear HD,et al:Bevacizumab added to neoadjuvant chemotherapy for breast cancer.N Engl J Med 366:310-320,2012.
PubMed
19) von Minckwitz G,et al:Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.N Engl J Med 366:299-309,2012.
PubMed
P.634 掲載の参考文献
1) Perou CM,et al:Molecular portraits of human breast tumours.Nature 406:747-752,2000.
PubMed
2) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22(8):1736-1747,2011.
PubMed
3) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials.Lancet 365:1687-1717,2005.
 
4) International Breast Cancer Study Group:Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer:International Breast Cancer Study Group Tria1 13-93.J Clin Oncol 24(9):1332-1341,2006.
 
5) Powles TJ,et al:Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.J Clin Oncol 14:78-84,1996.
 
6) Masuda N,et al:Neoadluvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer(STAGE):a double-blind,randomised phase 3 trial.Lancet Oncol 13:345-352,2012.
 
7) Gnant M,et al:Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial.Lancet Oncol 12:631-641,2011.
PubMed
8) Burstein HJ,et al:American Society of Clinical Oncology clinical practice guideline:update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.J Clin Oncol 28:3784-3796,2010.
 
9) EarlyBreast Cancer Trialists'Collaborative Group:Ovarian ablation for early breast cancer.Cochrane Database Syst Rev (3):CD000485,2000.
 
10) Hughes LL,et al:Efficacy of radiotherapy for ovarian ablation:results of a breast intergroup study.Cancer 101:969-729,2004.
PubMed
11) Goel S,et al:LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.Cochrane Database Syst Rev (4):CD004562,2009.
PubMed
12) Walshe JM,et al:Amenorrhea in premenopausal women after adjuvant chemotherapy for breastcancer.J Clin Oncol 24:5769-5779,2006.
 
13) Kaufmann M,et al:Survival analyses from the ZEBRA study.goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer.Eur J Cancer 39:1711-1717,2003.
PubMed
14) Castiglione-Gertsch M,et al:Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer:a randomized trial.J Natl Cancer Inst 95:1833-1846,2003.
 
15) Schmid P,et al:Cyclophosphamide methotrexate and fluorouracil(CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive,premenopausal breast cancer patients:preliminary results of the TABLE-study(Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).Anticancer Res 22(4):2325-2332,2002.
PubMed
16) Davidson NE,et al:Chemoendocrine therapy for premenopausal women with axillary lymph nodepositive,steroid hormone receptor-positive breast cancer:results from INT0101(E5188).J Clin Oncol 23:5973-5982,2005.
 
17) Hackshaw A,et al:Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.J Natl Cancer Inst 101:341-349,2009.
PubMed
18) Robert N,et al:Phase III comparison of Tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor positive breast cancer<3cm.Proc Am Soc Clin Oncol 22:16a,2003.
 
19) Hadji P,et al:Cancer treatment-induced bone loss in premenopausal women:A need for therapeutic intervention? Cancer Treat Rev,2012.[Epub ahead of print]
 
20) Gerber B,et al:Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study.J Clin Oncol 29:2334-2341,2011.
PubMed
21) Del Mastro L,et al:Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer:a randomized trial.JAMA 306:269-276,2011.
PubMed
22) Osborne CK,Schiff R:Mechanisms of endocrine resistance in breast cancer.Annu Rev Med 62:233-247,2011.
PubMed
P.639 掲載の参考文献
1) 日本乳癌学会:乳癌診療ガイドライン(1)治療編CQ9,p37-39,金原出版,2011.
 
2) Davies C,et al:Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials.Lancet 378:771-784,2011.
 
3) Amir E,et al:Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients:a systematic review and meta-analysis.J Natl Cancer Inst 103:1299-1309,2011.
PubMed
4) 日本乳癌学会:乳癌診療ガイドライン(1)治療CQ41,p153-155,金原出版,2011.
 
5) Crew KD,et al:Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.J Clin Oncol 25:3877-3883,2007.
PubMed
6) Cuzick J,et al:Etifect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial.Lancet Oncol 11:1135-1141,2010.
PubMed
7) Regan MM,et al:Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer:the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.Lancet Oncol 12:1101-1108,2011.
PubMed
8) Jonat W,et al:Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer:a meta-analysis.Lancet Oncol 7:991-996,2006.
PubMed
9) Kaufmann M,et al:Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen:the ARNO 95 Study.J Clin Oncol 25:2664-2670,2007.
PubMed
10) Aihara T,et al:Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer:N-SAS BCO3 study.Breast Cancer Res Treat 121:379-387,2010.
 
11) Coombes RC,et al:Survival and safety of exemestane versus tamoxifen after 2-3 yars'tamoxifen treatment(Intergroup Exemestane Study):a randomised controlled trial.Lancet 369:559-570,2007.
 
12) van de Velde CJ,et al:Adjuvant tamoxifen and exemestane in early breast cancer(TEAM):a randomised phase 3 trial.Lancet 377:321-331,2011.
 
13) Jakesz R,et al:Extended adjuvant therapy with anastrozole among Postmenopausal breast cancer patients:results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.J Natl Cancer Inst 99:1845-1853,2007.
 
14) Goss PE,et al:Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.J Clin Oncol 26:1948-1955,2008.
PubMed
15) Mamounas EP,et al:Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen:intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.J Clin Oncol 26:1965-1971,2008.
 
P.644 掲載の参考文献
1) Crump M,et al:An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.Breast Cancer Res Treat 44:201-210,1997.
PubMed
2) Boccardo F,et al:Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer:results of a multicentric Italian study.Ann Oncol 5:337-342,1994.
PubMed
3) Taylor CW,et al:Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:an intergroup study.J Clin Oncol 16:994-999,1998.
PubMed
4) Klijn JGM,et al:Combined tamoxifen and luteinizing hormone-releasing hormone(LHRH) agonist ersus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four ran-domized trials.J Clin Oncol 19:343-353,2001.
 
5) Klijn JGM,et al:Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer:a randomized study.J Natl Cancer Inst 92:903-911,2000.
 
6) Forward DP,et al:Clinical and endocrine date for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Br J Cancer 90:590-594,2004.
 
7) 渋谷和代ほか:閉経前再発乳癌に対するLH-RHアゴニスト・アナストロゾール併用療法の有用性-前治療の及ぼす影響-第19回日本乳癌学会学術総会プログラム抄録集,p480,2011.
 
8) Masuda N,et al:Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer(STAGE):a double-blind,randomized phase 3 trial.Lancet Oncol Online,2012.
 
9) Mauri D,et al:Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer:meta-analysis.J Natl Cancer Inst 98:1285-1291,2006.
PubMed
10) Robertson JFR,et al:Activity of fulvestrant 500mg versus anastrozole 1mg as first-line treatment for advanced breast cancer:results from the FIRST study.J Clin Oncol 27:4530-4535,2009.
 
11) Lonning PE,et al:Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors:a phase II trial.J Clin Oncol 18:2234-2244,2000.
PubMed
12) Thurlimann B,et al:Anastrozole('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer:results of double-blind cross-over SAKK trial 21/95-a sub-study of TARGET(tamoxifen or'Arimidex'randomized group efficacy and tolerability) trial.Breast Cancer Res Treat 85:247-254,2004.
PubMed
13) Chia S,et al:Double-blind,randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive,advanced breast cancer:results from EFECT.J Clin Oncol 26:1664-1670,2008.
PubMed
14) Leo AD,et al:Results of CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.J Clin Oncol 28:4594-4600,2010.
 
15) Baselga J,et al:Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.N Engl J Med published on line,2011.
 
P.648 掲載の参考文献
1) Center for Devices and Radiological Health U.S.Food and Drug Administration:Update on the Safety of Silicone Gel-Filled Breast Implants,2011.[http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm260090.pdf]
 
2) Bengtson BP,et al:Style 410 highly cohesive silicone breast implant core study results at 3 years.Plast Reconstr Surg 120:40S-48S,2007.
PubMed
3) Petit JY,et al:Can breast reconstruction with gel-filled silicone implants increase the risk of death and second primary cancer in patients treated by mastectomy for breast cancer? Plast Reconstr Surg 94 (1):115-119,1994.
PubMed
4) Petit JY,et al:Does long-term exposure to gel-filled silicone implants increase the risk of relapse after breast cancer? Tumori 84(5):525-528,1998.
PubMed
5) McCarthy CM,et al:Breast cancer recurrence following prosthetic, postmastectomy reconstruction:incidence,detection,and treatment.Plast Reconstr Surg 121(2):381-388,2008.
PubMed
6) Hed6n P,et al:Long-term safety and effectiveness of style 410 highly cohesive silicone breast implants.Aesth Plast Surg 33:430-436,2009.
 
P.653 掲載の参考文献
1) 水田成彦ほか:乳房温存術,センチネルリンパ節生検導入に伴う乳癌治療の変遷.京都府立医科大学雑誌 120(2):59-65,2011.
 
2) 中嶋啓雄ほか:吊り上げ法による鏡視下乳腺円状部分切除と広背筋脂肪弁による再建術.鏡視下乳腺手術の実際(沢井清司,福間英祐編),p126-138,金原出版,2002.
 
3) Nakajima H,et al:Video-assisted total glandectomy and immediate reconstruction for breast cancer.Biomed Pharmacother 56(Suppl 1):205s-208s,2002.
 
4) Nakajima H,et al:Video-assisted skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue:clinical outcomes.Ann Surg Oncol 16(7):1982-1989,2009.
PubMed
5) Nakajima H,et al:Clinical outcomes of video-assisted skin-sparing partial mastectomy for breast cancer and immediate reconstruction with latissimus dorsi muscle flap as breast-conserving therapy.World J Surg 34(9):2197-2203,2010.
PubMed
6) Takeda M,et al:Breast conserving surgery with primary volume replacement using a lateral tissue flap.Breast Cancer 12(1):16-20,2005.
PubMed
7) Heneghan HM,et al:Quality of life after immediate breast reconstruction and skin-sparing mastectomy-a comparison with patients undergoing breast conserving surgery.Eur J Surg Oncol 37(11):937-943,2011.
PubMed
8) Freitas-Silva R,et al:Comparison of quality of life,satisfaction with surgery and shoulder-arm morbidity in breast cancer survivors submitted to breast-conserving therapy or mastectomy followed by immediate breast reconstruction.Clinics(Sao Paulo) 65(8):781-787,2010.
PubMed
9) 沢井清司ほか:小切開法によるSentinel Lymph Node Biopsy.鏡視下乳腺手術の実際(沢井清司,福間英祐編),p139-145,金原出版,2002.
 
10) Harris JR,et al:Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast.Int J Radiat Oncol Biol Phys 5(2):257-261,1979.
PubMed
11) 田口哲也ほか:乳がんのOncoplastic Surgery乳房温存術後の一期的乳房再建術の検討.日癌治療会誌 45(2):488,2010.
 
P.657 掲載の参考文献
1) 大西清ほか:乳頭同時再建を行う腹直筋皮弁による即時乳房再建術.手術 50(2):195-199,1996.
 
2) 三鍋俊春,波利井清紀:Expanderを用いた乳房-期再建形成外科 47:S287-S293,2004.
 
3) Delay E,et al:Autologous latissimus breast reconstruction:a 3 year clinical experience with 100.Plast Reconstr Surg 102:1461-1478,1998.
PubMed
4) Delay E,et al:Immediate nipple reconstruction during immediate autologous latissimus breast reconstruction.Plast Reconstr Surg 118:1303-1312,2006.
PubMed
5) Roy MK,et al:Complications of latissimus dorsi myocutaneous fiap breast reconstruction.Eur Surg Oncol 24:162-165,1998.
 
6) Lam DG,et al:Latissimus dorsi donor-site quilting:less is more? Plast Reconstr Surg 105:2271,2000.
PubMed
7) Butler CE:Treatment of refractory donor-site seroma with percutaneous instillation of fibrin sealant.Plast Reconstr Surg 117:976-985,2006.
PubMed
8) Taghizadeh R,et al:Triamcinolone reduces seroma re-accumulation in the extended latissimus dorsi donor site.J Plast Reconstr Aesthet Surg 61(6):636-642,2008.
 
9) Klassen AF,et al:Satisfaction and quality of life in women who undergo breast surgery:a qualitative study.BMC Womens Health 9:11,2009.
PubMed
P.663 掲載の参考文献
1) Kayar R,et al:Five methods of breast volume measurement:a comparative study of measurements of specimen volume in 30 mastectomy cases.Breast Cancer(Auckl) 5:43-52,2011.
PubMed
2) Fujii T,et al:Accurate assessment of breast volume by computed tomography using three-dimen-sional imaging device.Am Surg.(in press)
 
3) Yamaguchi S, et al:Endoscopy-assisted subcutaneous mastectomy and immediate breast reconstruction for breast cancer:advantage of the posterior approach.Int Surg 93:99-102,2008.
PubMed
P.667 掲載の参考文献
1) Lanitis S,et al:Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer:a meta-analysis of observational studies.Ann Surg 251(4):632-639,2010.
PubMed
2) Carlson GW,et al:Local recurrence after skin-sparing mastectomy:tumor biology or surgical conservatism? Ann Surg Oncol 10(2):108-112,2003.
 
3) Ueda S,et al:Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast.Surgery 143(3):414-425,2008.
PubMed
4) Lim W,et al:Oncological safety of skin sparing mastectomy followed by immediate reconstruction for locally advanced breast cancer.J Surg Oncol 102(1):39-42,2010.
PubMed
5) Lindford AJ,et al:Skin-sparing mastectomy and immediate breast reconstruction in the management of locally recurrent breast cancer.Ann Surg Oncol 17(6):1669-1674,2010.
PubMed
6) Metetoja TJ,et al:Late results of skin-sparing mastectomy followed by immediate breast reconstruction.Br J Surg 94(10):1220-1225,2007.
 
7) 日本乳癌学会:乳癌診療ガイドライン(1)治療編,p195-196,金原出版,2011.
 
8) Rusby JE,et al:Nipple-sparing mastectomy.Br J Surg 97(3):305-316,2010.
PubMed
9) Paepke S,et al:Subcutaneous mastectomy with conservation of the nipple-areola skin:broadeningthe indications.Ann Surg 250(2):288-292,2009.
PubMed
10) Shimizu T,et al:A study on skin-sparing mastectomy in patients ineligible for breast-conserving therapy.Ann Cancer Res Ther 17(1):2-6,2009.
 
P.671 掲載の参考文献
1) NCI Common Terminology Criteria for Adverse Events v3.0(CTCAE).[http://ctep.cancer.gov/forms/CTCAEv3.pdf]
 
2) Markouizou A,et al:Radiation dermatitis:implicated fectors,clinical aspects,possible prevention,and medical care.J BUON 12:463-470,2007.
 
3) Campbell IR,Illingworth MH:Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial.Clin Oncol 4:78-82,1992.
PubMed
4) Mcquestion M:Evidence-based skin care management in radiation therapy.Semin Oncol Nurs 22:163-173,2006.
PubMed
5) Liguori V,et al:Double-blind randomized clinical trial comparing hyaluronic acid cream to placebo in patients treated with radiotherapy.Radiother Oncol 42:155-161,1997.
PubMed
6) Pinnix C,et al:Topical hyalurotic acid vs.standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer:single-blind randomized phase III clinical trial.Int J Radiat Oncol Biol Phys 83:1089-1094,2011.
PubMed
7) 淡河恵津世ほか:第24回日本放射線腫瘍学会抄録集.平成21・22年度日本放射線腫瘍学会課題研究「乳房温存療法における放射線治療後の皮膚ケアに関する研究」,2011.
 
P.675 掲載の参考文献
1) Masaoka T:Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan:executive summary.Clin Infect Dis 39(Suppl 1):S49-52,2004.
 
2) Klastersky J,et al:The Multinational Association for Supportive Care in Cancer risk index:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.J Clin Oncol 18:3038-3051,2000.
PubMed
3) Freifeld AG,et al:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of america.Clin Infect Dis 52:e56-93,2011.
 
4) Garcia-Carbonero R, et al:Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia:a multicenter randomized trial.J Natl Cancer Inst 93:31-38,2001.
 
5) NCCN Org.NCCN Clinical Practice Guideline in Oncology,Antiemesis Version 1,2012.
 
6) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン 治療編2011年版(第1版),金原出版,2011.
 
7) Saif MW,et al:Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.Anticancer Res 30(7):2927-2933,2010.
PubMed
8) Wolf SL,et al:Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome:North Central Cancer Treatment Group Study N05C5.J Clin Oncol 28(35):5182-5187,2010.
 
9) Kang YK,et al:Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy:results of a randomized,double-blind,placebo-controlled study.J Clin Onco128:3824-3829,2010.
PubMed
10) 熊本大学医学部附属病院外来化学療法センター運営委員会(編):がん化学療法における有害事象対応マニュアル,熊本大学医学部附属病院,2007年4月.
 
P.684 掲載の参考文献
1) http://chugai-pharm.jp/hc/ss/pr/onco/bt/drug/her_via0150/se/ser/index.html
 
2) Slamon DJ,et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 344:783-792,2001.
 
3) ハーセプチン適正使用ガイド,中外製薬,2009.
 
4) Crown JP,et al:Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.Breast Cancer Res Treat 112:317-325,2008.
PubMed
5) Lacouture ME,et al:Analysiof dermatologic events in patients with cancer treated with lapatinib.Breast Cancer Res Treat 114:485-493,2008,
PubMed
6) タイケルブ適正使用ガイド,グラクソ・スミスクライン株式会社,2011.
 
7) Perez EA,et al:Cardiac safety of lapatinib:pooled analysis of 3689 patients enrolled in clinical trials.Mayo Clin Proc 83:679-686,2008.
PubMed
8) Aogi K et al:First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer:efficacy and safety results from a large,open-label,single-arm Japanese study.Breast Cancer Rs Treat 129(3):829-838,2011.
 
9) アバスチン治療マネジメント・ガイドPart 3高血圧,中外製薬,2010.
 
10) アバスチン治療マネジメント・ガイドPart 4蛋白尿,中外製薬,2010.
 
11) Choueiri TK,et al:Congestive heart failure risk in patients with breast cancer treated with bevacizumab.J Clin Oncol 29:632-638,2011.
PubMed
P.691 掲載の参考文献
1) Diab SG,et al:Tumor characteristics and clinical outcome of elderly women with breast cancer.J Natl Cancer Inst 92:550-556,2000.
PubMed
2) 岡南裕子,岩瀬拓士:高齢者乳癌の特徴.乳癌診療TIPS&TRAPS 18:6-7,2007.
 
3) Wabebo HJ,et al:Is surgical management compromised in elderly patients with breast cancer? Ann Surg 225:579-586,1997.
 
4) Gennari R et al:Breast carcinoma in elderly women;features of disease presentation,choice of local and systemic treatments compared with younger postmenopausal patients.Cancer 101:1302-1310,2004.
PubMed
5) NCCN Clinical Practice Guidelines(NCCN Guidelines R)in Oncology for Senior Adult Oncology ver 2,2012.
 
6) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン(1)治療編2011年版,p248-249,金原出版,2011.
 
7) Hind D,et al:Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women(70 years plus).Cochrane Database Syst Rev(1):CDOO4272,2006.
PubMed
8) Clarke M,et al:Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366:2087-2106,2005.
PubMed
9) Smith BD,et al:Effectiveness of radiation therapy for older women with early breast cancer.J Natl Cancer Inst 98:681-690,2006.
PubMed
10) Hughes KS,et al:Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.N Engl J Med 351:971-977,2004.
 
11) Smith BD,et al:Postmastectomy radiation and survival in older women with breast cancer.J Clin Oncol 24:4901-4907,2006.
PubMed
12) Lyman GH,et al:American Society of Clinical Oncology guideline;Recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol 23:7703-7720,2005.
 
13) International Breast Cancer Study Group:Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer:first results of International Breast Cancer Study Group Trial 10-93.J Clin Oncol 24:337-344,2006.
 
14) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effects of chemotherapy and hormonaltherapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials.Lancet 365:1687-1717,2005.
 
15) Howell A,et al:Results of the ATAC(Arimidex,Tamoxifen,Alone or in Combination) trial after completion of 5 years'adjuvant treatment for breast cancer.Lancet 365:60-62,2005.
 
16) Iwata H:Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer:a new concept.Breast Cancer 18:92-97,2011.
PubMed
17) Giordano SH,et al:Use and outcomes of adjuvant chemotherapy in older women with breast cancer.J Clin Oncol 24:2750-2756,2006.
PubMed
18) De Laurentiis M,et al:Taxane-based combinations as adjuvant chemotherapy of early breast cancer:a meta-analysis of randomized trials.J Clin Oncol 26:44-53,2008.
PubMed
19) Muss HB,et al:Adjuvant chemotherapy in older women with early-stage breast cancer.N Engl J Med 360:2055-2065,2009.
PubMed
20) Noguchi S,et al:Postoperative adjuvant therapy with tamoxifen,tegafur plus uracil,or both in women with node-negative breast cancer:a pooled analysis of six randomized controlled trials.J Clin Oncol 23:2172-2184,2005.
PubMed
21) Ohashi Y,et al:Efficacy of oral tegafur-uracil(UFT) as adjuvant therapy as compared with classical cyclophosphamide,methotrexate,and 5-fluorouracil(CMF) in early breast cancer:a pooled analysisof two randomized controlled trials(N.SAS-BC 01 trial and CUBC trial).Breast Cancer Res Treat 119:633-641,2010.
 
22) Sawaki M,et al:Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients:randomized controlled trial[RESPECT(N-SAS BC07)].Jpn J Clin Oncol 41:709-712,2011.
PubMed
P.696 掲載の参考文献
1) 岡南裕子,岩瀬拓士:高齢者乳癌の特徴.Topics No.18,p6-7,乳癌診療TIPS&TRAPS,CMC Japan株式会社ティー・エル・エムジャパン,2007.
 
2) Bouchardy C,et al:Undertreatment strongly decreases prognosis of breast cancer in elderly women.J Clin Oncol 21:3580-3587,2003.
PubMed
3) Muss HB,et al;Cancer and Leukemia Group B:Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.JAMA 293(9):1073-1081,2005.
 
4) NCCN腫瘍学実践ガイドライン高齢者のがん治療2007年度第2版(NPO法人 日本乳がん情報ネットワーク訳),2007.[http://www.nccn.org]
 
5) Extermann M,et al;Task Force on CGA of the International Society of Geriatric Oncology:Use of comprehensive geriatric assessment in older cancer patients:recommendation from the task force on CGA of the International Society of Geriatric Oncology(SIOG).Crit Rev Oncol Hematol 55(3):241-252,2005.
PubMed
6) Taira N,et al:Comprihensive geriatric assessment in elderly breast cancer patients.Beast Cancer 17(3):183-189,2010.
 
7) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン(1)治療編2011年版,p99-103,金原出版,2011.
 
8) Sawaki M,et al:Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients:randomized controlled trial[RESPECT(N-SAS BC07)].Jpn J Clin Oncol 41(5):709-712,2011.
PubMed
9) Early Breast Cancer Trialists'Collaborative Group(EBCTCG):Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomized trials.Lancet 365(9472):1687-1717,2005.
 
10) Muss HB,et al:CALBG Investigators:Adjuvant chemotherapy in older women with early-stage breast cancer.N Engl J Med 360(20):2055-2065,2009.
 
11) Jones S,et al:Docetaxel with cyclophosphamide in associated with an overall survival benefit compared with doxorubicin and cyclophosphamide:7-year follow-up of US Oncolory Research Trial 9735.J Clin Oncol 27(8):1177-1183,2009.
 
12) Geyer CE,et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med 355(26):2733-2743,2006.
PubMed
13) Scappaticci FA,et al:Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.J Natl Cancer Inst 99(16):1232-1239,2007.
PubMed
14) Hurria A,et al:Predicting Chemotherapy toxicity in older adults with cancer:a prospective multicenter study.J Clin Oncol 29(25):3457-3465,2011.
 
P.700 掲載の参考文献
1) Iseki K,et al:Evidence for increased cancer death in chronic dialysis patients.Am J Kidney Dis 22:308-313,1993.
PubMed
2) 山崎親雄,前田憲志:透析患者の悪性腫瘍.臨床透析 10:747-752,1994、
 
3) Cuckvoic C,et al:Malignant tumors in hemodialysis patients.Nephron 73:710-712,1996.
 
4) Vamvkas S,et al:Cancer in end stage renal disease:potential factors involved.Am J Nephrol 18:89-95,1998.
 
5) 田村禎一:透析療法に伴う身体的・心理的問題とその対応を学ぼう ステップ15 透析患者の合併症を理解しよう.透析ケア2007夏季増刊 ベーシック透析ケア(小澤潔,萩原千鶴子編),p210-236,メディカ出版,2007.
 
6) 吉田克法ほか:奈良県における慢性透析患者の現況-2008年12月末の統計的観察-.奈良医師会透析会誌 15(1):87-92,2010.
 
7) 堀井理恵ほか:血液透析中の乳癌症例の臨床的検討.日臨外会誌 59:2972-2974,1998.
 
8) 内藤明広ほか:血液透析施行患者の乳癌症例の検討.腎と透析 66(別冊腎不全外科'09):30-32,2009.
 
9) 石崎 彰ほか:慢性腎不全に合併した乳癌5症例の検討.腎と透析 45(別冊腎不全外科'97):103-104,1997.
 
10) 太田和夫ほか:乳房.臨床透析 5:1205-1219,1989.
 
11) 佐藤馨ほか:血液透析中に発症した局所進行乳癌の1例.外科 68:702-704,2006.
 
12) 岡本雅彦ほか:透析医療に必要な薬の使い方 悪性腫瘍.腎と透析 70(4):671-675,2011.
 
13) 日本乳癌学会:科学的根拠に基づく乳癌診療ガイドライン 1.治療編,金原出版,2011.
 
P.705 掲載の参考文献
1) CQ33精神疾患を合併した乳癌患者において乳癌の薬物療法は勧められるか.科学的根拠に基づく乳癌診療ガイドライン(1)治療編2011年版(日本乳癌学会編),p122-123,金原出版,2011.
 
2) 赤羽晃寿,南光進一郎:統合失調症の病因と異種性(不均一性).別冊日本臨牀 精神医学症候群I,p25-29,日本臨牀社,2003.
 
3) 野村総一郎:感情障害の分類・診断・疫学.別冊日本臨牀 精神医学症候群1,p232-235,日本臨牀社,2003.
 
4) 野村総一郎:感情障害の症状・経過・予後.別冊日本臨牀 精神医学症候群1,p240-242,日本臨牀社,2003.
 
5) 青柳信嘉ほか:精神障害者における胃癌および大腸癌手術例の検討.日消外会誌 40:357-361,2007.
 
6) 青柳信嘉:精神疾患合併患者の大腸癌治療.日本臨牀 69:559-563,2011.
Medical*Online
7) 青柳信嘉ほか:精神疾患患者に対する肝切除13例の検討.日臨外会誌 65:891-895,2004.
 
8) 清野由輩ほか:精神神経系既往症を有する頭頸部進行癌症例の治療.頭頸部癌 36:119-124,2010.
 
9) 小南裕明,廣吉基己:精神疾患患者における乳癌治療の検討.臨床外科 66:659-662,2011.
 
10) 土井永史,岩淵正之:身体合併症病棟-手術前後の精神症状の管理を中心に.臨床精神医学講座17-リエゾン精神医学・精神科救急医療(松下正明編),p194-200,中山書店,1998.
 
11) 桑原達郎,日高真:精神疾患患者の手術.精神科治療学 19(増刊号:精神科リエゾンガイドライン):279-283,2004.
 
12) 仮屋暢聡,江畑敬介:インフォームド・コンセントおよび法律上の問題.精神障害者に対する身体合併症診療の実際(岩淵正之,江畑敬介編),p38-46,新興医学出版社,1996.
 
P.709 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン研究班:循環器疾患における抗凝固・抗血小板療法に関するガイドライン(2009年改訂版),2009.
 
2) Yasaka M,et al:Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular arterial fibrillation.Intern Med 40(12):1166-1167,2001.
 
3) Garcia DA,et al:Risk of thromboembolism with short-term interruption of warfarin therapy.Arch Intern Med 168(1):63-69,2008.
PubMed
4) Jaffer AK,et a1:Varidations in perioperative warfarin management:outcomes and practice patterns at nine hospitals.Am J Med 123(2):141-150,2010.
 
5) 矢坂正弘:外科手術や内視鏡手術時における抗血栓薬中止のリスクと対応.循環器内科 69(2):147-157,2011.
 
6) Jafifer AK,et al:When patients on warfarin need surgery.Cleve Clin J Med 70(11):973-984,2003.
 
7) White RH,et al:Temporary discontinuation of warfarin therapy:change in the intemational normalized ratio.Ann Intern Med 122(1):40-42,1995.
 
8) Harder S,et al:Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy:pharmacokinetic and pharmacodynamic considerations.Clin Pharmacokinet 43(14):963-981,2004.
PubMed
9) Wahl MJ:Dental surgery in anticoagulated patients.Arch Intern Med 158(15):1610-1616,1998.
PubMed
10) Yasaka M,et al:Ischemic stroke associated with brief cessation of warfarin.Thromb Res 118(2):290-293,2006.
PubMed
11) Palareti G,et al:Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants.A prospective study.Thromb Haemost 72(2):222-226,1994.
PubMed
12) Douketis JD,et al:The perioperative management of antithrombotic therapy:American College of Chest Physicians Evidence-based Clinical Practice Guidelines(8th Edition).Chest 133(6 Suppl):299S-339S,2008.
 
13) Kluft C,et al:The postoperative fibrinolytic shutdown:a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.Scand J Clin Lab Invest 45(7):605-610,1985.
PubMed
14) 小越和栄ほか:内視鏡治療時の抗凝固薬,抗血栓薬使用に関する指針.日消内視鏡技会報 47:2691-2695 2005.
 
P.713 掲載の参考文献
1) Folkman J:Angiogenesis-dependent diseases.Semin Oncol 28:536-542,2001.
PubMed
2) O'Reilly MS,et al:Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell88:277-285,1997.
PubMed
3) Folkman J:Antiangiogenic gene therapy.Proc Natl Acad Sci USA 95:9064-9066,1998.
PubMed
4) Shibata MA,et al:Electrogene therapy using endostatin,with or without suicide gene therapy,suppresses murine mammary tumor groWth and metastasis.Cancer Gene Ther 14:268-278,2007.
PubMed
5) Salven P,et al:Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am J Pathol 153:103-108,1998.
PubMed
6) Nakamura Y,et al:Lymph vessel density correlates with nodal status,VEGF-C expression,and prognosis in breast cancer.Breast Cancer Res Treat 91:125-132,2005.
PubMed
7) Skobe M,et al:Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.Nat Med 7:192-198,2001.
PubMed
8) Kim YM,et al:Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.J Biol Chem 277:27872-27879,2002.
PubMed
9) Brideau G,et al:Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice.Cancer Res 67:11528-11535,2007.
PubMed
10) Shibata MA,et al:The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model.BMC Med 8:69,2010.
 
11) Fire A,et al:Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature 391:806-811,1998.
PubMed
12) Shibata MA,et al:Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.Cancer Gene Ther 15:776-786,2008.
 
13) Albuquerque RJ,et al:Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.Nat Med 15:1023-1030,2009.
PubMed
14) Hirakawa S,et al:VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.J Exp Med 201:1089-1099,2005.
PubMed
15) Shibata MA,et al:α-Mangostin extracted from the pericarp of the mangosteen(Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation.BMC Med 9:69,2011.
 
P.718 掲載の参考文献
1) Mellan I,et al:Cancer immunotherapy come of age.Nature 480:480-489,2011.
 
2) Gennari S,et al:Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.Clin Cancer Res 10:5650-5655,2004.
 
3) Baselga J,et al:Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl JMed 366:109-119,2012.
 
4) Rosenberg SA:Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know.Nat Review Clin Oncol 8:577-585,2011.
PubMed
5) Porter DL,et al:Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl JMed 365:725-733,2011.
 
6) Palucka K,et al:Recent developments in cancer vaccine.J Immunol 186:1325-1331,2011.
PubMed
7) Bonifaz L,et al:Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+T cell tolerance.J Exp Med 196:1627-1638,2002.
 
8) Kantoff PW,et al:Sipuleucel-T immunotherapy for castration resisitant prostate cancer.N Engl J Med 363:411-422,2010.
 
9) Peethambaram PP,et al:Aphase I trial of immunotherapy with lapuleucel-T(APC8024) in patients with refractory metastatic tumors that express HER-2/neu.Clin Cancer Res 15:5937-5944,2009.
 
10) Gulley JL et al:Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.Clin Cancer Res 15:3060-3069,2008.
 
11) Neller MA,et al:Antigens for cancer immunotherapy.Semin Immunol 20:286-295,2008.
PubMed
12) Hodi FS,et al:Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 363:711-723,2010.
PubMed
13) Janetzki S,et al:Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consonium(CVC/SVI).Cancer Immunol Immunother 57:303-315,2008.
PubMed
14) Hoo A,et al:Improved endpoints for cancer immunotherapy trials.J Natl Cancer Inst 102:1388-1397,2010.
 
15) Schreiber RD,et al:Cancer immunoed iting:integrating immunity's roles in cancer suppression and promotion.Science 331:1565-1570,2011.
 

X 乳癌治療におけるQOL評価

P.726 掲載の参考文献
1) Fallowfield IJ:Assessment of quality of life in breast cancer.Acta Oncologia 34:689-694,1995.
 
2) 大住省三,下妻晃二郎:乳癌治療とQOL.乳癌の臨床 18:113-120,2003.
Medical*Online
3) 下妻晃二郎,園尾博司:乳癌をめぐる最近の話題 乳癌患者のQOL.Pharma Medica 16:89-95,1998.
 
4) 乳癌に対するQOL調査・解析のガイドライン作成に関する研究班(班長下妻晃二郎):乳癌患者のQOL評価研究のためのガイドラインVersion 1.0(日本乳癌学会編),2002.
 
5) Ware JE Jr,Sherbourne CD:The MOS 36-item short-form health survey(SF-36).I.Conceptual framework and item selection.Med Care 30:473-483,1992.
PubMed
6) Aaronson NK,et al:The European Organization for Research and Treatment of Cancer QLQ-C30;A quality-of-life instrument of use in international clinical trials in oncology.J Natl Cancer Inst 85:365-376,1993.
 
7) Cella DE et al:The Functional Assessment of Cancer Therapy scale;Development and validation of the general measure.J Clin Oncol 11:570-579,1993.
 
8) Kurihara M,et al:Development of quality of life questionnaire in Japan;Quality of life assessment of cancer patients receiving chemotherapy.Psychooncology 8:355-363,1999.
PubMed
9) Brady MJ,et al:Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.J Clin Oncol 15:974-986,1997.
PubMed
10) Sprangers MAG,et al:The European Organization for Research and Treatment of Cancer Breast-Cancer Specific Quality-of-Life Questionnaire Module:First results from a three-country field study.J Clin Oncol 14:2756-2768,1996.
 
11) Shimozuma K,et al:Analysis of factors associated with quality of life in breast cancer patients after surgery.Breast Cancer 1:123-129,1994.
 
12) Kiebert GM,et al:The impact of breast conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients;Areview.J Clin Oncol 9:1059-1070,1991.
 
13) Osoba D:Lessons learned from measuring health related quality of life in oncology.J Clin Oncol 12:608-616,1994.
 
14) 檜垣健二ほか:乳房温存療法と術後補助療法を行わない乳房切除術との術後QOLの比較.乳癌の臨床 13:320-326,1998.
 
15) Fallowfield L,et al:Quality of life of postmenopausal women in the Arimidex,Tamoxifen,Alone or in Combination(ATAC) Adjuvant Breast Cancer Trial.J Clin Oncol 22:4261-4271,2004.
 
16) Miller K,et al:Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 357:2666-2676,2007.
PubMed
17) 久繁哲徳ほか:乳癌治療とQOL生活の質に基づく乳癌治療法選択の判断分析.乳癌の臨床 12:3-12,1997.
 
18) 下妻晃二郎,園尾博司:高いQOLを目指して:その評価の臨床的意義 癌疾患のQOL評価;乳癌.Pharma Medica 14:81-87,1996.
 
P.729 掲載の参考文献
1) Yoshida K et al:Objective assessment of dermatitis following post-operative radiotherapy in patients with breast cancer treated with breast-conserving treatment.Strahlenther Onkol 186:621-629,2010.
PubMed
2) 関口建次ほか:乳房温存療法後5年間の晩期有害事象と整容性の推移.日本放射線腫瘍学会第24回学術大会報文集,p135,2011.
 
3) Sekine H,et al:Long-term,irradiation-induced effects on thermoregulation in the skin after thermal stimulation.Radiat Med 22:413-421,2004.
PubMed
4) Ogo E,et al:A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan.Int J Radiat Oncol Biol Phys 71:123-131,2008.
PubMed
5) Doyle JJ,et al:Radiation therapy,cardiac risk factors,and cardiac toxicity in early-stage breast cancer patients.Int J Radiat Oncol Biol Phys 68:82-93,2007.
PubMed
6) McGale P,et al:Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden.Radiother Oncol 100:167-175,2011.
PubMed
7) Coen JJ,et al:Risk of lymphedema after regional nodal irradiation with breast conservation therapy.Int J Radiat Oncol Biol Phys 55:1209-1215,2003.
PubMed
8) Land SR,et al:Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection:National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.J Clin Oncol 28:3929-3936,2010.
PubMed
9) Clarke M,et al;Early Breast Cancer Trialists'Collaborative Group:Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials.Lancet 366:2087-2106,2005.
 
10) Early Breast Cancer Trialists'Collaborative Group(EBCTCG);Correa C,et al:Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.J Natl Cancer Inst Monogr 2010:162-177,2010.
 
11) Berrington de Gonzalez A,et al:Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.Br J Cancer 102:220-226,2010.
PubMed
12) Lundstedt D,et al:Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial.Radiother Oncol 97:281-287,2010.
PubMed
13) Vrieling C,et al:The influence of patient,tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC'boost vs.no boost'trial. Radiother Oncol 55:219-232,2000.
PubMed
14) Arndt V,et al:Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy:a population-based study.J Cancer Res Clin Oncol 134:1311-1318,2008.
PubMed
15) Gomez SL,et al:Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California.J Clin Oncol 28:e155-157;author reply e158,2010.
 
P.735 掲載の参考文献
1) Howard-Anderson J,et al:Quality of life,fertility concerns,and behavioral health outcomes in younger breast cancer survivors:a systematic review.J Natl Cancer Inst 104:386-405,2012.
PubMed
2) Zhou P,Recht A:Ybung age and outcome for women with early-stage invasive breast carcinoma.Cancer 101:1264-1274,2004.
PubMed
3) Cancello G,et al:Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women(<35 years) with operable breast cancer.Ann Oncol 21:1974-1981,2010.
PubMed
4) Kim EK,et al:Prognostic significance of young age(<35 years) by subtype based on ER,PR,and HER2 status in breast cancer:a nationwide registry-based study.World J Surg 35:1244-1253,2011.
 
5) Thewes B,et al:Fear of cancer recurrence in young women with a history of early-stage breast cancer:across-sectional study of prevalence and association with health behaviours.Support Care Cancer,2012.[Epub ahead of print]
 
6) Vinatier E,et al:Breast cancer during pregnancy.Eur J Obstet Gynecol Reprod Biol 147:9-14,2009.
PubMed
7) Azim HA Jr,et al:Treatment of the pregnant mother with cancer:a systematic review on the use ofcytotoxic,endocrine,targeted agents and immunotherapy during pregnancy.Part II:Hematological tumors.Cancer Treat Rev 36:110-121,2010.
 
8) Mir O,et al:Taxanes for breast cancer during pregnancy:a systematic review.Ann Oncol 21:425-426,2010.
PubMed
9) Azim HA Jr,et al:Safety of pregnancy following breast cancer diagnosis:a meta-analysis of 14 studies.Eur J Cancer 47:74-83,2011.
PubMed
10) Shimizu C,et al:Physicians'knowledge,attitude,and behavior regarding fertility issues for young breast cancer patients:a national survey for breast care specialists.Breast Cancer,2012.[Epub ahead of print]
 
11) 高橋 都:がんサバイバーの性機能障害と性腺機能障害への支援.腫瘍内科 5:139-144,2010.
 
12) Takahashi M,et al:Attitudes and practices of breast cancer consultations regarding sexual issues:a nationwide survey of Japanese surgeons.J Clin Oncol 24:5763-5768,2006.
PubMed
13) de Boer AG,et al:Cancer survivors and unemployment:a meta-analysis and meta-regression.JAMA 301:753-762,2009.
PubMed
14) Wada K,et al:Awareness and behavior of oncologists and support measures in medical institutions related to ongoing employment of cancer patients in Japan.JPn J Clin Oncol 42:295-301,2012.
PubMed
15) Osborn T:The psychosocial impact of parental cancer on children and adolescents:a systematic review.Psychooncology 16:101-126,2007.
PubMed
P.738 掲載の参考文献
1) 林田裕美ほか:外来で化学療法を受けながら生活するがん患者の困難と対処.人間と科学:県立広島大学保健福祉学部誌 5:67-76,2005.
 
2) 濃沼信夫:がん診療の医療経済学.日本臨牀 67:17-24,2009.
Medical*Online
3) 日本乳癌学会:全国乳がん患者登録調査報告確定版(第39号),2008年次症例,2008.
 
4) 濃沼信夫:厚生労働科学研究費補助金 第3次対がん総合戦略研究「がんの医療経済的な解析を踏まえた患者負担最小化に関する研究」平成21年度総括・分担研究報告書,2009.
 
P.741 掲載の参考文献
1) がん対策基本法[http://law.e-gov.go.jp/announce/H18HO098.html].
 
2) 日本乳癌学会(編):乳癌診療ガイドライン 2疫学・診断編2011年版,p4,金原出版,2011.
 
3) 下妻晃二郎:がん医療におけるQOL研究の世界的動向-乳癌治療を中心に-.血液・腫瘍科 46:490-497,2000.
 
4) 三好和也ほか:「乳がん医療ネットワーク」の構築における広島県内の乳がん検診受診者実数集計の成果.日乳癌検診会誌 20:90-95,2011.
Medical*Online
5) 牧野春彦ほか:当科における乳腺外来効率化への取り組み-乳腺診療ネットワークの構築-.乳癌の臨床 24:727-732,2009.
 
6) 日本乳癌学会(編):乳癌診療ガイドライン 1治療編2011年版,p15-55,金原出版,2011.
 
7) 日本医療マネジメント学会(監修):がん地域連携クリティカルパス,じほう,2010
 
8) 谷水正人ほか:がん診療における地域連携パス.パスでできる1がん診療の地域連携と患者サポート,p41-44,医学書院2009.
 
9) 齋藤彩子:福島県立医科大学附属病院における在宅緩和ケア地域連携パスの活用.がん患者ケア 4:84-92,2010.
 

XI 乳癌治療とインフォームドコンセント

P.750 掲載の参考文献
1) 日本乳癌学会(編):患者さんのための乳がん診療ガイドライン(2009年版),金原出版,2009.
 
2) ASCO:Optimizing Cancer Care-The Importance of Symptom Management, Kendall/Hunt Publishing Co,Dubuque,2001.
 
3) 内富庸介,藤森麻衣子:がん医療におけるコミュニケーション・スキル,医学書院,2007.
 
4) 伊澤純:医療過誤訴訟における医師の説明義務違反.成城法学 (68):125-198,2002.
 
P.755 掲載の参考文献
1) ASCO Curriculum:Optimizing cancer care:the importance of symptom management.Kendal HuntPub,Dubuque,2001.
 
2) 国立がん研究センターがん対策情報センター.
 
3) 厚生労働科学研究費補助金「がん臨床研究事業」標準的な乳房温存療法の実施要項の研究班(編):乳房温存療法のガイドライン,金原出版,2005.
 
4) 梶原哲郎ほか:多中心性乳癌の研究.乳癌の臨床 7:535-540,1992.
Medical*Online
5) Fisher B,et al:Lumpectomy and radiation therapy for the treatment of intraductal breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-17.J Clin Oncol 16:441-452,1998.
PubMed
6) 高橋かおるほか:乳房内再発からみた乳房温存治療の長期成績.乳癌の臨床 20:354-361,2005.
Medical*Online
7) Chen Y,et al:Epidemiology of contralateral breast cancer.Cancer Epidemiol Biomarkers Prev 8(10):855-861,1999.
PubMed
8) Gao X,et al:Risk of second primary cancer in the contralateral breast in women treated for earlystage breast cancer:a population-based study.Int J Radiat Oncol Biol Phys 56(4):1038-1045,2003.
PubMed
9) 安田秀光ほか:超音波ガイド下乳房内血管マッピングの有用性.乳癌の臨床 25:722-723,2010.
Medical*Online
10) Krag DN,et al:Sentinel-lymphnode resection compared with conventional axillary-lymphnode dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 tiral.Lancet Oncol 11(10):927-933,2010.
 
P.760 掲載の参考文献
1) 日本癌治療学会(編):制吐薬適正使用ガイドライン,金原出版,2010.
 
2) 名郷直樹:EBM実践ワークブック よりよい治療を目指して,南江堂,1998.
 
3) 名郷直樹:続EBM実践ワークブック 今できる限りの医療を,南江堂,2002.
 
4) Goldhirsch A,et al:Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol 22(8):1736-1747,2011.
PubMed
5) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン (1)治療編2011年版,金原出版,2011.
 
6) Baile WF,et al:SPIKES-A six-step protocol for delivering bad news:application to the patient with cancer.Oncologist 5(4):302-311,2000.
 
7) Team SPIKES-BC:SPIKES-BC 乳がん診療におけるコミュニケーションスキルを学ぶ,じほう,2007.
 
8) 内富庸介,藤森麻衣子:がん医療におけるコミュニケーション・スキル 悪い知らせをどう伝えるか,医学書院,2007.
 

XII 特論

P.771 掲載の参考文献
1) 黒井克昌ほか:Japan Breast Cancer Research Group(JBCRG).腫瘍内科 6(4):360-368,2010.
 
2) Ohno S,et al:Update results of FEC followed by docetaxel neoadjuvant trials for primary breastcancer.Biomed Pharmacother 59:S323-324,2005.
 
3) Iwata H,et al:Interim analysis of a phase II trial of cyclophosphamide,epirubicin and 5-fluorouracil(CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.Breast Cancer 12:99-103,2005.
PubMed
4) Toi M,et al:Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.Breast Cancer Res Treat 110:531-539,2008.
PubMed
5) 増田慎三ほか:乳癌周術期化学療法の現状およびsupportive careの工夫.癌と化学療法 34:1609-1615,2007.
Medical*Online
6) Kuroi K,et al:Issues in the Assessment of the Pathologic Effect of Primary Systemic Therapy for Breast Cancer.Breast Cancer 13(1):38-48,2005.
 
7) Kuroi K,et al:Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.Biomed Pharmacother 59(Suppl 2):S387-S392,2005.
 
8) 中村清吾ほか:原発乳癌に対するFEC followed by Docetaxel 100mg/m2併用療法による術前化学療法の検討-JBCRG02-.乳癌の臨床 23(2):111-117,2008.
Medical*Online
9) Iwata H,et al:Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.JPn J Clin Oncol 41:867-875,2011.
PubMed
10) 増田慎三:On going clinical study.CREATE-X(JBCRG-04)試験.Cancer Board乳癌 2(1):70,2009.
 
11) 増田慎三:On going clinical study.JBCRG-09(HR陽性HER2陰性乳癌に対する術前TC/TC-FEC/FEC-TC療法).Cancer Board乳癌 3(1):93-94,2010.
 
12) 増田慎三:On going clinical study.JBCRG-10(HER2陽性乳癌に対する術前FEC-TCH/TCH-FEC/TCH療法).Cancer Board乳癌 3(1):94-95,2010.
 
13) 増田慎三:On going clinical study.JBCRG-13試験.Cancer Board乳癌 4(2):89-90,2011.
 
14) 増田慎三:On going clinical study.JBCRG-07. Cancer Board乳癌 3(1):92,2010.
 
15) Toi M,et al:Ki67 index changes,pathological response and clinical benefits in primary breast can-cer patients treated with 24 weeks of aromatase inhibition.Cancer Sci 102(4):858-865,2011.
 
16) Toi M,et al:Clinical significance of the 21-gene signature(Oncotype DX)in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116:3112-3118,2010.
PubMed
17) Kondo M,et al:Economic evaluation of the 21-gene signature(Oncotype DX)in lymph node-negative/positive,hormone receptor-positive early-stage breast cancer based on Japanese valida-tion study(JBCRG-TR03).Breast Cancer Res Treat 127:739-749,2011.
 
18) 黒井克昌:On going clinical study. JBCRG-M02試験Cancer Board 乳癌 23(1):91,2010.
 
19) Kawaguchi K,et al:Correlation between docetaxel-induced skin toxicity and the use of the steroids and H2 blockers:a multi-institution study.Breast Cancer Res Treat 130(2):627-634,2011.
PubMed
20) Grant M,et al:Developing an international network for breast cancer research:the BIG experience.Clinical Investigation 1:623-628,2011.
 
21) 黒井克昌:On going clinical study.ALTTO試験.Cancer Board 乳癌 1(1):58,2010.
 
22) 黒井克昌:On going clinical study.SUPREMO(BIG2-04)試験. Cancer Board 乳癌 2(1):68,2009.
 
23) 高橋将人:On going clinical study.SOLE試験.Cancer Board 乳癌 4(2):88-89,2011.
 
P.776 掲載の参考文献
1) 福田治彦:エビデンスをつくる臨床試験(8)エビデンスをつくる人々.EBMジャーナル 2:100-112,2001.
 
2) 福田治彦ほか:米国SWOGに学ぶがん臨床試験の実践,医学書院,2004.
 
3) 特定非営利活動法人日本放射線腫瘍学研究機構[accessed at http://www.jrosg.jp/].
 
4) 大橋靖夫,荒川義弘:臨床試験の進め方,南江堂,2006.
 
5) Fisher B,et al:Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.N Engl J Med 328:1581-1586,1993.
PubMed
6) Fisher B,et al:Lumpectomy and radiation therapy for the treatment of intraductal breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-17.J Clin Oncol 16:441-452,1998.
PubMed
7) Houghton J,et al:Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK,Australia,and New Zealand:randomised controlled trial Lancet 362:95-102,2003.
PubMed
8) Julien Jp,et al:Radiotherapy in breast-conserving treatment for ductal carcinoma in situ:first results of the EORTC randomised phase III trial 10853.EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.Lancet 355:528-533,2000.
PubMed
9) 山内智香子ほか:PCSによるわが国の放射線療法の現状とJROSGの活動について.臨床放射線 54:277-284,2009.
 
10) 唐澤久美子,鹿間直人:乳腺腫瘍委員会.癌の臨床 56:511-515,2010.
Medical*Online
11) 日本乳癌学会(編):科学的根拠に基づく乳癌診療ガイドライン (1)治療編2011年版,金原出版,2011.
 
P.779 掲載の参考文献
1) ICH:Tri-partite guideline on E5:Ethnic factors in the acceptability of foreign clinical data,1998.
 
2) 厚生省医薬安全局審査管理課:外国臨床データを受け入れる際に考慮すべき民族的要因についての指針.医薬審第672号,平成10年8月11日.
 
3) van de Velde CJ,et al:Adjuvant tamoxifen and exemestane in early breast cancer(TEAM):a randomised phase 3 trial.Lancet 377:321-331,2011.
 
4) van Nes JG,et al:Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.Br J Surg 97(5):671-679,2010.
PubMed
P.784 掲載の参考文献
1) 久道茂:がん検診の有効性評価に関する研究報告書,p173-216,日本公衆衛生協会,1998.
 
2) 厚生労働省:市区町村におけるがん検診の実施状況等調査結果[http://www.mhlw.go.jp/bunya/kenkou/gan09/].
 
3) 厚生労働省:平成21年度地域保健・健康増進事業報告の概況[http://www.mhlw.go.jp/toukei/saikin/hw/c-hoken/09/index.html].
 
4) 厚生労働省:国民生活基礎調査[http://www.mhlw.go.jp/toukei/list/20-21.html].
 
5) Task Force on Community Preventive Services:Recommendations for client-and provider-directed interventions to increase breast,cervical,and colorectal cancer screening.Am J Prev Med 35:S21-25,2008.
PubMed
6) Ohuchi N,et al:Randomized controlled trial on effectiveness of ultrasonography screening for breast cancer in women aged 40-49(J-START):research design.JPn J Clin Oncol 41(2):275-277,2011.
PubMed
7) US Preventive Services Task Force:Screening for breast cancer:U.S.Preventive Services Task Force recommendation statement.Ann Intern Med 151(10):716-726,2009.
PubMed
8) 日本乳癌検診学会:米国予防医学専門委員会による乳がん検診推奨に対する日本乳癌検診学会の見解[http://www.jabcs.jp/pages/uspfts.html].
 
P.797 掲載の参考文献
1) 水本清久:チーム医療とは.実践 チーム医療論実践と教育プログラム(水本清久ほか編),p2-7,医歯薬出版,2011.
 
2) 小川朝生:がんの治療の流れと心のケア.これだけは知っておきたいがん医療における心のケア(小川朝生,内富庸介編),p6-15,創造出版社,2010.
 
3) 厚生労働省:「チーム医療の推進について」(チーム医療の推進に関する検討会 報告書),2010.
 
4) 久木元理恵:各専門職の職能と医療従事者のとらえるチーム医療.実践チーム医療論 実践と教育プログラム(水本清久ほか編),p14-21,医歯薬出版,2011.
 
5) 有田悦子:チーム医療におけるコミュニケーション.実践チーム医療論 実践と教育プログラム(水本清久ほか編),p61-70,医歯薬出版,2011.
 
6) Emanuel EJ,et al:Four models of the physician-patient relationship.JAMA 267(16):2221-2226,1992.
PubMed
7) Temel JS,et al:Early palliative care for patients with metastatic non-small-cell lung cancer.N Engl J Med 363:733-742,2010.
PubMed
P.802 掲載の参考文献
1) Shiroiwa T,et al:International survey on willingness-to-pay(WTP) for one additional QALY gained:what is the threshold of cost effectiveness? Health Econ 19(4):422-437,2010.
 
2) Piccart-Gebhart MJ,et al:Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med 353(16):1659-1672,2005.
PubMed
3) Romond EH,et al:Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med 353(16):1673-1684,2005.
PubMed
4) Joensuu H,et al:Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.N Engl J Med 354(8):809-820,2006.
 
5) Shiroiwa T,et al:The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment:based on 2-year follow-up HERA trial data.Breast Cancer Res Treat 109(3):559-566,2008.
PubMed
6) Miller K,et al:Paclitaxe1 plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 357(26):2666-2676,2007.
PubMed
7) Dedes KJ,et al:Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer:an economic evaluation.Eur J Cancer 45(8):1397-1406,2009.
PubMed
8) Cortes J,et al:Eribulin monotherapy versus treatment of physician'schoice in patients with meta-static breast cancer(EMBRACE):a phase 3 open-label randomised study.Lancet 377(9769):914-923,2011.
 

書評

最近チェックした商品履歴

Loading...